An Analysis of Treatment Patterns, Receipt of Guideline-Concordant Care, and Survival Outcomes among Elderly Women with Non-Metastatic Breast Cancer Using the SEER-Medicare Linked Dataset by LeMasters, Traci
Graduate Theses, Dissertations, and Problem Reports 
2015 
An Analysis of Treatment Patterns, Receipt of Guideline-
Concordant Care, and Survival Outcomes among Elderly Women 
with Non-Metastatic Breast Cancer Using the SEER-Medicare 
Linked Dataset 
Traci LeMasters 
Follow this and additional works at: https://researchrepository.wvu.edu/etd 
Recommended Citation 
LeMasters, Traci, "An Analysis of Treatment Patterns, Receipt of Guideline-Concordant Care, and Survival 
Outcomes among Elderly Women with Non-Metastatic Breast Cancer Using the SEER-Medicare Linked 
Dataset" (2015). Graduate Theses, Dissertations, and Problem Reports. 6057. 
https://researchrepository.wvu.edu/etd/6057 
This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research 
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is 
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain 
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license 
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, 
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. 
For more information, please contact researchrepository@mail.wvu.edu. 
i 
 
An Analysis of Treatment Patterns, Receipt of Guideline-Concordant Care, and Survival 
Outcomes among Elderly Women with Non-Metastatic Breast Cancer Using the SEER-
Medicare Linked Dataset 
 
Traci LeMasters 1 
 
Dissertation submitted to the School of Pharmacy 
at West Virginia University 
 
in partial fulfillment of the requirements for the degree of 
 
Doctor of Philosophy 
in 
Health Outcomes Research 
 
 
S. Suresh Madhavan, M.B.A, Ph.D. Chair 1 
Usha Sambamoorthi Ph.D. 1 
Kimberly M Kelly Ph.D. 1, 2 
Dustin Long Ph.D. 3 
Hannah Hazard M.D. 4 
 
 
1 Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia 
University 
2 Mary Babb Randolph Cancer Center, West Virginia University 
3 Department of Biostatistics, School of Public Health, West Virginia University 
4 Department of Medical Education, School of Medicine, West Virginia University 
 
 
Morgantown, West Virginia 
2015 
 
 
Keywords: Breast Cancer, Treatment Patterns, Guideline-Concordant Care, Survival, 
Elderly, Loco-Regional Treatment, Radiation Therapy, Chemotherapy, Undertreatment 
 
 
Copyright 2015 Traci LeMasters 
 
 
 
 
ii 
 
ABSTRACT 
An Analysis of Treatment Patterns, Receipt of Guideline-Concordant Care, and Survival 
Outcomes among Elderly Women with Non-Metastatic Breast Cancer Using the SEER-
Medicare Linked Dataset 
Traci LeMasters 
Breast cancer (BC) is the 2nd most commonly diagnosed type of cancer in the United States (US) 
and the 1st among women, with 57% of incident cases in those age > 60 years. Relative to other 
cancers, BC has high survival rates, with a 89% 5-year overall survival rate. High survival rates are 
due to improvements in disease understanding, treatment, and earlier stage at diagnosis from  
increased routine BC screening. Yet, disparities in treatment and survival outcomes persist. 
Epidemiologic studies suggest that elderly women experience disparities uniquely associated with 
increasing age and comorbidity, in addition to those associated with socio-demographic 
characteristics, access to oncology care resources, and clinical prognostic factors. This sequence of 
retrospective database studies sought to characterize and examine associations with initial loco-
regional treatment for stage I and II BC, receipt of guideline-concordant care (GCC) and individual 
tests and treatments for stage I-III BC, and overall 5-year survival among using the first two study 
cohorts and a third, more broadly inclusive cohort of elderly women with stage I-III BC. Cohorts of 
women age > 66 years diagnosed in 2003-2009 were selected from the Surveillance, Epidemiology, 
and End Results-Medicare (SEER-Medicare) linked dataset. Regarding the 1st study, 55% of women 
had breast-conserving surgery (BCS) plus radiation therapy (RT), 23% has mastectomy, and 22% 
had BCS without RT as their initial loco-regional treatment. Compared to women who received BCS 
plus RT, those who were older, of greater comorbidity, later stage, or non-white race were more 
likely to have had mastectomy or BCS without RT. Women who were less likely to have had 
mastectomy or BCS without RT were those treated by an oncology surgeon or both an oncology and 
general surgeon vs. a general surgeon only, from areas of less education, lower income, or lived in 
metro areas. Regarding the 2nd study, only 34% received GCC, 61% had RT, and 25% had 
chemotherapy but, most women had their hormone receptor (HR) statuses and lymph nodes tested. 
Women who were older, of greater comorbidity, stage II vs. I, lymph node negative, or non-white 
race were less likely to receive GCC, while those who were HR negative or treated by an oncology 
surgeon or both an oncology and general surgeon, vs. a general surgeon only were more likely to 
receive GCC. Regarding the 3rd study, overall 5-year survival ranged from 82%-88% among the 
three cohorts. The risk of death was greater for women who were older, of greater comorbidity, 
diagnosed at a later stage, HR negative, treated by mastectomy, BCS without RT, did not received 
GCC, RT, or chemotherapy, but was lower for women treated by an oncology surgeon or both an 
oncology and general surgeon vs. a general surgeon only. Despite recommended treatment 
guidelines, increasing age and comorbidity are strongly associated with less aggressive BC among 
elderly women. Older women with BC should receive treatment according to guidelines as it would 
be otherwise given to younger women, health permitting. While the increased risk of death 
associated with increasing age is inevitable, targeting health behaviors to decrease comorbidity and 
continued routine BC screening for earlier stage at diagnosis may go a long way to improve survival.   
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CHAPTER 1 
Background  
Epidemiology 
 Female breast cancer is the second most prevalent type of cancer diagnosed in the United 
States (US) population and the first among women.1 It is estimated that in 2014, 232,670 incident 
diagnoses and 40,000 deaths will be attributed to breast cancer. It is estimated that about 1/8 
women will develop breast cancer in their lifetime and as of January 1st, 2012, over 2.9 million 
women with a history of breast cancer were living in the US. 2 The average age at diagnosis is 61 
years. About 20% of breast cancer cases occur in women age < 50 years, 40% among women 
age 50 – 64 years, and 40% among women age > 65 years. 3 Although breast cancer can occur in 
men, it only accounts for about 1% of incident cases. 4 
Risk Factors 
 Non-modifiable risk factors include gender, age, genetic mutations, race, family history 
of breast cancer, personal history of breast cancer, history of DCIS or LCIS, age at menarche, 
age at menopause, and radiation to the chest. Female gender, age > 55 years, and genetic 
mutations increase the risk for breast cancer. Non-Hispanic White women have slightly higher 
rates of breast cancer overall, but in women age < 45 years, rates are higher among non-Hispanic 
Blacks. Although 85% of women who develop breast cancer do not have an immediate family 
history of the disease (mother, sister, or daughter), women with an immediate family history are 
almost twice as likely to develop breast cancer. Women who begin their menstrual cycle at age < 
12 years and experience menopause at age > 55 years are at increased risk of developing breast 
cancer due to prolonged exposure to the female hormones estrogen and progesterone, which can 
stimulate malignant cell growth in breast tissue. Radiation to chest area, for treatment of an 
earlier cancer, increases a woman’s chance of breast cancer if radiation was received earlier in 
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life, especially during the teenage years of breast development, but does not appear to increase 
breast cancer risk if radiation treatment was received after the age of 40 years. 2, 5, 6 About 5% - 
10% of incident cases of breast cancer are attributable to inheritable genetic mutations, with 
about 15% - 20% of those mutations to the BRCA1 and BRCA2 genes. While genetic mutations 
are present in less than 1% of the population, they are more common among women of certain 
ethnic groups, particularly those of Ashkenazi (Eastern European) Jewish descent. Genetic 
testing for mutations to several genes that increase the risk of breast cancer are available, but 
interpretation of results and subsequent treatment decisions remains challenging. The United 
States Preventive Services Task Force (USPSTF) recommends that women with a very strong 
family history of breast cancer be tested for BRCA mutations, while the American Cancer 
Society (ACS) and American Society for Clinical Oncology (ASCO) recommend that any 
women wanting genetic testing first meet with a genetic counselor to assess individual level of 
risk for mutations, and the benefits and harms of testing. 4   
 Modifiable risk factors include age at first childbirth, history of breast feeding, use of oral 
contraception, use of hormone replacement therapy, alcohol consumption, weight, and exercise. 
Women who have not had children, or had children after the age of 30 years, are at a slightly 
higher risk of breast cancer due to prolonged estrogen and progesterone exposure. Similarly, use 
of oral contraceptives or combination estrogen/progesterone hormone replacement therapy after 
menopause increases breast cancer risk. Also, since breast feeding lowers a woman’s total 
number of menstrual cycles, women who do not breast feed are at an increased risk for breast 
cancer. Elevated risk for breast cancer is also associated with a lack of exercise and being 
overweight or obese.  Although the relationship between weight and breast cancer is not well 
understood, it is thought that women with higher percentages of body fat, particularly in the 
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abdomen, have higher levels of estrogen in their bodies.  Finally, women who consume 2 – 5 
alcoholic drinks a day are about 1.5 times more likely to develop breast cancer, compared to 
women who do not drink alcohol. 2, 5 
Types of Breast Cancer 
  Female breast cancer, from here on referred to as “breast cancer”, can be classified into 
two general categories, non-invasive and invasive. Non-invasive breast cancers, called “in situ” 
are confined to either the ductal (ductal carcinoma in situ or DCIS) or lobular (lobular carcinoma 
in situ or LCIS) regions of the breast tissue and are benign masses. Ductal carcinoma in situ 
accounts for the majority (83%) of non-invasive breast cancer diagnoses. Together, DCIS and 
LCIS comprise less than 11% of all breast cancer cases, but may increase the risk for developing 
invasive breast cancer. The majority of breast cancer cases are invasive and can spread to areas 
outside the breast tissue. Inflammatory breast cancer (IBC) is a rare form of invasive breast 
cancer and accounts for 1% - 3% of all breast cancer cases. It is not characterized by any single 
lump or tumor, making it hard to detect at an early stage. 2, 4   
Breast Cancer Screening 
 Methods of breast cancer screening include mammography, magnetic resonance imaging 
(MRI), ultrasound, and clinical breast exam (CBE). However, mammography is used at the 
primary method to detect breast cancer. Recommended guidelines for the use of mammography 
screening vary across agencies and remain controversial.  
  The American Cancer Society (ACS) and the National Comprehensive Cancer Network 
(NCCN) recommend annual mammograms for women age > 40 years. 2, 7 The United States 
Preventive Services Task Force (USPSTF) had previously recommended biennial screening 
mammography in women age > 40 years.   However, in 2009 the USPSTF released an updated 
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statement that recommended against routine screening mammography in women 40 – 49 years of 
age, biennial screening mammography for women 50 – 74 years of age, and rescinded any 
recommendation for screening mammography among women age > 75 years. Changes to 
recommended screening mammography guidelines were due to an internal USPSTF review of 
evidence concluding that mammography resulted in only a small net benefit among women 40 – 
49 and benefits were inconclusive evidence among women age > 75 years. 8    
 The sensitivity and specificity of mammography varies by study and patient 
characteristics. The overall sensitivity of mammography ranges from 67.8% - 84.1%. 9 - 12 
Mammography has been found to be less sensitive in younger women with denser breast tissue 
(33% - 50%), compared to more fatty breast tissue (75% - 100%). 2, 4, 9 The overall specificity of 
mammography ranges from 75% - 92%, but is also lower in younger women with more dense 
breast tissue. 9, 11, 12 Additionally, longer intervals between mammography have been associated 
with increased sensitivity and decreased specificity. 13   
 Reasons for false-positive mammography results include dense breast tissue, reading by a 
less experienced radiologist, time since last screening, and availability of prior mammography 
film for comparison.  Additionally, benign breast abnormalities such as micro calcifications, 
fibro adenomas, and cysts can make it difficult to distinguish between benign and cancerous 
lesions.   
Diagnosis & Characterization 
 Women with screening mammography results found to be normal, require no additional 
testing and should continue routine screening. However, if a suspicious image cannot be 
determined as benign or malignant, then a diagnostic mammogram should be performed, with or 
without a breast ultrasound. Although, breast ultrasound is a complementary method to 
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mammography, it does not detect the majority of micro calcifications. Mammography results 
determined to be positive for breast cancer will require additional imaging and tests that may 
include diagnostic mammography, breast ultrasound, MRI, and breast biopsy. Methods for a 
breast biopsy include Fine Needle Aspiration Biopsy (FNA), Core Needle Biopsy (CNB), and 
Excisional Biopsy. 
 Additional characteristics used to classify the type of cancer are the presence or absence of 
certain hormone receptors. If receptors for estrogen or progesterone are present in the tumor, 
they can also stimulate the growth of the tumor. Similarly, when the growth promoting protein 
HER-2/neu is present, tumors will grow and spread more rapidly. Hormone receptor assay tests 
identify the presence or absence of these hormone receptors.  If a hormone receptor is present the 
breast cancer is further classified as estrogen-receptor positive (ER-positive), progesterone-
receptor positive (PR-positive), and/or HER-2 positive. These hormone classifications, in 
conjunction with staging, determine the appropriate course of treatment. 14   
Staging  
 Once a case of breast cancer has been diagnosed, the stage of cancer development is used 
to characterize the severity and/or extent that the cancer has spread. Two commonly used 
systems of staging are the American Joint Committee on Cancer (AJCC) TNM (See Tables 1 & 
2) and the Surveillance Epidemiology End Results (SEER) Summary Stage systems. 14, 15   
The SEER Summary Stage system for breast cancer is a more general system of staging breast 
cancer.  Under this system, stages are categorized into three groups: local-stage, regional-stage, 
and distant-stage. In the local-stage, the cancer is confined to the breast tissue. In the regional-
stage, the breast cancer has spread to surrounding tissue and lymph nodes. In the distant-stage, 
the breast cancer has metastasized to distant organs. 4 
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Treatment 
 Local treatment focuses only on the area of the breast where the cancer is confined to, 
while systematic treatment is given throughout the entire body to treat cancer that has spread 
beyond the breast. Local treatment includes surgery and radiation therapy. The two primary 
surgeries used to remove breast cancer are breast conserving surgery (BCS), i.e. lumpectomy, 
and mastectomy. Many women may also undergo a lymphadenectomy to remove affected lymph 
nodes. BCS removes the cancerous tumor and a small rim of healthy tissue surrounding the 
tumor for earlier stage breast cancer. Surgical mastectomy removes the entire breast for later 
stage diagnoses, or upon patient request. Two forms of lymphadenectomy are used to remove 
affected lymph nodes. A sentinel lymph node biopsy examines lymph nodes when there is no 
evidence that the cancer has spread to the nodes. A radioactive dye is injected into the breast, and 
as the dye leaves the breast and travels through the lymph system, it leaves a path identifying the 
first node nearest the breast. This node is removed and tested for cancer. If the test is negative, 
no further node removal is necessary, otherwise more nodes will be removed. The number of 
affected nodes influences the course of treatments. An axillary lymph node dissection is used to 
remove lymph nodes under the armpit when there is sufficient evidence of malignancy.   
Radiation therapy, another form of local treatment, directs a beam of high-energy rays to the 
chest and breast area. External beam radiation therapy (EBRT) is most often used after BCS 5 
days of week for 6 to 7 weeks to destroy any remaining cancerous cells. Radiation therapy is 
recommended after BCS and after mastectomy if the tumor is > 5 cm.  Radiation is also used to 
treat the area where affected lymph nodes were removed.   
 Systematic treatment can be chemotherapy, hormone therapy, and targeted therapy. 
Chemotherapy is a single drug or a mix of drugs used to kill cancerous cells that can be 
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administered intravenously or orally with a pill. Chemotherapy is used if cancerous cells have 
spread throughout the body in early stage breast cancers, or when the cancer has metastasized to 
other parts of the body in later stages, to control the tumor growths.  Chemotherapy can also be 
used as neoadjuvant treatment to shrink tumors > 5 cm before surgery to remove the tumor. 
Treatment is given in cycles of 14, 21, or 28 days, with days of rest in between over a period of 3 
to 6 months.   
 Hormone therapy treats tumors that test positive for estrogen and/or progesterone 
receptors. Estrogen and progesterone are hormones that promote the growth of normal breast 
tissue in women, but can also promote the growth of cancerous cells when present in breast 
tumors. Hormone therapies work by either blocking the receptors from receiving the hormones 
or by reducing the body’s hormone production. Adjuvant hormone therapy is typically 
prescribed for 5 years to women with early stage breast cancers after primary treatment to 
prevent recurrence. Hormone therapy may be given as the first line of treatment for advanced 
staged breast cancer.   
 Targeted therapy is form of systematic treatment that targets only cancerous cells. When 
the protein for the Human Epidermal Growth Factor Receptor 2 is found in breast tumors, the 
breast cancer is classified as HER-2/neu positive. Trastuzumab is a targeted intravenous drug 
therapy that may be given as a neo-adjuvant to shrink the tumor before surgery, but it is most 
often given as an adjuvant treatment for 1 year. It is commonly started when chemotherapy is 
initiated. 14  
Stage 0 (LCIS) 
 LCIS is usually not treated with any surgery other than a surgical biopsy. Depending on 
individual preference and level of risk, a woman may choose to take hormone therapy for 5 years 
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to reduce the risk of recurrence. Some women may also choose to have a prophylactic 
mastectomy, but this option should only be chosen for high risk women who first undergo 
genetic counseling. 14 
Stage 0 (DCIS) 
 DCIS is most often treated with BCS. If there is only 1 tumor and the margin is 
noncancerous, radiation therapy may not be necessary, depending on the patient’s risk for 
recurrence. If the rim of tissue removed around the tumor is positive for cancerous cells, the 
patient may require another excision or a mastectomy if the cancer cannot be completely 
removed or continues to return. BCS should be followed up with radiation therapy, but if a 
mastectomy is performed, then radiation therapy is not necessary. Some patients may choose to 
have a mastectomy when it is not necessary for preventive reasons. However, studies have 
shown that women who receive BCS with radiation have the same survival rates as women 
treated with mastectomy. If primary treatment includes BCS, adjuvant hormone therapy should 
be given to prevent recurrence if the tumor is estrogen or progesterone receptor positive. 14  
Stages I - IIIA 
 Women diagnosed with breast cancer Stage IA, IB, IIA, IIB, and some cases of Stage 
IIIA will have the option for BCS. Patients with tumors > 2 cm, and who desire to have BCS vs. 
mastectomy should consider neo-adjuvant chemotherapy to shrink the tumor.  BCS should be 
followed by radiation therapy. Patients with tumors > 2 cm that do not shrink with first or second 
rounds of chemotherapy will require a mastectomy. Depending on the degree of nodal 
involvement, patients will have any necessary lymph node removal at the time of tumor removal 
or shortly after. Adjuvant chemotherapy may be given for patients with tumors > 1 cm, have 2 or 
more cancerous lymph nodes, or at high risk of recurrence. If the patient’s tumor was found to be 
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HER-2/neu positive, they will start targeted therapy at the time of diagnosis. If the patient’s 
tumor is estrogen or progesterone receptor positive, they will begin adjuvant hormone therapy 
after radiation. 14   
Stages IIIA – IV 
 Some patients diagnosed with Stage IIIA breast cancer may still have the option of BCS 
if the tumor can be shrunk with neo-adjuvant chemotherapy. However, most patients with Stage 
IIIA and beyond will undergo mastectomy. Patients in these stages will most likely also require 
radiation therapy after surgery, regardless of which type of surgery they receive, due to the 
advanced stage of the disease and lymph node involvement. Moreover, patients in theses stages 
will most likely undergo neo-adjuvant and adjuvant chemotherapy.  Targeted therapy and 
adjuvant hormone therapy will also be given if tumors are receptor positive for either type of 
hormones. Patients with Stage IV breast cancer that has metastasized to other areas of their body 
may have inoperable tumors, but may still elect for mastectomy to relieve pain. Combinations of 
radiation therapy, chemotherapy, targeted therapy, and hormone therapy can be used to shrink 
and slow cancer growth and spread in order to prolong life. 14  
Treatment Considerations 
 While these are recommended guidelines for breast cancer treatment put forth by the 
NCCN, treatment should and may vary according to individual patient characteristics such as 
age, health, and menopausal status.  Women who may consider BCS without radiation therapy 
are those whose age > 70 years, tumor < 2cm, tumor was completely removed, tumor contained 
hormone receptors, had no lymph node involvement, and received hormone therapy. 
Chemotherapy should be given on a case-by-case basis for women age > 70 years, considering 
patient health. Lymph node removal may be optional for small tumors and for whom lymph node 
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spread is unlikely, elderly women, and those with poor health. Pregnant women should not 
undergo radiation therapy or chemotherapy. Women who are elderly or in poor health may also 
be recommended to not receive chemotherapy. Choice of adjuvant hormone therapy, if needed, 
should consider the woman’s menopausal status and future pregnancy plans. 4, 14   
Patterns of Care 
 In 2008, among women with early stage breast cancer (Stages I – II), 10% had BCS only, 
30% had BCS and radiation therapy, 17% had BCS, radiation therapy, and chemotherapy, 17% 
had mastectomy alone, 14% had mastectomy and chemotherapy, 1% had mastectomy and 
radiation therapy, 4% had mastectomy, radiation therapy, and chemotherapy, 6% had 
nonsurgical treatment, and 1% received no treatment at all. Overall, 57% had BCS either alone 
or in combination with some other form of treatment, and 36% had mastectomy alone or in 
combination with some other treatment. Among women with late stage breast cancer (Stages III 
– IV), 2% had BCS only, 1% had BCS and radiation therapy, 10% had BCS, radiation therapy, 
and chemotherapy, 7% had mastectomy only, 20% had mastectomy and chemotherapy, 2% had 
mastectomy and radiation therapy, 31% had mastectomy, radiation therapy, and chemotherapy, 
18% had nonsurgical treatment, and 7% received no treatment at all. 3 
Variations in treatment patterns among women with breast cancer occur for a variety of reasons. 
It may seem intuitive that women with early stage breast cancer who have the choice of BCS vs. 
mastectomy would choose BCS in order to preserve their physical appearance and upper body 
functioning. However, over 1/3 of women with early stage breast cancer receive a mastectomy. 
In fact, several recent studies have shown that the rates of elective mastectomy have been on the 
rise since about the mid 2000’s among women who are candidates for BCS. 16-18 Many women 
may choose mastectomy over BCS due to fear of side effects from radiation therapy, 
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inconvenience and time to comply with the radiation therapy schedule, advances in surgical 
techniques for reconstructive surgery, and fear of recurrence. 19, 20 Similarly, higher rates of 
mastectomy among early stage breast cancer patients have been observed among women residing 
in rural locations (60% vs. 45%), as compared to metro or urban areas. 21, 22 Women residing in 
rural areas may elect to have mastectomy over BCS because of the time and distance to travel for 
radiation therapy after BCS, out-of-pocket expenditures for travel for radiation therapy, 
opportunity cost of time off work for radiation therapy, the increased demand for coordination of 
care with BCS and radiation therapy, and lack of radiation oncologist in or near rural areas.  22-24 
Additional reasons for receipt of mastectomy vs. BCS among women with early stage breast 
cancer include reasons commonly associated with health disparities in general. Higher rates of 
mastectomy vs. BCS among early stage breast cancer patients have been observed in women 
who are white, or a race other than white or black, unmarried women, lower levels of education, 
women insured by Medicaid or uninsured, had a male surgeon, are younger than 40 or older than 
70 years of age, since breast cancer is usually more aggressive among younger women, and the 
risks and side effects of additional and extensive treatments may outweigh the benefits for 
women of older age . 17, 18, 21, 24, 25  Women who are of low income and/or socio-demographically 
disadvantaged with early stage breast cancer may have higher rates of mastectomy than higher 
income women due to the additional costs of treatment associated with BCS. 23, 26-29 Similar 
factors have been associated with lack of lymph node biopsy among early stage breast cancer 
patients, lack of radiation therapy following BCS, lack of radiation therapy and chemotherapy 
among patients with local-regionally advanced, or later staged breast cancers, and non-initiation 
or early discontinuation of adjuvant hormone therapy. 30-46   
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Survival & Recurrence 
 Five-year survival rates have improved substantially since 1975.  In 1975 – 1977, the 
average 5-year survival rate for women of all ages and race/ethnicities in the US was 75.1% and 
has increased to 90.0% for 2001 – 2007. 3 Increased survival rates can be attributed to treatment 
advancements and more cases diagnosed at an earlier stage due to widespread adoption of 
mammography screening. Additionally, in 2008, 82% of breast cancer survivors were alive after 
10 years, and 77% after 15% years. 4 However, survival rates vary greatly according to stage at 
diagnosis, age, and race/ethnicity.  Five-year survival rates decrease with advancing stage at 
diagnosis. 2 See Table 3. Similarly, breast cancer mortality tends to increase with age. 47 See 
Table 4.  Although 5-year survival rates have improved for all race/ethnicity groups, disparities 
persist, especially between whites and blacks. See Table 5. These differences are largely 
attributable to later stage at diagnosis and poorer stage-specific survival, and aggressive tumor 
characteristics among black women. 4 Other factors associated with poor breast cancer survival 
are low levels of education and income, being uninsured or insured through Medicaid, receipt of 
guideline appropriate care, and number of comorbidities. 48-53  
 Among women diagnosed with Stage I, II, and III breast cancer, about 11% will 
experience recurrence within 5 years and 20% within 10 years. Recurrence rates are higher 
among survivors diagnosed at advanced stages with recurrence rates of 7% among Stage I, 11% 
among Stage II, and 13% among those diagnosed at Stage III. 54 The likelihood of recurrence has 
been found to increase among survivors that had large tumors, poorly differentiated tumors, 
greater nodal involvement, estrogen receptor positive tumors, did not receive radiation therapy 
after BCS, and did not receive adjuvant hormone therapy. 54-57 Additionally, unhealthy lifestyle 
factors such as obesity, lack of physical activity, poor diet, heavy alcohol consumption, and 
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smoking have been associated with poorer breast cancer survival and greater risk of recurrence. 
Although, it should be noted that studies of the association between diet, physical activity, and 
breast cancer survival and recurrence have not yielded consistent findings. 58-66   
Statement of the Problem 
 Despite advances in breast cancer treatment and survival, disparities in treatment patterns 
and survival outcomes persist. The most common disparities in treatment are the omission of 
recommended treatments and services or receiving non-preferential treatments. The most 
commonly omitted treatments are radiation therapy (RT) following breast-conserving surgery 
(BCS) or mastectomy when indicated, chemotherapy, adjuvant hormone therapy, and lymph 
node sampling. The appropriate course of treatment for each women is determined by tumor size, 
lymph node invasion, and hormone receptor status. However, when diagnosed at an early-stage, 
women often have an option for the type of local treatment received. Women with tumors < 5 cm 
have the option of mastectomy or BCS followed by RT. Multiple randomized clinical studies 
have shown BCS followed by RT to be as equally effective as mastectomy for long-term survival 
of invasive early-stage breast cancer.67-70 Since the National Institutes of Health's (NIH) 1991 
endorsement of BCS plus RT as an appropriate alternative to mastectomy for treatment of 
invasive early-stage breast cancer, mastectomy rates have decreased while rates of BCS plus RT 
have steadily increased.71  In fact, BCS, with or without RT, has become the preferred choice of 
primary surgical treatment among women with early-stage breast cancer, with ~ 60% or more 
receiving BCS. 18,72,73 Yet, in recent years, rates of mastectomy have started to slowly 
increase.18,73,74 Associations with receipt of mastectomy when BCS is an option, include a desire 
to avoid radiation therapy due to side effects, fear of recurrence, larger tumor size, positive 
lymph nodes, tumors with negative hormone receptors, moderately or poorly differentiated 
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tumors, lower income, being insured by Medicaid or uninsured, residing in a rural location, 
increased travel distance for RT, the increased cost of BCS plus RT vs. mastectomy, and surgeon 
characteristics that include being male, not trained in the U.S., and less recent training.18,73,75-79  
 In fact, many of the same factors are associated with treatment disparities at all stages of 
diagnosis and include age, health, socio-demographic characteristics, and access to specialty 
care. Age and comorbidity are two inter-related factors that are strongly associated with 
treatment. While increasing age has its own associated frailty, it is also associated with 
increasing comorbidity, that together, may make some treatments with adverse and toxic effects 
intolerable for some women, to the point that the harms of such treatments outweigh the benefits. 
80-85 In fact, clinical evidence-based treatment guidelines put forth by the National 
Comprehensive Cancer Network (NCCN) do not make recommendations for or against 
chemotherapy in women age > 70 years, but suggest chemotherapy be given on a case-by-case 
basis, depending on the patient's health.86 Additionally, guidelines specify that RT following 
BCS may be omitted among women meeting the following requirements: age > 70 years, tumors 
< 2 cm, node negative, estrogen-receptor positive, and receiving adjuvant hormone therapy.87 
This change to recommended treatment guidelines that had previously recommended RT 
following BCS for all age groups, was made after the 2004 publication of the Cancer and 
Leukemia Group B (CALGB) C9343 trial study results were demonstrating similar 5-year 
survival between women with these clinical characteristics who received BCS plus RT or BCS 
alone. However, since this change in treatment recommendations, evidence suggests that a 
greater number of elderly women do not receive RT or chemotherapy, than those that meet 
exemption requirements from RT or who are in too poor of health to undergo chemotherapy. 88-90 
The course of breast cancer care is often affected by the woman's access to oncology services 
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due to their location of residence and socio-demographic characteristics. Women residing in 
rural vs. urban areas, in areas with a lower density of oncology service providers, and that have 
greater distances to travel for care are more likely to not receive adjuvant treatments such as RT 
and chemotherapy, or delay the initiation of treatment. 80,90-92 Lastly, as frequently observed with 
many health disparities, women who are of black or non-white Hispanic race, lower income, 
lower education, publically insured or uninsured are more likely to experience breast cancer 
treatment disparities. 81,93,94    
 In similar fashion, these factors, as well as clinical prognostic characteristics are also 
associated with overall breast cancer survival. Clinical characteristics associated with greater 
survival are earlier stage at diagnosis, smaller tumor size, less or no lymph node invasion, well 
differentiated tumor grade, and estrogen and progesterone positive tumors. 1,96-98 Receiving 
guideline-concordant care (GCC) is associated with greater breast cancer survival, while 
treatment disparities, i.e. guideline-discordant care (GDC), are associated with poorer survival. 
99-102 While age and comorbidity are inherently associated with poorer overall survival, survival 
differences have also been observed between different races. Black women have markedly worse 
survival outcomes, as compared to white women, such that 5-year survival for white and black 
women is 90% and 79%, respectively. 103-105 Aside from being less likely to receive GCC due to 
various socio-demographic factors, black women diagnosed with breast cancer are more likely to 
have tumors with less favorable characteristics and aggressive cancers. 106,107   
 In order to address gaps in the literature and build upon existing knowledge this series of 
studies will focus upon the treatment patterns and survival of elderly women with invasive breast 
cancer, a population with the highest incidence of the disease, but for whom many are 
undertreated due to age. These studies will also determine how age, health, clinical prognostic 
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factors, oncology care resources, and socio-demographic characteristics are associated with these 
outcomes. The first study will investigate the initial type of loco-regional treatment received for 
early-stage breast cancer. Most studies reporting on treatment patterns for early-stage breast 
cancer present rates that reflects the end result of multiple surgeries, such that a woman who first 
had BCS with or without RT, but eventually had a mastectomy, would be classified as having a 
mastectomy and not BCS. This study will capture, the initial treatment, may reflect treatment 
preferences of elderly women with early-stage breast cancer, as many women with this diagnosis 
have a choice of treatment. The second study will determine to what degree women with stage I, 
II, and III breast cancer receive GCC according to NCCN and ASCO treatment guidelines, by 
comprehensively comparing clinical characteristics and the care received by each women, 
including individual diagnostic tests and treatment. This will address gaps in previous studies 
that have only studied early stages or loco-regional treatment. The third study will examine 
overall 5-year survival among the two previously described study populations and how each of 
those study outcomes (initial loco-regional treatment and receipt of GCC) and independent 
variables are associated with survival. Additionally, overall 5-year survival will be examined 
among a third, more broadly inclusive sample of women with stage I, II, III breast cancer, to gain 
a baseline understanding of overall survival of elderly women with invasive non-metastatic 
breast cancer.    
 Using samples of female fee-for-service Medicare beneficiaries diagnosed with breast 
cancer in the SEER-Medicare dataset, the goals of this study are to determine 1) rates and factors 
associated with receipt of BCS plus RT, mastectomy, and BCS only among elderly women with 
stage I and II breast cancer; 2) rates and factors associated with receipt of guideline-concordant 
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care among elderly women with stage I, II, and III breast cancer; and 3) 5-year survival rates and 
associated factors among elderly women with stage I, II, and III breast cancer. 
Specific Aims & Objectives 
 
Specific Aim 1:  To determine patterns of initial loco-regional treatment following an 
incident diagnosis of stage I and II breast cancer among female fee-for-service Medicare 
beneficiaries identified in the SEER-Medicare linked dataset. 
 
Objective 1.1:  To determine the proportion of women who received breast-conserving surgery 
plus radiation therapy, mastectomy, or breast-conserving surgery only following an incident 
diagnosis of stage I and II breast cancer among fee-for-service Medicare beneficiaries in the 
SEER-Medicare linked datasets. 
 
Objective 1.2:  To determine group differences between women who received breast-conserving 
surgery plus radiation therapy, mastectomy, or breast-conserving surgery only following an 
incident diagnosis of stage I and II breast cancer among fee-for-service Medicare beneficiaries in 
the SEER-Medicare linked datasets. 
 
Objective 1.3:  To determine factors associated with type of initial loco-regional treatment 
received following an incident diagnosis of stage I and II breast cancer among fee-for-service 
Medicare beneficiaries in the SEER-Medicare linked datasets. 
 
Specific Aim 2:  To determine receipt of guideline-concordant care following an incident 
diagnosis of pathologically staged I, II, and III breast cancer among female fee-for-service 
Medicare beneficiaries identified in the SEER-Medicare linked dataset. 
 
Objective 2.1:  To determine the proportion of women receiving guideline-concordant care 
following an incident diagnosis of pathologically staged I, II, and III breast cancer among fee-
for-service Medicare beneficiaries in the SEER-Medicare linked datasets. 
 
Objective 2.2:  To determine group differences between women receiving guideline-concordant 
vs. guideline-discordant care following an incident diagnosis of pathologically staged I, II, and 
III breast cancer among fee-for-service Medicare beneficiaries in the SEER-Medicare linked 
datasets. 
 
Objective 2.3:  To determine the factors associated with receipt of guideline-concordant care 
following an incident diagnosis of pathologically staged I, II, and III breast cancer among fee-
for-service Medicare beneficiaries in the SEER-Medicare linked datasets. 
 
Specific Aim 3:  To determine overall 5-year survival rates and associated factors following 
an incident diagnosis of invasive breast cancer among three different samples of female fee-
for-service Medicare beneficiaries identified in the SEER-Medicare linked dataset. 
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Objective 3.1:  To determine overall 5-year survival rates following an incident diagnosis of 
breast cancer and by stage among a broad sample of fee-for-service Medicare beneficiaries 
diagnosed at stage I, II, and III from 2003 to 2009 in the SEER-Medicare linked datasets. 
 
Objective 3.2:  To determine group differences between women who lived and died within 5 
years of diagnosis of breast cancer among a broad sample of fee-for-service Medicare 
beneficiaries diagnosed at stage I, II, and III from 2003 to 2009 in the SEER-Medicare linked 
datasets. 
 
Objective 3.3:  To determine factors associated with overall 5-year survival following an incident 
diagnosis of breast cancer among a broad sample of fee-for-service Medicare beneficiaries 
diagnosed at stage I, II, and III from 2003 to 2009 in the SEER-Medicare linked datasets. 
 
Objective 3.4:  To determine overall 5-year survival rates following an incident diagnosis of 
breast cancer and by receipt of BCS plus RT, mastectomy, and BCS only among fee-for-service 
Medicare beneficiaries diagnosed at stage I and II breast cancer from 2003 to 2009 in the SEER-
Medicare linked datasets. 
 
Objective 3.5:  To determine group differences between women who lived and died within 5 
years of diagnosis of breast cancer among fee-for-service Medicare beneficiaries diagnosed at 
stage I and II breast cancer from 2003 to 2009 in the SEER-Medicare linked datasets. 
 
Objective 3.6:  To determine factors associated with overall 5-year survival following an incident 
diagnosis of breast cancer among fee-for-service Medicare beneficiaries diagnosed at stage I and 
II breast cancer from 2003 to 2009 in the SEER-Medicare linked datasets. 
 
Objective 3.7:  To determine overall 5-year survival rates following an incident diagnosis of 
pathologically staged I, II, and III breast cancer and by receipt of GCC among fee-for-service 
Medicare beneficiaries diagnosed from 2004 to 2009 in the SEER-Medicare linked datasets. 
 
Objective 3.8:  To determine group differences between women who lived and died within 5 
years of diagnosis of pathologically staged I, II, and III breast cancer among fee-for-service 
Medicare beneficiaries diagnosed from 2004 to 2009 in the SEER-Medicare linked datasets. 
 
Objective 3.9:  To determine factors associated with overall 5-year survival following an incident 
diagnosis of breast cancer among fee-for-service Medicare beneficiaries diagnosed from 2004 to 
2009 in the SEER-Medicare linked datasets. 
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Table 1. Definition of "T", "N", and "M" Categories of the TNM Staging System  
 
Breast Cancer Staging Categories  
T N M 
Tis: non-invasive breast 
cancer (DCIS of LCIS) 
N0: cancer has not spread to 
lymph nodes 
M0: no distant cancer spread 
T0: no evidence of primary 
tumor 
N1: cancer has spread to 1 – 3 
lymph nodes under the arm on 
the same side but are not 
attached 
M1: cancer has spread to 
distant organs 
T1: tumor < 2 cm in 
diameter  
N2: cancer has spread to 4 – 9 
lymph nodes under the arm on 
the same side and are attached 
 
T2: 2 cm < tumor < 5 cm in 
diameter 
N3: cancer has spread to 10 or 
more lymph nodes including 
those under the arm and 
surrounding areas on the same 
side 
 
T3: tumor > 5 cm in 
diameter 
  
T4: tumor is any size, but 
has spread to the chest wall 
or skin 
  
 
Table 2. TNM Staging System for Breast Cancer           
 
Breast Cancer Stages 
Overall Stage T Category N Category M Category 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage IIA T0 
T1 
T2 
N1 
N1 
N0 
M0 
M0 
M0 
Stage IIB T2 
T3 
N1 
N0 
M0 
M0 
Stage IIIA T0 
T1 
T2 
T3 
T3 
N2 
N2 
N2 
N1 
N2 
M0 
M0 
M0 
M0 
M0 
Stage IIIB T4 Any N M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
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Table 3. Breast Cancer Survival, 2001 – 2007             
 
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Breast Cancer Mortality by Age, 2005 – 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Breast Cancer Survival by Race/Ethnicity, 2001 – 2007 
 
 
 
 
 
 
 
 
5-Year Breast Cancer Survival 
Rates by Stage at Diagnosis 
Stage Rate 
0 93% 
I 88% 
IIA 81% 
IIB 74% 
IIIA 67% 
IIIB 41% 
IIIC 49% 
IV 15% 
Average Annual Breast Cancer 
Mortality Rate by Age 
Age Rate 
< 20 years 0.0% 
20 – 34 years 0.9% 
35 – 44 years 5.6% 
45 – 54 years 14.8% 
55 – 64 years 21.4% 
65 – 74 years 19.9% 
75 – 84 years 22.0% 
> 85 years 15.5% 
5-Year Breast Cancer Survival Rates 
by Race/Ethnicity 
Race/Ethnicity Rate 
Non-Hispanic White 88.8% 
Black 77.5% 
AI/AN 85.6% 
Asian 90.7% 
Pacific Islander 85.4% 
Hispanic 83.8% 
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Abstract 
Background: Breast-conserving surgery (BCS) plus radiation therapy (RT) is an equally 
effective loco-regional treatment for long-term early-stage breast cancer survival as mastectomy, 
and is often the preferred choice of treatment by the majority of women. While some women 
may eventually require mastectomy after treatment failure with BCS plus RT, a considerable 
number of elderly women receive mastectomy as their initial loco-regional treatment or do not 
receive RT following BCS. Therefore, the purpose of this study was to examine patterns of 
initial loco-regional treatment (BCS plus RT, mastectomy, or BCS without RT) among elderly 
women with early-stage breast cancer and differences between women who received mastectomy 
or BCS without RT, compared to BCS plus RT as initial loco-regional treatment.  
Methods: A sample of 45,981 women age > 66 diagnosed with stage I and II breast cancer from 
2003 to 2009 were selected from the SEER-Medicare linked dataset. The chi-square statistic was 
used to test for group differences between type of treatment and independent variables that 
included year of diagnosis, age, health, clinical prognostic factors, oncology care resources, and 
socio-demographic characteristics. Multinomial logistic regression was used to identify 
predictors of mastectomy or BCS without RT, compared to BCS plus RT for initial loco-regional 
treatment.  
Results: In all, 55% of elderly women with early-stage breast cancer received BCS plus RT, 
23% received mastectomy, and 22% received BCS without RT as their initial type of loco-
regional treatment. Compared to women who received BCS plus RT, women of older age, 
greater comorbidity, with a higher frequency of PCP visits, later stage,  and non-white race were 
more likely to receive mastectomy or BCS without RT. Whereas women who lived in areas of 
higher education, higher income, metro areas, and were treatment by an oncology surgeon or 
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both and oncology and general surgeon were less likely to receive mastectomy or BCS without 
RT, than BCS plus RT. Additionally, women who resided in areas with a high density of 
oncology centers were less likely to receive mastectomy, while women with negative estrogen 
and progesterone tumor receptors and less differentiated tumors were more likely to receive 
mastectomy, compared to BCS plus RT.  
Conclusions: Over half of elderly women have BCS plus RT, while the other half undergo 
mastectomy or have BCS without RT, in nearly equal proportions. Yet, many may eventually 
undergo mastectomy after initial treatment with BCS. Elderly women who were more likely to 
have mastectomy or BCS without RT share similar associations with many of the same socio-
demographic characteristics and measures of access to oncology care, indicating they face 
additional barriers to receiving preferential and/or optimal treatment. Moreover, positive 
associations with increasing age and comorbidity among women who received mastectomy or 
BCS without RT may reflect a notion that RT is not well tolerated or will not significantly 
increase life-expectancy among some elderly women. Loco-regional treatment of elderly women 
with early-stage breast cancer could be improved by ensuring all patients are informed of and 
have access to all treatment options, as well as, emphasizing receipt of all recommended 
treatments among patients who do not meet specific criteria for exemption.   
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 Introduction 
 Breast conserving surgery (BCS) followed by radiation therapy (RT), has been found to 
be an equally effective loco-regional treatment as mastectomy for long-term survival of invasive 
early-stage breast cancer.1-5 Since the National Institutes of Health's (NIH) 1991 endorsement of 
BCS plus RT as an appropriate alternative to mastectomy for treatment of invasive early-stage 
breast cancer, mastectomy rates have decreased while rates of BCS plus RT have steadily 
increased.6  In fact, BCS, with or without RT, has become the preferred choice of primary 
surgical treatment among women with early-stage breast cancer, with ~ 60% or more receiving 
BCS. 7-9 Yet, one in four women who have BCS will undergo additional surgery, and about one 
in ten will eventually undergo mastectomy after treatment failure with BCS. 10,11  Whether it is 
the initial choice of surgery or not, epidemiological studies have reported an increase in the use 
of mastectomy in recent years. 8,9,12 Women who elect for mastectomy when BCS plus RT is an 
option tend to be younger, have a desire to avoid RT, fear recurrence, have larger and/or more 
aggressive tumors, positive lymph nodes, tumors with negative hormone receptors, and 
moderately or poorly differentiated tumors. Additional associations with receipt of mastectomy 
are being of lower income, insured by Medicaid or uninsured, residing in a rural location, 
increased travel distance for RT, the increased cost of BCS plus RT compared to mastectomy, 
and surgeon characteristics that include being male, not trained in the U.S., and less recent 
training.8,9, 12-17 In fact, many of these same factors are similarly associated with omission of RT 
following BCS. Additional associations with not receiving RT following BCS include being 
African American, increased comorbidity, and older age.18-21 
 Among several issues to consider when choosing local treatment for early-stage breast 
cancer, is a willingness to undergo RT when opting to have BCS. Omitting RT following BCS 
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may result in short-term treatment failure, and consequently, mastectomy. Moreover, women 
who do not received RT following BCS when recommended to do so are at increased risk for 
recurrence and poorer survival. 18,22-26 However, guidelines allow for a select group of women to 
omit RT following BCS. Following the 2004 publication of the Cancer and Leukemia Group B 
(CALGB) C9343 trial study results demonstrating similar 5-year survival between women age > 
70 years with specific clinical characteristics who received BCS plus RT or BCS alone, the 
National Comprehensive Cancer Network's (NCCN) updated treatment guidelines to allow for 
the omission of RT following BCS among women meeting the following requirements: age > 70 
years, tumors < 2 cm, node negative, estrogen-receptor positive, and receiving adjuvant hormone 
therapy. 27,28 Following this controversial guideline change, rates RT following BCS appeared to 
decrease, particularly among women age > 80 years regardless of clinical factors or evidence of 
increased breast cancer mortality and recurrence among women receiving BCS only.18, 22-25,29,30  
 Statement of the Problem 
 Until now, epidemiological studies of treatment for early-stage breast cancer have 
included women of all ages or have limited studies of older women with stage I breast cancer or 
who would already meet NCCN guidelines for RT omission. 8,9,12,13,22- 24,31,33 Samples have also 
included women with Stage 0, for which surgical guidelines are not clear, or women with Stage 
III, a stage where mastectomy is the predominant surgical choice. 12,22,31,33 Moreover, when 
reporting surgical patterns, studies have included mastectomy when it may not have been the 
initial surgery. 34 Therefore, to gain a better understanding of the intended initial choice of 
treatment among elderly women with invasive early-stage breast cancer, this study examine 
patterns of initial loco-regional treatment (BCS plus RT, mastectomy, or BCS only) among 
women age > 66 years, with stage I and I breast cancer using SEER using a U.S. population-
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based linked SEER-Medicare dataset. Furthermore, this study aims to determine how age, health, 
clinical prognostic factors, oncology care resources, and socio-demographic characteristics are 
associated with initial choice of loco-regional treatment.  
Methods 
Data 
 The SEER-Medicare database was created in a collaborative effort by the National 
Cancer Institute (NCI) and Centers for Medicare and Medicaid Services (CMS) to combine 
clinical information gathered by the Surveillance Epidemiology and End Results cancer registry 
program with Medicare insurance claims. The SEER program collects basic socio-demographic, 
clinical, and vital status information on incident cancer cases from multiple reporting sources. 
This information is found the Patient Entitlement and Diagnosis Summary File (PEDSF). SEER 
data used for this study consisted of 17 population-based registries, representing 26% of the U.S. 
population. An algorithm based on name, Social Security number, sex, and date of birth 
successfully matched 94% SEER cases to their Medicare claims beginning from the time of 
eligibility till death.35 This study used Medicare claims providing information regarding 
beneficiary enrollment (Denominator File), hospital inpatient claims (Med-PAR file), hospital 
outpatient claim (Outpatient file), physician office visits (NCH file), and durable medical 
equipment (DME file).36 Additionally, county and state of diagnosis were used to identify the 
area-level density of mammography screening and oncology centers from the U.S. Department 
of Health and Human Resource's 2009 Area Resource File (ARF).37    
Study Population 
 This retrospective cohort study selected American Joint Commission on Cancer (AJCC) 
staged I and II incident cases of breast cancer recorded in SEER during years 2003 to 2009, 
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among female age-eligible Medicare beneficiaries who were continuously enrolled in Medicare 
Part A and B fee-for-service programs 1 year before and after diagnosis, and were therefore age 
> 66 years at the time of diagnosis. Women were excluded if they were enrolled in a managed 
care program at any time during year before or the year after diagnosis, diagnosed at the time of 
death or upon autopsy, died within the first year of diagnosis, had end-stage renal disease, did 
not have primary surgical treatment, or surgeon specialty was missing. The final sample size was 
n = 45,981 elderly women.  
Measures 
Dependent Variable 
 The dependent variable of interest was the initial loco-regional treatment received for 
early-stage breast cancer (BCS plus RT, mastectomy, or BCS only) identified using surgical and 
radiation claims where the claim date was no later than 366 days from the date of diagnosis. 
Surgery claims were taken from the MEDPAR, NCH, and Outpatient files using ICD-9 
procedure codes 85.20 - 85.29 and CPT/HCPCS 19120, 19125, 19126, 19160, 19162, 19301, 
19302 to identify BCS (i.e. lumpectomy, partial mastectomy, segmental mastectomy) and ICD-9 
procedure codes 85.33 - 85.48 and CPT/HCPCS 19140, 19180, 19182, 19300, 19303, 19304, 
19200, 19220, 19240, 19305, 19306, 19307, 19260, 19271, 19272 to identify mastectomy. When 
multiple claims for lumpectomy were present, or when a claim for lumpectomy was followed by 
a claim for mastectomy, only the first surgical claim was used, to identify initial choice for 
definitive surgical treatment. Receipt of RT was identified from MEDPAR, NCH, Outpatient, 
and DME files using ICD-9 diagnosis codes V580,V661,V671, ICD-9 procedure codes 9220 - 
9239, and HCPCS codes 77261 - 77799, G0256, G0261, G0173, G0174, G0243, G0251, G0338-
G03340. Only the first claim was used to identify the initiation of RT.  
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Independent Variables 
 This study examined the relationship between primary treatment and year of diagnosis, 
age, health, clinical prognostic factors, oncology care resources, and socio-demographic 
characteristics. Year of diagnosis (2003 thru 2009) was included in analytic models to assess 
differences in treatment over time, considering the NCCN's change in recommended treatment 
for early-stage breast cancer among elderly women during this time period.  
Age & Health 
 Age at diagnosis (66-69, 70-74, 75-79, > 80) and health were considered together since 
declining health associated with increasing age is the reason given by NCCN guidelines for case-
by-case use of chemotherapy in women older than 70 years, and are often cited as associations 
with undertreatment among elderly women in retrospective studies. Health was measured by 
calculating patient comorbidity by applying an algorithm to Medicare claims that identifies a 
comorbid condition as the presence of at least one in-patient or two out-patient claims using 
ICD-9 diagnoses codes for each co-morbid condition. Overall comorbidity was then classified 
using the Klabunde adaption of the Charlson comorbidity index score (0, 1, > 2).38,39 Frequency 
of primary care provider (PCP) visits was also used as a proxy for health status, with a higher 
number of visits considered an indication of poorer health. An index of PCP visit intensity was 
identified by counting of number of unique PCP claim dates the year before diagnosis in the 
NCH file. PCP visits were categorized by lower and upper 50th percent median cutoff (low, 
high).  
Clinical Prognostic Factors 
 Clinical prognostic factors examined were stage at diagnosis, estrogen receptor (ER) 
tumor status (positive, negative, borderline/unknown), progesterone receptor (PR) tumor status 
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(positive, negative, borderline/unknown), and tumor grade (well differentiated, moderately 
differentiated, poorly differentiated, undifferentiated/unknown). Stage diagnosis was categorized 
using the AJCC Stage Group 6th edition (I, II).  
Oncology Care Resources 
 Patient's access to oncology care resources was measured as the area-level density of 
mammography screening and oncology treatment centers where they resided and the specialty of 
the surgeon that provided their surgical treatment. The density of area-level mammography 
screening centers and oncology treatment centers, relative to each women, was measured using 
data from the ARF and categorized in similar fashion (low, high). Surgeon specialty was 
assessed using provider specialty claims codes 02, 49 (general) and 83, 90, 91, 98 (oncology) 
from the NCH file to determine the type of surgeon seen (general only, oncology only, both).  
Socio-Demographic Characteristics 
 Demographic characteristics examined were race (white, other), education (measured by 
the 2000 Census tract survey of percent of persons age > 25 with at least 4 years college 
education) (< 15%, > 15%), and annual income (measured by the 2000 Census tract survey of 
median income by census) (< $35,000, > $35,000). Location of residence was measured as metro 
status (non-metro, metro).  
Analysis 
 Descriptive analysis was performed for all study variables. Mantel-Haenszel chi-square 
tests of location shift using modified ridit scores or table scores and Mantel-Haenszel chi-square 
tests of general association (depending on whether the independent measure was dichotomous, 
nominal, or ordinal) were used to compare significant group differences between type of primary 
treatment and independent measures, with significance set at P < .05.  The probability of 
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receiving a type of primary treatment was estimated using multinomial logistic regression 
models for each of the independent variables described above. Parameter estimates calculated in 
the regression models are presented as adjusted odds ratios (AOR) with their corresponding 95% 
confidence intervals (CI). All analysis were conducted using SAS version 9.4 software (SAS 
Institute Inc., Cary, NC).  
Results 
Population Characteristics  
 In the years of 2003 thru 2009, a total of 45,981 fee-for-service female Medicare 
beneficiaries age > 66 years were diagnosed with Stage I (62.9%) and Stage II (37.1%) breast 
cancer. The majority were treated with BCS plus RT (54.5%), while the rest received 
mastectomy (23.4%) and BCS only (22.1%) in similar proportions, and the majority saw both 
general and oncology surgeons (75.6%). In this sample 89.4% of the women were white, 70.5% 
lived in an area where greater than 15% of the population was college educated, 76.4% in an area 
with an average annual income > $35,000, and 83.3% lived in a metro area (Table 1).  
Group Differences by Treatment 
 All group differences by treatment were significant at the P < .001 level (Table 2). Rates 
of BCS plus RT for among elderly women with invasive early-stage breast cancer increased 
steadily from 52.8% in 2003 to 56.4% in 2009, while mastectomy rates decreased from 24.8% to 
21.9% in 2006 and then increased to 24.3% in 2009. Similar to mastectomy, rates of BCS 
without RT increased from 22.3% in 2003 to 24.4% in 2005, and then decreased to 19.3% in 
2009.  
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Age & Health 
 Rates of BCS plus RT were the highest among women age 66 - 69 years at 65.0% and 
lowest for those age > 80 years (38.3%). In contrast, rates of mastectomy and BCS without RT 
were the highest among those age > 80 years (27.7% & 34.0%) and lowest among women age 66 
- 69 years (20.0% & 15.0%). Women with a comorbidity score = 0 had the highest rates of BCS 
plus RT (57.5%), whereas women with a comorbidity score = 2 had the lowest rates of BCS plus 
RT 9 47.8%). Conversely, mastectomy and BCS with RT rates were the highest among women 
with a comorbidity score = 2 (25.6% & 26.6%), and the lowest for women with no comorbidity 
(22.6% & 19.9%). Possibly reflective of comorbidity, women with a low frequency of PCP visits 
had higher rates of BCS plus RT (57.0%), while women with a high frequency of PCP visits had 
higher rates of mastectomy and BCS without RT (24.0% & 24.4%).  
Clinical Prognostic Factors 
 Women with favorable prognostic clinical characteristics also had the highest rates of 
BCS plus RT. Women who were stage I, had ER and PR positive tumors, and well-differentiated 
tumors had the highest rates of BCS plus RT (61.4%, 56.7%, 57.1%, 58.8%), than women who 
were stage II, had borderline/unknown ER and PR tumors, and undifferentiated tumors (42.9%, 
39.5%, 40.8%, and 46.8%, respectively). In comparison, women with poor prognostic factors 
had the highest rates of mastectomy and BCS without RT, and the lowest rates of BCS plus RT.  
Oncology Care Resources 
 Those who resided in area with a high density of mammography screening and oncology 
treatment centers had higher rates of BCS plus RT, while those who resided in low density areas 
had higher rates of mastectomy and BCS without RT. Women who were treated by a general 
surgeon had the lowest rates o BCS plus RT (42.9%), while those treated by a oncology surgeon 
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or both types of surgeons had higher rates of BCS plus RT (59.0% & 56.2%). In contrast, women 
treated by a general surgeon had higher rates of BCS without RT (33.8%), and those who saw an 
oncology surgeon or both had similarly lower rates (19.0% & 19.4%).  
Socio-demographic Characteristics 
 Treatment differences by socio-demographic characteristics were in the expected 
direction with women who were of white race, lived in areas of greater education, higher income, 
and of metro status having higher rates of BCS plus RT (55.2%, 57.8%, 57.5%, 56.7%), than did 
women of other race, lived in less educated, lower income, and non-metro areas (48.5%, 46.6%, 
45.5%, 43.8%, respectively). Comparatively, women of other race, lived in less educated, lower 
income, and non-metro areas had the higher rates of mastectomy (28.2%, 28.6%, 28.9%, 29.8%) 
and BCS without RT (23.3%, 24.8%, 26.1%, 26.4%).  
Associations with Type of Treatment 
Age & Health  
 Compared to women who were age 66-69 years at diagnosis, all other age groups were 
more likely to be treated with mastectomy and BCS only, compared to BCS plus RT, with 
women age > 80 years being the most likely to have mastectomy vs. BCS plus RT (AOR, 2.32; 
95% CI, 2.17, 2.49) and BCS without RT vs. BCS plus RT (AOR, 3.48; 95% CI, 3.25, 3.74). 
Women with greater comorbidity were more likely to have mastectomy or BCS without RT vs. 
BCS plus RT, compared to women with a comorbidity score of "0". In fact, women with the 
highest comorbidity were 38% more likely to receive BCS without RT vs. BCS plus RT (AOR, 
1.38, 95% CI, 1.28, 1.47). Correspondingly, women with a high number of PCP visits were more 
likely to receive mastectomy (AOR, 1.05; 95% CI, 1.00, 1.08) and BCS only (AOR, 1.13; 95% 
CI, 1.06, 1.21) vs. BCS plus RT, compared to women with a low PCP visits (Table 3). 
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Clinical Prognostics Factors 
 Women diagnosed with stage II breast cancer were more than three times as likely to 
receive mastectomy (AOR, 3.18; 95% CI, 3.03, 3.34) and 1.29 times more likely (95% CI, 1.22, 
1.36) to receive BCS without RT vs. BCS plus RT, compared to women diagnosed with stage I 
breast cancer. Those with negative and borderline/unknown ER tumors were more likely to be 
treated with mastectomy or BCS without RT vs. BCS plus RT. Women with a negative and 
borderline/unknown PR status were also more likely to receive mastectomy vs. BCS plus RT. 
Finally, women with moderately, poorly, and undifferentiated/unknown tumors were more likely 
to receive mastectomy vs. BCS plus RT, as compared to women with well differentiated tumors. 
Women with undifferentiated/unknown tumors were also more likely to receive BCS without RT 
vs. BCS plus RT (AOR, 1.47; 95% CI, 1.29, 1.66), compared to women with well differentiated 
tumors.  
Oncology Care Resources 
 Women, residing in areas with a high density mammography screening centers were less 
likely to be treated with BS without vs. BCS plus RT (AOR, 0.88; 95% CI, 0.79, 0.97), than 
women residing in low density screening areas. Similarly, women residing in areas with a high 
density of oncology treatment centers (AOR, 0.87; 95% CI, 0.79, 0.96) were less likely to have 
mastectomy vs. BCS plus RT, than women residing in low density areas. Compared to women 
treated by a general surgeon only, women treated by an oncology surgeon only or treated by both 
types of surgeons were 23% (AOR, 0.77; 95% CI, 0.69, 0.86) and 24% less likely (AOR, 0.76; 
95% CI, 0.72, 0.82) to receive mastectomy vs. BCS plus RT. Likewise, women treated by an 
oncology surgeon only or treated by both types of surgeons were 47% less likely (AOR, 0.53; 
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95% CI, 0.47, 0.60) (AOR, 0.53; 95% CI, 0.50, 0.56) to receive BCS without RT vs. BCS plus 
RT, than those treated by a general surgeon only. 
Socio-Demographic Characteristics 
 Women of other races were 30% and 27% more likely to have mastectomy (AOR, 1.30; 
95% CI, 1.20, 1.40) or BCS without RT vs. BCS plus RT (AOR, 1.24; 95% CI, 1.14, 1.34), 
compared to women of white race. In contrast, women living in an area where > 15% of the 
population was college educated were less likely to receive mastectomy or BCS without RT vs. 
BCS plus RT, than women living in an area that was < 15% college educated. Women residing 
in areas with an average annual income > $35,000 were also less likely to receive mastectomy or 
BCS without RT vs. BCS plus RT, than women residing in areas with an average annual income 
< $35,000. Lastly, women residing in metro areas were 30% and 27% less likely to receive 
mastectomy (AOR, 0.70; 95% CI, 0.65, 0.75) or BCS without RT vs. BCS plus RT (AOR, 0.73; 
95% CI, 0.68, 0.79), compared to women residing in non-metro areas.  
Discussion 
 Among elderly women diagnosed with invasive early-stage breast cancer in 2003 thru 
2009, 55% received BCS plus RT as their initial loco-regional treatment, while 23% had 
mastectomy, and 22% had BCS without RT. Somewhat different rates were found by DeSantis 
and colleagues (2014) who examined patterns of treatment for early-stage breast cancer among 
women of all ages from the National Cancer Data Base. They reported that 50% of women 
received BCS plus RT, 36% had mastectomy, and 9% had BCS without RT. 40 An international 
comparison of treatment for early-stage breast cancer limited to women age > 65 years, reported 
that among US women sampled from 1995 to 2005 SEER-Medicare data, 30% had BCS plus 
RT, 41% had mastectomy, and 19% had BCS without RT. 41 While these rates of BCS without 
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RT are similar to those found by this study, the rates of BCS with RT are lower and mastectomy 
are higher. This discrepancy in findings is likely due to differences in study design. Whereas, this 
study looked at initial definitive surgery, Kiderlan and colleagues (2011) classified surgery as 
mastectomy if a mastectomy was recorded at any time following BCS. The higher rates of BCS 
plus RT and lower rates of mastectomy found by this study suggest that a greater number of 
older women with early-stage breast cancer prefer BCS plus RT vs. mastectomy as their first 
choice of surgery, but a substantial number eventually require mastectomy. In concurrence with 
studies that noted a increase in rates of BCS without RT following the publication of the CALGB 
C9343 trial study results and subsequent NCCN guideline update, this study also found that from 
2004 to 2006 elderly women with early-stage breast cancer were more likely to have BCS only 
than BCS with RT, but after 2006 women were just as likely to receive BCS without RT as they 
were to have BCS with RT. 22,24,30 This increase in BCS without RT from 2004 to 2006 mostly 
likely reflects a change in oncology practice immediately following the guideline change, but 
this increasing trend may have reversed after 2006 amidst the ensuing controversy over omission 
of RT for some elderly women.    
Age & Health 
 In accordance with findings of previous studies, this study found that elderly women with 
breast cancer had an increased chance of being receiving BCS without RT or mastectomy, 
compared to BCS plus RT. Lack of RT following BCS among elderly women has been strongly 
linked to increasing age, irrespective of risk factors.22,42 In fact, this study found women who 
were age 80 years and older to be more than 3 times likely to not receive RT, as women age 66-
69 years. Increasing age is commonly cited as the main reason for omission of RT among elderly 
women due to greater comorbidity, intolerance to RT toxicity, adverse effects, and shorter life-
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expectancy.42-46 Likewise, elderly women may be more likely to receive mastectomy for the 
same reasons RT is omitted following BCS, to avoid any adverse effects of RT or possible 
intolerance to toxicity from RT due to greater comorbidity and a general frailty associated with 
old age. However, not all experts agree that RT is more toxic or less tolerable among elderly 
women, than younger women. In fact, several studies have found RT to be well-tolerated among 
elderly women, and determined that it did not increase the risk of myocardial infarction or 
cardiovascular disease (CVD).47-50  
 Declining health is a burden commonly experienced by the elderly population, and 
presents additional challenges for tolerating cancer treatments, particularly RT. Accordingly, this 
study found that elderly women with 2 or more comorbid conditions were ~ 40% more likely to 
not receive RT following BCS and 14% more likely to be treated with mastectomy. The 
association between women with greater comorbidity being more likely to have mastectomy or 
BCS without RT, may explain why women with a high frequency of PCP visits were more likely 
to be treated with mastectomy or BCS without RT. However, over 20% of women with a 
comorbidity score = 0 did not receive RT following BCS and 23% were treated with 
mastectomy, suggesting that increased comorbidity does not always predict type of treatment. 
This may reflect a preference for mastectomy, due to a desire to avoid necessary RT.  
Clinical Prognostic Factors 
 Women diagnosed with stage II breast cancer were 30% more likely to not receive RT, 
compared to women with stage I breast cancer, a finding that may also be explained by older 
age. Declines in routine mammography screening are commonly observed among elderly 
women, particularly the oldest of the old. A decline in mammography screening among elderly 
women occurs due to decreased perceived risk of breast cancer, lack of physician 
49 
 
recommendation, competing health demands, life-expectancy and potential for more harm than 
benefit from screening, as indicated by the latest United States Preventive Services Task Force 
(USPSTF) recommendation on mammography screening for women age > 74 years. 51-56 This 
decrease in screening can, in turn, result in a later stage diagnosis, at which point they are already 
less likely to receive RT following BCS due to older age. Similarly, women diagnosed at stage II 
vs. I, were over three times more likely to undergo mastectomy. While the likelihood of 
mastectomy intuitively increases with increasing stage, it may be that older women are even 
more likely to have mastectomy at a later stage when BCS plus RT is an option, in order to avoid 
the toxic and adverse effects of RT and the burden of multiple treatments with RT.   
Other clinical prognostic factors were associated with receipt of mastectomy in the expected 
direction, such that women with negative and borderline/unknown ER and PR tumors statuses, 
and less differentiated tumor grades had an increased likelihood for mastectomy.8,31 These 
clinical characteristics are associated with poorer prognosis among women with breast cancer 
and are often more challenging to treat with BCS plus RT. 18 
Oncology Care Resources 
 Women who were treated by an oncology surgeon or an oncology surgeon and a general 
surgeon, opposed to a general surgeon only, were 26% to 47% less likely to be treated with 
mastectomy or BCS without RT, compared to BCS with RT. Surgeon characteristics, such as 
gender, country of training, year or training, and case-load have be linked to type surgery 
received for early-stage breast cancer.19, 33 Evidence suggest that surgeon specialty is also 
associated with more advanced methods of breast cancer treatment.57 Being treated by both an 
oncology and general surgeon may be an indication of case-load sharing and/or division of 
services within high volume treatment centers, which are commonly associated with better 
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treatment practices. 58 Moreover, those who have an oncology surgeon as a part of the oncology 
treatment care may have shorter travel distances to access specialty care. In fact, women residing 
in areas with a high density of mammography screening centers were less likely to have BCS 
without RT, while women residing in areas with a high density of oncology treatment centers 
were less likely to have mastectomy, compared to BCS plus RT. These finding reflect the benefit 
of residing closer to available oncology care resources. Women who have shorter driving 
distances to treatment centers may be more likely to choose a treatment such as BCS plus RT, 
that required multiple trips for repeated treatments. 59   
Socio-Demographic Characteristics 
 Vulnerable socio-demographic and unfavorable clinical characteristics have long been 
established as factors associated with health disparities in general and in breast cancer treatment. 
19,20,22,23 Accordingly, findings from this study confirmed these associations. Women of non-
white race, residing in areas that were non-metro, less educated, and low income, were less more 
likely to be treated with mastectomy or not have RT following BCS. Women with these 
characteristics may not receive RT following BCS or undergo mastectomy for many of the same 
reasons. This reasons include a lack of access to specialty care, high quality hospitals, greater 
travel distances to oncology care, and fewer financial resources, even after accounting for less 
favorable tumor characteristics observed in African American and Hispanic women.59-62 What is 
more, increased mastectomy rates among various races and ethnicities of non-white women may 
be associated with country of birth, mastery of the English language, navigation of the healthcare 
system, and awareness of available treatment options.63   
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Limitations & Strengths 
 Several limitations should be kept in mind when interpreting the results of this study. 
First, many women have multiple surgical claims for lumpectomies, mastectomies, or 
lumpectomies and mastectomies in various combinations. This study examined only the first 
surgical claim for purposes of continuity and capturing the initial intended primary treatment. 
This method does not capture the total number of mastectomies and may overestimate the 
number of lumpectomies without radiation, due to initial treatment failure. While this study 
examined the relationships between type of treatment and a range of covariates, it was unable to 
measure how changing attitudes toward mastectomy were associated with type of primary 
treatment. Moreover, completion of radiation therapy was not assessed, only the initiation of 
therapy. Additionally, several of socio-demographic characteristics examined were aggregate 
census level measures, rather than individual level measures. Finally, the SEER individuals 
within the SEER database have been found to be of higher income, and higher concentrations of 
racial and ethnic minorities, as compared to the U.S. population.64  
 Despite these limitations, this study holds several strengths that impart credibility to its 
findings. To the authors’ best knowledge, this is the first study to examine the initial choice of 
loco-regional treatment for early-stage breast cancer among elderly women. This study examined 
treatment patterns during times before and after a change in treatment guideline 
recommendations, pertaining to necessity of RT among a subset of women in this population. 
Concern has been raised whether this guideline change influenced receipt of RT among women 
whom RT would have been recommended. A wide range of covariates were examined in relation 
to type of treatment that included socio-demographic, access, health, clinical, and physician 
characteristics. Despite containing slightly greater proportions of affluent and minority 
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individuals, SEER is widely accepted as representative of the U.S. population, making these 
results generalizable to the greater population of elderly women with invasive early-stage breast 
cancer insured by Medicare.     
Significance & Conclusions 
 In conclusion, more than half of older women with early-stage breast cancer have BCS 
plus RT as their initial loco-regional treatment, while fewer than one-fourth have BCS without 
RT. However, a substantial number may eventually require mastectomy due to treatment failure.  
Women of increasing age, comorbidity, and stage were the most likely to have mastectomy or 
BCS without RT, possibly reflecting a reluctance to aggressively treat older women with breast 
cancer, thereby increasing their risk of recurrence and mortality. Current study findings also 
highlight the importance of access to oncology care resources on receipt of initial type of 
treatment. These findings suggest that many elderly women are being undertreated for invasive 
early-stage breast cancer, and therefore at increased risk for breast cancer mortality and 
recurrence. Aggressive treatment, including adjuvant therapy should be recommended to all 
elderly women with early-stage breast who are healthy enough and choose to do so. Some 
women may require additional patient support resources such as patient education and navigation 
to ensure equity of care.  
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Table 1 
Characteristics of Elderly Women with Early-Stage Breast Cancer  
SEER -Medicare, 2003-2009 
   
N 
 
% 
  All     45,981   100.0     
Treatment 
      
 
BCS+Radiation 
 
25067 
 
54.5 
  
 
Mastectomy 
 
10768 
 
23.4 
  
 
BCS only 
 
10146 
 
22.1 
  Year of Diagnosis 
      
 
2003 
 
6667 
 
14.5 
  
 
2004 
 
6527 
 
14.2 
  
 
2005 
 
6418 
 
14.0 
  
 
2006 
 
6494 
 
14.1 
  
 
2007 
 
6564 
 
14.3 
  
 
2008 
 
6629 
 
14.4 
  
 
2009 
 
6682 
 
14.5 
  Age & Health  
Age at Diagnosis 
      
 
66-69 
 
10331 
 
22.5 
  
 
70-74 
 
11741 
 
25.5 
  
 
75-79 
 
10731 
 
23.3 
  
 
> 80 
 
13178 
 
28.7 
  Comorbidity Score 
      
 
0 
 
26061 
 
56.7 
  
 
1 
 
12439 
 
27.1 
  
 
> 2 
 
7481 
 
16.3 
  PCP Visits 
      
 
Low 
 
24834 
 
54.0 
  
 
High 
 
21147 
 
46.0 
  Clinical Prognostic Factors 
Stage at Diagnosis 
      
 
I 
 
28931 
 
62.9 
  
 
II 
 
17050 
 
37.1 
  ER Status 
      
 
Positive 
 
36364 
 
79.1 
  
 
Negative 
 
6301 
 
13.7 
  
 
Borderline/Unknown 
 
3316 
 
7.2 
  PR Status 
      
 
Positive 
 
30504 
 
66.3 
  
 
Negative 
 
11766 
 
25.6 
  
 
Borderline/Unknown 
 
3711 
 
8.1 
  BCS = breast-conserving surgery 
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Table 1 
Characteristics of Elderly Women with Early-Stage Breast Cancer  
SEER -Medicare, 2003-2009 
   
N 
 
% 
  All     45,981   100.0     
Tumor Grade 
      
 
Well Differentiated 
 
12118 
 
26.4 
  
 
Moderately Differentiated 
 
20046 
 
43.6 
  
 
Poorly Differentiated 
 
10831 
 
23.6 
  
 
Undifferentiated/Unknown 
 
2986 
 
6.5 
  Oncology Care Resources 
Mammography Screening Centers 
      
 
Low 
 
23789 
 
51.7 
  
 
High 
 
22192 
 
48.3 
  Oncology Treatment Centers 
      
 
Low 
 
25761 
 
56.0 
  
 
High 
 
20220 
 
44.0 
  Type of Surgeon Seen 
      
 
General Only 
 
8555 
 
18.6 
  
 
Oncology Only 
 
2644 
 
5.8 
  
 
Both 
 
34782 
 
75.6 
  Socio-Demographic Characteristics 
Race 
       
 
White 
 
23441 
 
89.4 
  
 
Other 
 
4891 
 
10.6 
  Education 
      
 
< 15% college degree 
 
13557 
 
29.5 
  
 
> 15%  college degree 
 
32424 
 
70.5 
  Annual Income 
      
 
< $35,000 
 
10853 
 
23.6 
  
 
> $35,000 
 
35128 
 
76.4 
  Metro Status 
      
 
Non-metro 
 
7686 
 
16.7 
    Metro   38295   83.3     
BCS = breast-conserving surgery 
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Table 2 
Comparison of Initial Loco-Regional Treatment Among Elderly Women with Early-Stage Breast Cancer  
SEER-Medicare, 2003-2009 
  
BCS+Radiation Mastectomy BCS Only   
  
N % 
 
N % 
 
N % 
 
p-value 
All 25067 54.5  10768 23.4  10146 22.1    
Year of Diagnosisb 
         
<0.001*** 
 
2003 3523 52.8 
 
1656 24.8 
 
1488 22.3 
  
 
2004 3503 53.7 
 
1437 22.0 
 
1587 24.3 
  
 
2005 3389 52.8 
 
1462 22.8 
 
1567 24.4 
  
 
2006 3572 55.0 
 
1419 21.9 
 
1503 23.1 
  
 
2007 3637 55.4 
 
1560 23.8 
 
1367 20.8 
  
 
2008 3676 55.5 
 
1610 24.3 
 
1343 20.3 
  
 
2009 3767 56.4 
 
1624 24.3 
 
1291 19.3 
  Age & Health 
Age at Diagnosisc 
         
<0.001*** 
 
66-69 6714 65.0 
 
2067 20.0 
 
1550 15.0 
  
 
70-74 7266 61.9 
 
2524 21.5 
 
1951 16.6 
  
 
75-79 6035 56.2 
 
2525 23.5 
 
2171 20.2 
  
 
> 80 5052 38.3 
 
3652 27.7 
 
4474 34.0 
  Comorbidity Scorec 
         
<0.001***
 
0 14986 57.5 
 
5892 22.6 
 
5183 19.9 
  
 
1 6504 52.3 
 
2959 23.8 
 
2976 23.9 
  
 
> 2 3577 47.8 
 
1917 25.6 
 
1987 26.6 
  PCP Visitsa 
         
<0.001***
 
Low 14157 57.0 
 
5685 22.9 
 
4992 20.1 
  
 
High 10910 51.6 
 
5083 24.0 
 
5154 24.4 
  Clinical Prognostic Factors 
Stage at Diagnosisa 
         
<0.001*** 
 
I 17759 61.4 
 
4517 15.6 
 
6655 23.0 
  
 
II 7308 42.9 
 
6251 36.7 
 
3491 20.5 
  ER Statusa 
         
<0.001***
 
Positive 20599 56.7 
 
7866 21.6 
 
7899 21.7 
  
 
Negative 3158 50.1 
 
1912 30.3 
 
1231 19.5 
  
 
Borderline/Unknown 1310 39.5 
 
990 29.9 
 
1016 30.6 
  PR Statusa 
         
<0.001***
 
Positive 17405 57.1 
 
6461 21.2 
 
6638 21.8 
  
 
Negative 6148 52.3 
 
3221 27.4 
 
2397 20.4 
  
 
Borderline/Unknown 1514 40.8 
 
1086 29.3 
 
1111 29.9 
  a = cmh chi square test of general association 
     b = cmh chi square test of location shift using table scores 
     c = cmh chi square test of location shift using modified ridit scores 
     BCS = breast conserving surgery 
     * p < 0.05; ** p < 0.01; *** p < 0.001 
     
      
           
           Tumor Gradea 
         
<0.001***
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Table 2 
Comparison of Initial Loco-Regional Treatment Among Elderly Women with Early-Stage Breast Cancer  
SEER-Medicare, 2003-2009 
  
BCS+Radiation Mastectomy BCS Only   
  
N % 
 
N % 
 
N % 
 
p-value 
All 25067 54.5  10768 23.4  10146 22.1    
 
Well Differentiated 7128 58.8 
 
2197 18.1 
 
2793 23.1 
  
 
Moderately Differentiated 11129 55.5 
 
4606 23.0 
 
4311 21.5 
  
 
Poorly Differentiated 5414 50.0 
 
3267 30.2 
 
2150 19.9 
  
 
Undifferentiated/Unknown 1396 46.8 
 
698 23.4 
 
892 29.9 
  Oncology Care Resources 
Mammography Screening Centersa 
      
<0.001*** 
 
Low 12276 51.6 
 
6018 25.3 
 
5495 23.1 
  
 
High 12791 57.6 
 
4750 21.4 
 
4651 21.0 
  Oncology Treatment Centersa 
       
<0.001***
 
Low 13392 52.0 
 
6492 25.2 
 
5877 22.8 
  
 
High 11675 57.7 
 
4276 21.2 
 
4269 21.1 
  Type of Surgeon Seena 
        
<0.001***
 
General Only 3636 42.9 
 
2031 23.7 
 
2888 33.8 
  
 
Oncology Only 1536 59.0 
 
607 23.0 
 
501 19.0 
  
 
Both 19895 56.2 
 
8130 23.4 
 
6757 19.4 
  Socio-Demographic Characteristics 
Racea 
         
<0.001*** 
 
White 22696 55.2 
 
9389 22.9 
 
9005 21.9 
  
 
Other 2371 48.5 
 
1379 28.2 
 
1141 23.3 
  Educationa 
         
<0.001***
 
< 15% college degree 6318 46.6 
 
3874 28.6 
 
3365 24.8 
  
 
> 15%  college degree 18749 57.8 
 
6894 21.3 
 
6781 20.9 
  Annual Incomea 
         
<0.001***
 
< $35,000 4878 45.0 
 
3141 28.9 
 
2834 26.1 
  
 
> $35,000 20189 57.5 
 
7627 21.7 
 
7312 20.8 
  Metro Statusa 
         
<0.001***
 
Non-metro 3367 43.8 
 
2289 29.8 
 
2030 26.4 
   Metro 21700 56.7  8479 22.1  8116 21.2   
a = cmh chi square test of general association 
      b = cmh chi square test of location shift using table scores 
    c = cmh chi square test of location shift using modified ridit scores 
   BCS = breast conserving surgery 
        * p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 3 
Associations with Initial Loco-Regional Treatment Among Elderly Women with Early-Stage Breast 
Cancer  
SEER-Medicare, 2003-2009 
    Treatment 
  
Mastectomy vs.BCS + RT BCS Only vs. BCS + RT 
  AOR 95% CI Sig. AOR 95% CI Sig. 
Year of Diagnosis 
      
 
2003 1.00 ― 
 
1.00 ― 
 
 
2004 0.95 [0.87,1.04] 
 
1.16 [1.06,1.26] ** 
 
2005 1.01 [0.92,1.10] 
 
1.22 [1.11,1.33] *** 
 
2006 0.95 [0.87,1.04] 
 
1.13 [1.04,1.24] ** 
 
2007 1.03 [0.95,1.13] 
 
1.01 [0.92,1.11] 
 
 
2008 1.08 [0.99,1.18] 
 
1.01 [0.92,1.11] 
 
 
2009 1.08 [0.99,1.18] 
 
0.95 [0.87,1.05] 
 Age & Health 
Age at Diagnosis 
      
 
66-69 1.00 ― 
 
1.00 ― 
 
 
70-74 1.12 [1.05,1.20] ** 1.12 [1.04,1.21] ** 
 
75-79 1.39 [1.30,1.49] *** 1.48 [1.38,1.60] *** 
 
> 80 2.32 [2.17,2.49] *** 3.48 [3.25,3.74] *** 
Comorbidity Score 
      
 
0 1.00 ― 
 
1.00 ― 
 
 
1 1.07 [1.01,1.14] * 1.22 [1.15,1.29] *** 
 
> 2 1.14 [1.06,1.22] *** 1.38 [1.28,1.47] *** 
PCP Visits 
      
 
Low 1.00 ― 
 
1.00 ― 
 
 
High 1.05 [1.00,1.11] * 1.11 [1.05,1.16] *** 
Clinical Prognostic Factors 
Stage at Diagnosis 
      
 
I 1.00 ― 
 
1.00 ― 
 
 
II 3.18 [3.03,3.34] *** 1.29 [1.22,1.36] *** 
ER Status 
      
 
Positive 1.00 ― 
 
1.00 ― 
 
 
Negative 1.18 [1.08,1.29] *** 1.02 [0.92,1.12] 
 
 
Borderline/Unknown 1.57 [1.25,1.97] *** 1.48 [1.18,1.86] *** 
PR Status 
      
 
Positive 1.00 ― 
 
1.00 ― 
 
 
Negative 1.13 [1.05,1.21] *** 1.00 [0.93,1.08] 
 
 
Borderline/Unknown 1.18 [0.95,1.47] 
 
1.18 [0.95,1.47] 
 Tumor Grade 
      
 
Well Differentiated 1.00 ― 
 
1.00 ― 
 
 
Moderately Differentiated 1.12 [1.05,1.19] *** 0.96 [0.90,1.02] 
 
 
Poorly Differentiated 1.26 [1.17,1.35] *** 0.95 [0.88,1.02] 
 
 
Undifferentiated/Unknown 1.21 [1.08,1.35] *** 1.42 [1.29,1.57] *** 
BCS = breast-conserving surgery 
* p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 3 
Associations with Initial Loco-Regional Treatment Among Elderly Women with Early-Stage Breast 
Cancer  
SEER-Medicare, 2003-2009 
    Treatment 
  
Mastectomy vs.BCS + RT BCS Only vs. BCS + RT 
  AOR 95% CI Sig. AOR 95% CI Sig. 
Oncology Care Resources 
Mammography Screening Centers 
     
 
Low 1.00 ― 
 
1.00 ― 
 
 
High 0.98 [0.89,1.08] 
 
0.88 [0.79,0.97] ** 
Oncology Treatment Centers 
     
 
Low 1.00 ― 
 
1.00 ― 
 
 
High 0.87 [0.79,0.96] ** 1.05 [0.95,1.16] 
 Type of Surgeon Seen 
      
 
General Only 1.00 ― 
 
1.00 ― 
 
 
Oncology Only 0.77 [0.69,0.86] *** 0.53 [0.47,0.60] *** 
 
Both 0.76 [0.72,0.82] *** 0.53 [0.50,0.56] *** 
Socio-Demographic Characteristics 
Race 
      
 
White 1.00 ― 
 
1.00 ― 
 
 
Other 1.30 [1.20,1.40] *** 1.24 [1.14,1.34] *** 
Education 
      
 
< 15% college degree 1.00 ― 
 
1.00 ― 
 
 
> 15%  college degree 0.75 [0.70,0.79] *** 0.82 [0.77,0.87] *** 
Annual Income 
      
 
< $35,000 1.00 ― 
 
1.00 ― 
 
 
> $35,000 0.87 [0.82,0.93] *** 0.84 [0.78,0.89] *** 
Metro Status 
      
 
Non-metro 1.00 ― 
 
1.00 ― 
  Metro 0.70 [0.65,0.75] *** 0.73 [0.68,0.79] *** 
BCS = breast-conserving surgery 
     * p < 0.05; ** p < 0.01; *** p < 0.001 
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Abstract 
Objectives: Evidenced-based guidelines for the treatment of breast cancer have been put forth 
by agencies such as the National Comprehensive Cancer Network (NCCN). Yet, even with 
specific guidelines, gaps in the receipt of appropriate care exist, particularly among the aged 
population. This study examined factors associated with receipt of guideline-concordant care 
(GCC) vs. guideline-discordant care (GDC) and receipt of distinct treatments and testing among 
elderly U.S. women with breast cancer. 
Methods: A sample of 27,883 women age > 66 with pathologically staged I, II, and III breast 
cancer diagnosed from 2004 to 2009 were selected from the SEER-Medicare linked dataset. 
Algorithms that considered clinical cancer characteristics and the appropriate course of care as 
per guidelines vs. the actual care received, were used to determine receipt of GCC (yes vs. no). 
Logistic regression models were used to examine the relationship between GCC and independent 
variables that included of age, health, clinical prognostic factors, oncology care resources, and 
socio-demographic characteristics. Age was dichotomized to estimate the likelihood for receipt 
of specific tests and treatments between younger (age 66-69) and older (age > 70) women. 
Results: Less than 34% of elderly women received guideline appropriate care. Women of non-
white race (AOR, 0.81; 95% CI, 0.73, 0.89), increasing age (> 80 vs. 66-69) (AOR, 0.19; 95% 
CI, 0.17, 0.21), increasing comorbidity (> 2 vs. 0) (AOR, 0.71; 95% CI, 0.65, 0.78), and 
increasing stage (II vs. I) (AOR, 0.46; 95% CI, 0.40, 0.54) were less likely to receive GCC. 
Women with node negative cancer, larger tumors, poorly differentiated tumors, negative and 
borderline/unknown tumor receptors were also less likely to receive appropriate care. Yet, the 
likelihood of appropriate care was increased for women who were treated by an oncology 
surgeon (AOR, 1.84; 95% CI, 1.67, 2.03) or both a general and oncology surgeon vs. general 
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surgeon only (AOR, 1.47; 95% CI, 1.26, 1.72). Compared to women age 66-69 years, those age 
> 70 years were more likely to have mastectomy (AOR, 1.31; 95% CI, 1.23, 1.39) or have any 
definitive surgery (AOR, 2.51; 95% CI, 1.76, 3.58), but less likely to have GCC (AOR, 0.51; 
95% CI, 0.48, 0.54), estrogen-receptor status testing (AOR, 0.80; 95% CI, 0.70, 0.92), 
progesterone-receptor status testing (AOR, 0.78; 95% CI, 0.68, 0.89), breast-conserving surgery 
(AOR, 0.76; 95% CI, 0.71, 0.81), radiation therapy (AOR, 0.63; 95% CI, 0.60, 0.67), 
chemotherapy (AOR, 0.30; 95%CI, 0.28, 0.32), and appropriate time to chemotherapy (AOR, 
0.78; 95% CI, 0.68, 0.89). 
Conclusions:  Irrespective of guidelines, younger, less complex patients with greater resources 
are more likely to receive GCC. Better efforts should be made for all elderly women with breast 
cancer who are healthy enough to receive the aggressive standard of care.  
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Introduction 
 Breast cancer is the most commonly diagnosed and prevalent cancer among women. As 
of 2012, over 2.9 million women living with breast cancer in the U.S., and in 2015, an estimated 
231,840 incident cases and 40,730 deaths with be attributable to invasive breast cancer (IBC).1,2 
However, with early detection from routine screening and appropriate treatment according to 
recommended guidelines, prognosis is relatively good with an 89% overall 5-year survival rate.2  
Based on the results of clinical trials, evidenced-based recommended guidelines for the treatment 
of non-metastatic breast cancer have been put forth by the National Comprehensive Cancer 
Network (NCCN) to direct the course of breast cancer care and treatment according to cancer 
and patient characteristics.3 Tumor size, spread of cancer to lymph nodes and the number of 
nodes affected and tumor hormone receptor status determine the type of primary surgery (breast 
conserving surgery or mastectomy) that a patient is eligible for, and if radiation therapy (RT), 
chemotherapy, and/or adjuvant hormone therapy (AHT) is recommended. Surgery choice will 
also determine recommendation for receipt of adjuvant treatments. Moreover, all women with 
IBC should have their lymph nodes tested for spread of disease and biopsies of breast tissue 
should be tested to establish whether the tumor is estrogen receptor (ER) positive, progesterone 
receptor (PR) positive, and/or HER2/neu positive or negative. Additional quality measures for 
breast cancer treatment jointly published by the American Society of Clinical Oncology (ASCO) 
and the NCCN suggest that AHT should begin within the first year of diagnosis, RT should 
begin within the first year of diagnosis, and chemotherapy should begin within 120 days of 
diagnosis.4  
 Despite the existence of evidence-based treatment guidelines, many women with breast 
cancer still do not receive appropriate, or guideline-concordant care (GCC). As with other health 
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disparities, access to specialty care and vulnerable socio-demographic characteristics such as 
being of non-white race, publicly insured or uninsured, residing in areas of low income, low 
education, and/or locations, having greater driving distances to treatment centers, and even 
surgeon characteristics have been associated with guideline-discordant care (GDC) for breast 
cancer.5-11 In addition to these factors, poor clinical characteristics including unknown receptor 
status and tumor grade have also been linked with GDC.6,9,11 The most commonly reported 
causes for GDC is the omission of lymph node testing, RT following breast-conserving surgery 
(BCS), RT following mastectomy, chemotherapy, and adjuvant hormone therapy.5,6,8-12 An 
unknown tumor receptor status may also be an indication that the test for receptor status was not 
conducted.13  
 In addition to these associations, older age and its relationship with increased 
comorbidity and frailty, and thereby a possible intolerance and/or toxicity to RT or 
chemotherapy have been strongly associated with GDC among elderly women with breast 
cancer.5,6,8-11,14-17 However, the belief that RT and/or chemotherapy is less tolerable or more 
toxic in older women compared to younger women, is not universal. In fact, many studies have 
shown RT and chemotherapy to be well-tolerated and safe among the elderly.18-21 Guidelines do 
not make recommendations for or against chemotherapy in women age > 70 years, but suggest 
chemotherapy be given on a case-by-case basis, considering comorbidity.22 Moreover, NCCN 
treatment guidelines make an exception for the omission of RT following BCS among a specific 
group of women meeting the following requirements: age > 70 years, tumors < 2 cm, node 
negative, estrogen-receptor positive, and receiving adjuvant hormone therapy.23 This change to 
recommended treatment guidelines was made after the 2004 publication of the Cancer and 
Leukemia Group B (CALGB) C9343 trial study results that demonstrated similar 5-year survival 
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between women with these clinical characteristics who received BCS plus RT or BCS alone. 
Since then, rates of RT following BCS have decreased, regardless of clinical factors or the 
increased risk for breast cancer mortality and recurrence among elderly women not receiving RT 
after BCS.24-26 This trend raises the questions as to what other recommended care are they not 
receiving and to how often do elderly women with breast cancer receive GCC? 
Statement of the Problem 
 Few studies have comprehensively studied receipt of GCC among women with breast 
cancer. One study by Kimmick and colleagues (2014) comprehensively examined GCC in 
relation to comorbidity among women of all ages diagnosed with stage 0 thru stage III, but their 
sample was limited to women diagnosed in 2004 from seven cancer registries. 27 Other studies 
investigating GCC have done so in piecemeal fashion, either looking at GCC among women 
with early-stage breast cancer only, specific racial/ethnic populations, limited  loco-regional 
treatment, systematic treatment, using small study samples, older data, and/or allowed for the 
omission of RT or chemotherapy among women age > 70 years from GCC criteria. 5, 13,27-31 To 
address gaps in the literature and build upon existing knowledge of GCC among elderly women, 
this study will comprehensively examine receipt of hormone receptor and lymph node status 
testing, definitive surgery, RT, chemotherapy, and timeliness of chemotherapy among women 
age > 66 years diagnosed with stage I, II, III breast cancer from 2004 to 2009 using a large, 
nationally representative database. In order to determine to what degree older populations of 
women with breast cancer receive care according to recommended treatment guidelines as they 
would otherwise be applied to younger age groups, this study included treatment with RT and 
chemotherapy for women age > 70 years with clinical indications in the definition of GCC.  
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 Bearing these thoughts in mind, the purpose of this study was to determine to what 
degree elderly women with breast cancer receive GCC, factors associated with receipt of GCC, 
and how likely women age > 70 vs. age 66-69 years are to receive specific tests and treatments.  
Methods 
Data 
 The SEER-Medicare database was created in a collaborative effort by the National 
Cancer Institute (NCI) and Centers for Medicare and Medicaid Services (CMS) to combine 
clinical information gathered by the Surveillance Epidemiology and End Results cancer registry 
program with Medicare insurance claims. The SEER program collects basic socio-demographic, 
clinical, and vital status information on incident cancer cases from multiple reporting sources. 
This information is found the Patient Entitlement and Diagnosis Summary File (PEDSF). SEER 
data used for this study consisted of 17 population-based registries, representing 26% of the U.S. 
population. An algorithm based on name, Social Security number, sex, and date of birth 
successfully matched 94% SEER cases to their Medicare claims beginning from the time of 
eligibility till death.32 This study used Medicare claims providing information regarding 
beneficiary enrollment (Denominator File), hospital inpatient claims (Med-PAR file), hospital 
outpatient claim (Outpatient file), physician office visits (NCH file), and durable medical 
equipment (DME file).33  Additionally, county and state of diagnosis were used to identify the 
area-level density of mammography screening and oncology centers from the U.S. Department 
of Health and Human Resource's 2009 Area Resource File (ARF).34    
Study Population 
 This retrospective cohort study selected American Joint Commission on Cancer (AJCC) 
staged I, II, and III incident cases of breast cancer recorded in SEER during years 2004 to 2009, 
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among female age-eligible Medicare beneficiaries who were continuously enrolled in Medicare 
Part A and B fee-for-service programs 1 year before and after diagnosis, and were therefore age 
> 66 years at the time of diagnosis. Women were excluded if they were enrolled in a managed 
care program at any time during year before to the year after diagnosis, diagnosed at the time of 
death or upon autopsy, died within the first year of diagnosis, had end-stage renal disease, did 
not have primary surgical treatment, or if surgeon specialty or tumor size was missing. The final 
sample size was n = 27,883 elderly women.  
Measures 
Dependent Variables 
 The primary outcome of interest was receipt of GCC vs. GDC. This was determined by 
comparing the correct course of care according to tumor size and nodal status of each women as 
per NCCN evidence-based clinical practice guidelines, to the actual care received (Table 1.) Care 
was also determined to be guideline-concordant if chemotherapy was initiated within 120 days of 
diagnosis, when chemotherapy was indicated, as per ASCO/NCCN quality measures, and if 
lymph node invasion, and hormone receptor statuses were tested. Although ASCO/NCCN 
quality measures indicate RT should be initiated within 1 year of diagnosis, this was not 
considered in the determination of GCC, as all claims used for this study were made within 1 
year after diagnosis. For this study purpose, being of age > 70 years was not considered a 
determining factor for GCC vs. GDC when RT or chemotherapy was indicated, in order to 
determine the extent that younger and older women receive differential care.  
 The secondary outcome of interest was the receipt of individual treatments and tests. 
These included lymph node testing (yes or no), ER status testing (yes or no), PR status testing 
(yes or no), had any primary surgery (BCS or mastectomy) (yes or no), had BCS (yes or no), had 
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mastectomy (yes or no), had RT (yes or no), had chemotherapy (yes or no), and chemotherapy 
was initiated within 120 day of diagnosis (yes, no, or not applicable). For women who had BCS 
and mastectomy, both types of surgery were included in analysis, with totals from both category 
adding to greater than 100%. Hormone receptor status testing was assessed using the status given 
by the ER status and PR status variable in the Patient Entitlement and Diagnosis Summary File 
(PEDSF) file. If the status was listed as "positive", "negative", or "borderline", then the receptor 
status was determined to have been tested. If the status was listed as "unknown", then it was 
considered as not having been tested. Lymph node testing was defined by the claims codes for 
axillary lymph node dissection (ALND) or sentinel lymph node (SNB) biopsy. Surgical, RT, and 
chemotherapy treatments were determined using International Classification of Diseases, 9th 
Revision (ICD-9) diagnostic and procedure, Healthcare Common Procedure Coding System 
(HCPCS) and Current Procedural Terminology (CPT) codes found in Medicare Provider and 
Analysis Review (MEDPAR), Outpatient, and Physician/Supplier Data File data files. See 
Appendix 1.  
Independent Variables 
 Independent variables examined in this study encompassed year of diagnosis, age, health, 
clinical prognostic factors, specific tests and treatments, oncology care resources, and socio-
demographic characteristics. Age at diagnosis (66-69, 70-74, 75-79, > 80) and health were 
considered together since declining health associated with increasing age is the reason given by 
NCCN guidelines for case-by-case use of chemotherapy in women older than 70 years, and are 
often cited as associations with undertreatment among elderly women in retrospective studies. 
Age was also dichotomized (66-69 or > 70) to test for differences between younger and older 
elderly women. Health was measured by calculating patient comorbidity by applying an 
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algorithm to Medicare claims that identifies a comorbid condition as the presence of at least one 
in-patient or two out-patient claims using ICD-9 diagnoses codes for each co-morbid condition. 
Overall comorbidity was then classified using the Klabunde adaption of the Charlson 
comorbidity index score (0, 1, > 2). 35,36 Frequency of primary care provider (PCP) visits was 
also used as a proxy for health status, with a higher number of visits considered an indication of 
poorer health. An index of PCP visit intensity was identified by counting of number of unique 
PCP claim dates the year before diagnosis in the NCH file. PCP visits were categorized by lower 
and upper 50th percent median cutoff (low, high). Clinical prognostic factors examined were 
stage at diagnosis, tumor size (< 1cm, < 2 cm, 2 - 5 cm, > 5 cm), lymph node status (positive or 
negative), ER tumor status (positive, negative, borderline/unknown), PR tumor status (positive, 
negative, borderline/unknown), and tumor grade (well differentiated, moderately differentiated, 
poorly differentiated, undifferentiated/unknown). Stage diagnosis was categorized using the 
pathologically staged AJCC Stage Group 6th edition (I, II, III). Individual tests and treatments 
examined were ER tumor status testing (yes or no), PR tumor status testing (yes or no), lymph 
node status testing (yes or no), receipt of any definitive surgery (yes or no), mastectomy (yes or 
no), BCS (yes or no), RT (yes or no), chemotherapy (yes or no), and initiation of chemotherapy 
within 120 days of diagnosis (yes or no). Measures of oncology care resources were the density 
of area-level mammography screening centers and oncology treatment centers relative to each 
woman's location of residence. This area-level density was measured using data from the ARF 
and was categorized by lower and upper 50th percent median cutoff (low, high). Surgeon 
specialty was assessed using provider specialty claims codes 02, 49 (general) and 83, 90, 91, 98 
(oncology) from the NCH file to determine the type of surgeon seen (general only, oncology 
only, both). Socio-demographic characteristics examined were race (white, other), education 
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(measured by the 2000 Census tract survey of percent of persons age > 25 with at least 4 years 
college education) (< 15%, > 15%), annual income (measured by the 2000 Census tract survey of 
median income by census) (< $35,000, > $35,000), and metro status (non-metro, metro).  
Analysis 
 Descriptive analysis was conducted for all study variables. Mantel-Haenszel chi-square 
tests of location shift using modified ridit scores or table scores and Mantel-Haenszel chi-square 
tests of general association (depending on whether the independent measure was dichotomous, 
nominal, or ordinal) were used to test for significant group differences between GCC vs. GDC 
and independent measures, with significance set at P < .05.  Binomial logistic regression models 
were used to estimate the adjusted odds of receiving GCC vs. GDC for each of the independent 
variables described above and for receipt of specific tests and treatments for women age > 70 
years vs. age 66-69 years old, controlling for the independent measures. Parameter estimates 
calculated in the regression models are presented as adjusted odds ratios (AOR) with their 
corresponding 95% confidence intervals (CI). All analysis were conducted using SAS version 
9.4 software (SAS Institute Inc., Cary, NC).  
Results 
Population Characteristics  
 Among this sample of elderly female fee-for-service Medicare beneficiaries diagnosed 
with pathologically staged breast cancer in 2004 thru 2009, the majority were age 70-74 years at 
diagnosis (27.1%), of white race (88.2%), lived in metro areas (83.3%), areas where the 
population was > 15% college educated (69.5%) and had an annual income > $35,000 (75.6%). 
The majority had a comorbidity score = 0 (55.7%), were diagnosed at Stage I (56.4%), had their 
were lymph node negative (73.1%), had BCS (74.8%), had RT (61.1%), did not have 
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chemotherapy (74.9%), saw both a general and oncology surgeon (79.6%), and did not receive 
GCC (66.5%).  
Group Differences by Receipt of GCC 
 All group differences were significant at the P < .001 level, with the exception of density 
of mammography screening centers (P = .219) and density of oncology centers (P = .083). 
Receipt of GCC increased from 31.9% in 2004 to 35.2% in 2009. Yet, receipt of GCC decreased 
with increasing age (45.8% for those age 66-69 years vs. 17.2% for those age > 80 years) and 
increasing comorbidity (35.3% for those with comorbidity score = 0 vs. 27.9% with comorbidity 
score > 2). Women diagnosed as Stage I had the highest rates of GCC (39.7%), whereas those 
diagnosed at II had the lowest rates of GCC (22.6%). Additional clinical prognostic factors with 
lower rates of GCC were positive lymph nodes, larger tumor size, positive and 
borderline/unknown ER status, positive and borderline/unknown PR status, and 
undifferentiated/unknown tumor grades. Women who were treated by an oncology surgeon or 
both an oncology and general surgeon had higher rates of GCC (32.8% & 35.1%, respectively) 
than women treated by a general surgeon only (25.2%). In regards to socio-demographic 
characteristics women of white race vs. non-white, lived in metro areas vs. non-metro, areas 
where > 15% of the population was college educated vs. < 15%, or average annual income was > 
$35,000 vs. < $35,000 had higher rates of GCC. 
Associations with Receipt of GCC 
 Receipt of GCC became less likely with increasing age, such that women age > 80 years 
(AOR, 0.19; 95% CI, 0.17, 0.21) were the least likely to receive GCC, compared to women age 
66-69 years. Women with a comorbidity score > 2 were about 30% less likely (AOR, 0.71; 95% 
CI, 0.65, 0.78) to receive GCC, than women with a score = zero. Compared to women diagnosed 
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at Stage I, those diagnosed at Stage II were less than half as likely to receive GCC (AOR, 0.46; 
95% CI, 0.40, 0.54). Likewise, women with larger tumors were less likely to have had GCC, 
than women with tumors < 1 cm. Elderly women with lymph node negative breast cancer were 
less than half as likely to have had GCC (AOR, 0.49; 95% CI, 0.44, 0.56), than women who 
were lymph node positive. However, women who had tumors that were ER and PR negative vs. 
positive were more likely to receive GCC (AOR, 1.89; 95% CI, 1.69, 2.11) and (AOR, 1.20; 
95% CI, 1.10, 1.32), respectively. Whereas, those whose tumors were ER and PR 
borderline/unknown were 96% and 68% less likely to receive GCC (AOR, 0.04; 95% CI, 0.02, 
0.07) and PR statuses (AOR, 0.32; 95% CI, 0.22, 0.47), respectively. In contrast, women with 
moderately and poorly differentiated tumors vs. well-differentiated, were more likely to have had 
GCC. Women treated by an oncology surgeon or both a general and oncology surgeon were 47% 
(AOR, 1.47; 95% CI, 1.26, 1.72) and 84% (AOR, 1.84; 95% CI, 1.67, 2.03), more likely to 
receive GCC, respectively, than women treated by a general surgeon only. Women of non-white 
race vs. white were less likely to receive GCC (AOR, 0.81; 95% CI, 0.73, 0.89), whereas women 
who resided in areas where > 15% was college educated vs. < 15% were more likely to receive 
GCC.  
Associations with Tests & Treatments among Women Age > 70 vs. 66-69 years 
 Women age > 70 years were half as likely (AOR, 0.51; 95% CI, 0.48, 0.54) to receive 
GCC, than women age 66-69 years. Compared to younger women, older women were less likely 
to have ER status testing (AOR, 0.80; 95% CI, 0.70, 0.92) and PR status testing (AOR, 0.78; 
95% CI, 0.68, 0.89). However, older women were 2.5 times more likely than younger women to 
have had any definitive surgery (AOR, 2.51; 95% CI, 1.76, 3.58). In regards to type of surgery, 
older women were less likely to have BCS (AOR, 0.76; 95% CI, 0.71, 0.81), but more likely to 
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have mastectomy (AOR, 1.31; 95% CI, 1.23, 1.39), than younger women. Finally, older women 
were older women were less likely to have RT (AOR, 0.63; 95% CI, 0.60, 0.67), chemotherapy 
(AOR, 0.30; 95% CI, 0.28, 0.32), or appropriate time to chemotherapy (AOR, 0.78; 95% CI, 
0.68, 0.89), compared to younger women.  
Discussion 
 To these authors knowledge, this is the first study to comprehensively examine GCC as 
treatment guidelines are applied to all women with breast cancer among a large nationally 
representative sample of elderly women diagnosed at stage I, II, and III, stages for which 
guidelines are clearly defined. Applying to a strict definition of GCC, this study found that fewer 
than 34% of elderly women diagnosed with breast cancer in 2004 thru 2009 received care 
concordant with NCCN and ASCO recommended treatment guidelines.  
Age & Health 
 In regards to age, the highest rates of GCC were observed among women age 66-69 
years, at 46% and lowest rates among women age > 80 years, at 17%. In fact, women age > 70 
years were less than half as likely to receive GCC, than women age 66-69 years. Previous studies 
have reported receipt of GCC to range from 35% - 88% among women with breast cancer. 5, 27-
29,37 The variation in these rates of GCC are likely attributable to differences in study design and 
sample selection, that include varying definitions of GCC (local and systematic treatment, local 
treatment only, or systematic therapy only), exempting women age > 70 years from 
recommended RT or chemotherapy, the inclusion of women age < 65 years in their study 
sample, data collected from different years, samples that were limited to earlier stages or 
included Stage 0, sampled from smaller registries, and/or fewer number of registries. Despite 
their differences, all studies reported a strong inverse relationship between receipt of GCC and 
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age. Increasing age, along with increasing comorbidity and declining functional performance, is 
commonly cited by oncologists as a primary reason for less aggressive breast cancer treatment. 
38,39 Among elderly women, those age > 70 are particularly less likely to receive RT after BCS or 
chemotherapy when indicated, than younger women. In fact, a greater number of women than 
those meeting guideline exemption from RT, and many women who could benefit from 
chemotherapy, do not receive these treatments. 40-42 This study found women age > 70 years to 
be as much as 45%, 73%, and 34% less likely to have RT, chemotherapy, or receive 
chemotherapy within an appropriate time period, respectively, than those 66-69 years of age. 
Undertreatment of the elderly is a phenomenon observed across different cancers and countries. 
43-46 Although the disparity in aggressive treatment between younger and older elderly breast 
cancer patients is widely acknowledged, the application of aggressive treatment among older 
patients continues to be debated. Conflicting findings have been reported regarding the benefits 
of adjuvant treatments. Ten-year results of the  CALGB 9343 trial comparing BCS only vs. BCS 
plus RT among women age > 70 years with Stage I, ER positive breast cancer taking tamoxifen 
showed no differences in breast cancer specific and overall survival, and minimal difference in 
recurrence (2% vs. 10%). 47 Similar findings were reported by the more recent PRIME II 
randomized controlled trial, but with no difference in 5-year overall survival, and little difference 
in recurrence (1% vs. 4%). 48 However, the National Surgical Adjuvant Breast and Bowel Project 
(NSABP) B-17 randomized trial demonstrated that women treated with BCS only had 
significantly higher rates of recurrence after 15 years (19% vs. 9%), than women treated with 
BCS plus RT. 49 Multiple retrospective database studies support these findings. A recently 
published study using SEER-Medicare data to compare treatment outcomes among women age 
70-79 years with Stage I, ER positive breast cancer treated with BCS only vs. BCS plus RT, 
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found that after 10 years, women treated with BCS only ended up having a mastectomy twice as 
often, as women treated with BCS plus RT. 50 Further studies comparing these treatment groups 
using SEER-Medicare and cancer registry data from the British Columbia Cancer Agency also 
reported an increased risk for breast cancer recurrence and mortality among women treated with 
BCS only, compared to BCS plus RT. 51-54 In contrast to study findings of RT outcomes, the 
survival and disease-free benefits of chemotherapy for women with breast cancer of all ages is 
generally agreed upon. 55-57 Despite the demonstrated benefits of chemotherapy and RT, whether 
these adjuvant therapies should be administered to elderly women as often as younger women 
with breast cancer when indicated, remains a topic of debate due to their possible harm. Toxic 
effects and treatment burden from RT and chemotherapy have the potential for adverse effects on 
health and quality of life. 58-61 Often, these effects may be amplified in the elderly due to 
increased comorbidity, impaired organ function, declining functional status, lack of reliable 
transportation for repeated treatments, or are unjustifiable depending on projected life 
expectancy. 62,63 Yet, among elderly women with low comorbidity and good functional status, 
adjuvant therapy may be well tolerated just and no more toxic, than among younger women. 64,65 
Moreover, many maintain that the harm of potential toxic and adverse side effects of adjuvant 
therapy, outweigh the potential benefits. 60,61 Nevertheless, chemotherapy should be initiated 
within a timely manner as to not compromise survival. 66,67  
 In conjunction with increasing age, increasing comorbidity has been strongly associated 
with less aggressive treatment and GDC among elderly breast cancer patients. 37,39,40 Patients 
with increased comorbidity may be less likely to receive GCC for reasons similarly associated 
with increasing age, that include competing health demands, decreased functional status, and 
decreased overall survival because of their comorbidity. 68,69 Despite these concerns, comorbidity 
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itself has not been linked with increased toxicity to adjuvant treatment or time to recurrence, and 
thus, should not prevent GCC when patients are strong and functional enough to endure the 
demands of adjuvant treatments. 70  
Clinical Prognostic Factors 
 Aside from age and health, clinical characteristics were strongly associated with GCC. 
Women who were diagnosed at later stages, had larger tumors, moderately and poorly tumor 
grades, borderline/unknown tumors hormone receptors, and were lymph node negative were less 
likely to receive GCC. This most likely reflects the reluctance of providers to use aggressive 
treatment in elderly women that would otherwise be recommended for more advanced cancers. It 
is possible that while women who were lymph node negative did not require chemotherapy, they 
may have been indicated for RT following BCS, but were less likely to receive it due to older 
age. In contrast to these associations, women with ER and PR negative tumors were 90% to 20%  
more likely to receive GCC, respectively. A plausible explanation for these findings may lie with 
the poorer survival outcomes observed among women negative hormone receptors. 71,72 
Therefore, they may be more likely to be aggressively treated with RT and chemotherapy, 
women with positive hormone receptors, thus making them likely to receive GCC 
Oncology Care Resources 
 Women who were treated by an oncology surgeon only or both a general and oncology 
surgeon, compared to a general surgeon only, were more likely to receive GCC. This sharing of 
care may be a sign of high patient volume, a factor that has been associated with increased GCC. 
Also, the involvement of an oncology surgeon in coordination of care may ensure that lymph 
node surgery is performed. 29 
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Socio-Demographic Characteristics  
 Additional factors associated with receipt of GCC were race and education. Women of 
non-white race, and those residing in areas of lower education were less likely to receive GCC. 
The association between vulnerable socio-demographic characteristics and disparities in breast 
cancer care have been well documented. 13,27 While the relationship between health disparities 
and residents of low education areas may be explained by limited resources and access to 
specialty services, the relationship between race and receipt of GCC is not well understood, 
especially in the context of uniform Medicare coverage. A recently published study by Freedman 
and colleagues (2015) may shed light on this subject. 73 Compared to white women, black and 
Hispanic women were less likely to be knowledgeable about their breast cancer characteristics, a 
factor that may prevent them from taking part in the treatment decision process. Similarly, 
increasing age was also associated with decreased breast cancer knowledge. While it is not 
realistic to recommend aggressive breast cancer treatment to all elderly patients due to variation 
in health and functional status, treatment patterns among this population could be improved if 
emphasis was placed upon dissemination of GCC, unless patients are otherwise unable to do so. 
In the meantime, patient navigation programs have shown to help direct patients to receipt of 
GCC and adhere to the course of treatment. 74,75 Vulnerable populations, including the elderly, 
may benefit from such patient navigation and education programs to aid in their understanding, 
decision making process, and ultimately receipt of GCC.  
Limitations & Strengths 
 Several limitations should be kept in mind when interpreting the results of this study. 
This study did not exempt women age > 70 with tumors < 2 cm, node negative, estrogen-
receptor positive, and receiving adjuvant hormone therapy from radiation or women age > 70 
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years from chemotherapy in determining GCC, and instead examined the application of GCC to 
all ages to compare treatment differences. This method may have underestimated the number of 
women receiving GCC due to poor health or functional status. This study did not assess the 
completion of radiation or chemotherapy, only the initiation of therapy, nor did this study 
distinguish between the receipt of neoadjuvant or adjuvant chemotherapy. Neoadjuvant 
chemotherapy is received by some women to shrink larger tumors and provide an opportunity for 
BCS, after clinical staging, but before pathological staging has been conducted. Thus, this study 
did not capture how the use of neoadjuvant chemotherapy, and resulting differences in clinical 
and pathological staging were associated with receipt of GCC or individual tests and treatments. 
Furthermore, this study did not examine how genetic testing for specific genetic mutations 
related to breast cancer and subsequent findings were associated with treatment. Also, tumor 
receptor status was used as a proxy measure of for tumor receptor testing and does not provide 
any information regarding the initiation of adjuvant hormone therapy when indicated. Moreover, 
this study was unable to examine receipt of adjuvant hormone therapy. Additionally, several of 
socio-demographic characteristics examined were aggregate census level measures, rather than 
individual level measures. Finally, the SEER individuals within the SEER database have been 
found to be of higher income, and higher concentrations of racial and ethnic minorities, as 
compared to the U.S. population.76  
 Despite these limitations, this study holds several strengths that impart confidence in its 
findings. This is one of few studies to investigate GCC among women with breast cancer and 
possibly the first to do so comprehensively among elderly women using a large, nationally 
representative database. Pathological staging was used to determine the cancer characteristics of 
the study sample and algorithms were used to identify receipt of GCC based on the 
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recommended course of treatment according to cancer characteristics put forth by the NCCN and 
ACSO. A variety of tests and treatments were included in this study and examined in relation to 
younger and older elderly women. Additionally, a wide range of covariates were controlled for 
that included age, health, clinical prognostic factors, access to oncology care resources, and 
socio-demographic characteristics. Despite containing slightly greater proportions of affluent and 
minority individuals, SEER is widely accepted as representative of the U.S. population, making 
these results generalizable to the greater population of elderly women with invasive early-stage 
breast cancer insured by Medicare.     
Significance & Conclusions  
 In conclusion, rates of GCC among elderly women as determined the current study are 
much lower than those observed by other studies that were heavily populated by younger 
women. These findings indicate that older women with breast cancer receive considerably less 
aggressive treatment than younger women, although they have the highest incidence of breast 
cancer. Among elderly women, receipt of GCC decreases with increasing age and comorbidity. 
Yet, about 2/3s of women with no comorbidity still do not receive GCC, suggesting that age 
alone or other factors not related to strength and vitality are affecting receipt of GCC. Receipt of 
GCC also decreases with later stage at diagnosis and worse prognostic clinical factors, 
circumstances that necessitate more aggressive treatment, but perhaps reflect a reluctance to do 
so. Women older than 70 years are especially less likely to receive RT and/or chemotherapy. A 
greater number of elderly women may benefit from receiving GCC than those that actually 
receive it. In order to maximize the probability of disease-free survival and life-expectancy, 
patients, family members, and oncology care providers should be encouraged to accept the same 
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standard of aggressive breast cancer treatment to older women, as would be applied to younger 
women.  
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Table 1 
Characteristics of Elderly Women with Stages I, II, and III Breast Cancer  
SEER-Medicare, 2004-2009 
   
N 
 
% 
  All   27,883  100.0   
Year of Diagnosis 
      
 
2004 
 
3885
 
13.9
  
 
2005 
 
3726 
 
13.4 
  
 
2006 
 
3873 
 
13.9 
  
 
2007 
 
4025 
 
14.4 
  
 
2008 
 
6151 
 
22.1 
  
 
2009 
 
6223 
 
22.3 
  Age & Health 
Age at Diagnosis 
      
 
66-69 
 
6694
 
24.0
  
 
70-74 
 
7551 
 
27.1 
  
 
75-79 
 
6704 
 
24.0 
  
 
> 80 
 
6934 
 
24.9 
  Comorbidity Score 
      
 
0 
 
15520
 
55.7
  
 
1 
 
7559 
 
27.1 
  
 
> 2 
 
4804 
 
17.2 
  PCP Visits 
      
 
Low 
 
15354
 
55.1
  
 
High 
 
12529 
 
44.9 
  Clinical Prognostic Factors 
Stage at Diagnosis 
      
 
I 
 
15731
 
56.4
  
 
II 
 
9514 
 
34.1 
  
 
III 
 
2638 
 
9.5 
  Tumor Size  
      
 
< 1 cm 
 
8201
 
29.4
  
 
< 2 cm 
 
10701 
 
38.4 
  
 
2 - 5 cm 
 
7834 
 
28.1 
  
 
> 5 cm 
 
1147 
 
4.1 
  Lymph Nodes 
      
 
Positive 
 
7505
 
26.9
  
 
Negative 
 
20378 
 
73.1 
  ER Status 
      
 
Positive 
 
22298
 
80.0
  
 
Negative 
 
4136 
 
14.8 
  
 
Borderline/Unknown 1449 
 
5.2 
  PR Status 
      
 
Positive 
 
18762
 
67.3
  
 
Negative 
 
7463 
 
26.8 
  
 
Borderline/Unknown 1658 
 
6.0 
  BCS = breast-conserving surgery 
      GCC = Guideline-Concordant Care 
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Table 1 
Characteristics of Elderly Women with Stages I, II, and III Breast Cancer  
SEER-Medicare, 2004-2009 
   
N 
 
% 
  All   27,883  100.0   
Tumor Grade 
      
 
Well Differentiated 6741
 
24.2
  
 
Moderately Differentiated 12287 
 
44.1 
  
 
Poorly Differentiated 7302 
 
26.2 
  
 
Undifferentiated/Unknown 1553 
 
5.6 
  Tests & Treatments 
ER Status Tested 
      
 
Yes 
 
26482
 
95.0
  
 
No  
 
1401 
 
5.0 
  PR Status Tested 
      
 
Yes 
 
26435
 
94.8
  
 
No 
 
1448 
 
5.2 
  Lymph Nodes Tested 
      
 
Yes 
 
25685
 
92.1
  
 
No  
 
2198 
 
7.9 
  Had any Surgery 
      
 
Yes 
 
27754
 
99.5
  
 
No 
 
129 
 
0.5 
  Had BCS 
      
 
Yes 
 
20865
 
74.8
  
 
No 
 
7018 
 
25.2 
  Had Mastectomy 
      
 
Yes 
 
11636
 
41.7
  
 
No 
 
16247 
 
58.3 
  Had Radiation  
      
 
Yes 
 
17023
 
61.1
  
 
No 
 
10860 
 
39.0 
  Had Chemotherapy 
      
 
Yes 
 
6992
 
25.1
  
 
No 
 
20891 
 
74.9 
  Time to Chemotherapy 
      
 
Appropriate 
 
5796
 
20.8
  
 
Not Appropriate 
 
1196 
 
4.3 
  
 
No Chemotherapy 
 
20891 
 
74.9 
  Received GCC 
      
 
Yes 
 
9336
 
33.5
  
 
No 
 
18547 
 
66.5 
  Oncology Care Resources 
Mammography Screening Centers 
    
 
Low 
 
15665 
 
56.2
  
 
High 
 
12218 
 
43.8 
  BCS = breast-conserving surgery 
     GCC = Guideline-Concordant Care 
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Table 1 
Characteristics of Elderly Women with Stages I, II, and III Breast Cancer  
SEER-Medicare, 2004-2009 
   
N 
 
% 
  All   27,883  100.0   
Oncology Treatment Centers 
     
 
Low 
 
12541
 
45.0
  
 
High 
 
15342 
 
55.0 
  Type of Surgeon Seen 
      
 
General Only  
 
4045 
 
14.5 
  
 
Oncology Only 
 
1638 
 
5.9 
  
 
Both 
 
22200 
 
79.6 
  Socio-Demographic Characteristics 
Race 
      
 
White 
 
24594
 
88.2
  
 
Other 
 
3289 
 
11.8 
  Education 
      
 
< 15% college degree 8493
 
30.5
  
 
> 15%  college degree 19390 
 
69.5 
  Annual Income 
      
 
< $35,000 
 
6806
 
24.4
  
 
> $35,000 
 
21077 
 
75.6 
  Metro Status 
      
 
Non-metro 
 
4660
 
16.7
   Metro  23223  83.3   
BCS = breast-conserving surgery 
     GCC = Guideline-Concordant Care 
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Table 2 
Comparison of Guideline-Concordant Care among Elderly Women with Stages I, II, and III Breast 
Cancer  
SEER-Medicare, 2004-2009 
  
Concordant 
 
Discordant 
 
  
  
N % 
 
N % 
 
p-value 
All  9,336 33.5  18,547 66.5    
Year of Diagnosisb 
      
< 0.001*** 
 
2004 1240 31.9
 
2645 68.1 
  
 
2005 1166 31.3 
 
2560 68.7 
  
 
2006 1234 31.9 
 
2639 68.1 
  
 
2007 1334 33.1 
 
2691 66.9 
  
 
2008 2170 35.3 
 
3981 64.7 
  
 
2009 2192 35.2 
 
4031 64.8 
  Age & Health 
Age at Diagnosisc 
      
< 0.001*** 
 
66-69 3066 45.8
 
3628 54.2 
  
 
70-74 2966 39.3 
 
4585 60.7 
  
 
75-79 2114 31.5 
 
4590 68.5 
  
 
> 80 1190 17.2 
 
5744 82.8 
  Comorbidity Scorec 
      
< 0.001***
 
0 5484 35.3
 
10036 64.7 
  
 
1 2513 33.3 
 
5046 66.8 
  
 
> 2 1339 27.9 
 
3465 72.1 
  PCP Visitse 
      
< 0.001***
 
Low 5300 34.5
 
10054 65.5 
  
 
High 4036 32.2 
 
8493 67.8 
  Clinical Prognostic Factors
Stage at Diagnosisc 
      
< 0.001*** 
 
I 6250 39.7
 
9481 60.3 
  
 
II 2152 22.6 
 
7362 77.4 
  
 
III 934 35.4 
 
1704 64.6 
  Tumor Sizec  
      
< 0.001***
 
< 1 cm 5613 68.4
 
2588 31.6 
  
 
< 2 cm 1564 14.6 
 
9137 85.4 
  
 
2 - 5 cm 1932 24.7 
 
5902 75.3 
  
 
> 5 cm 227 19.8 
 
920 80.2 
  Lymph Nodese 
      
< 0.001***
 
Positive 2307 30.7 
 
5198 69.3 
  
 
Negative 7029 34.5 
 
13349 65.5 
  a = cmh chi square test of general association 
   b = cmh chi square test of location shift using table scores 
   c =  cmh chi square test of location shift using modified ridit scores 
   d = Fisher's exact chi square test 
       e = Pearson's chi square test of association 
       BCS = breast-conserving surgery 
       * p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 2 
Comparison of Guideline-Concordant Care among Elderly Women with Stages I, II, and III Breast 
Cancer  
SEER-Medicare, 2004-2009 
  
Concordant 
 
Discordant 
 
  
  
N % 
 
N % 
 
p-value 
All  9,336 33.5  18,547 66.5    
ER Statusa 
      
< 0.001*** 
 
Positive 7437 33.4
 
14861 66.7 
  
 
Negative 1880 45.5 
 
2256 54.6 
  
 
Borderline/Unknown 19 1.3 
 
1430 98.7 
  PR Statusa 
      
< 0.001***
 
Positive 6248 33.3
 
12514 66.7 
  
 
Negative 3025 40.5 
 
4438 59.5 
  
 
Borderline/Unknown 63 3.8 
 
1595 96.2 
  Tumor Gradea 
      
< 0.001***
 
Well Differentiated 2456 36.4
 
4285 63.6 
  
 
Moderately Differentiated 3810 31.0 
 
8477 69.0 
  
 
Poorly Differentiated 2595 35.5 
 
4707 64.5 
  
 
Undifferentiated/Unknown 475 30.6 
 
1078 69.4 
  Tests & Treatments 
ER Status Testedd 
      
< 0.001*** 
 
Yes 9336 35.3 
 
17146 64.8 
  
 
No  0 0.0 
 
1401 100.0 
  PR Status Testedd 
      
< 0.001***
 
Yes 9336 35.3 
 
17099 64.7 
  
 
No 0 0.0 
 
1448 100.0 
  Lymph Nodes Testedd 
      
< 0.001***
 
Yes 9336 36.4
 
16349 63.7 
  
 
No  0 0.0 
 
2198 100.0 
  Had any Surgeryd 
      
< 0.001***
 
Yes 9336 33.6
 
18418 66.4 
  
 
No 0 0.0 
 
129 100.0 
  Had BCSe 
      
< 0.001***
 
Yes 7152 34.3
 
13713 65.7 
  
 
No 2184 31.1 
 
4834 68.9 
  Had Mastectomye 
      
< 0.001***
 
Yes 2651 22.8
 
8985 77.2 
  
 
No 6685 41.2 
 
9562 58.9 
  a = cmh chi square test of general association 
   b = cmh chi square test of location shift using table scores 
   c =  cmh chi square test of location shift using modified ridit scores 
   d = Fisher's exact chi square test  
       e = Pearson's chi square test of association 
       BCS = breast-conserving surgery 
       * p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 2 
Comparison of Guideline-Concordant Care among Elderly Women with Stages I, II, and III Breast 
Cancer  
SEER-Medicare, 2004-2009 
  
Concordant 
 
Discordant 
 
  
  
N % 
 
N % 
 
p-value 
All  9,336 33.5  18,547 66.5    
Had Radiatione  
      
< 0.001*** 
 
Yes 7836 46.0
 
9187 54.0 
  
 
No 1500 13.8 
 
9360 86.2 
  Had Chemotherapye 
      
< 0.001***
 
Yes 4218 60.3
 
2774 39.7 
  
 
No 5118 24.5 
 
15773 75.5 
  Time to Chemotherapya 
      
< 0.001***
 
Appropriate 4218 72.8
 
1578 27.2 
  
 
Not Appropriate 0 0.0 
 
1196 100.0 
  
 
No Chemotherapy 5118 24.5 
 
15773 75.5 
  Oncology Care Resources 
Mammography Screening Centerse 
     
0.219 
 
Low 5197 33.2
 
10468 66.8 
  
 
High 4139 33.9 
 
8079 66.1 
  Oncology Treatment Centerse 
     
0.083
 
Low 4131 32.9
 
8410 67.1 
  
 
High 5205 33.9 
 
10137 66.1 
  Type of Surgeon Seena 
      
< 0.001***
 
General Only  1019 25.2
 
3026 74.8 
  
 
Oncology Only 537 32.8 
 
1101 67.2 
  
 
Both 7780 35.1 
 
14420 65.0 
  Socio-Demographic Characteristics 
Racee 
       
< 0.001*** 
 
White 8335 33.9
 
16259 66.1 
  
 
Other 1001 30.4 
 
2288 69.6 
  Educatione 
      
< 0.001***
 
< 15% college degree 2567 30.2
 
5926 69.8 
  
 
> 15%  college degree 6769 34.9 
 
12621 65.1 
  Annual Incomee 
      
< 0.001***
 
< $35,000 1930 28.4
 
4876 71.6 
  
 
> $35,000 7406 35.1 
 
13671 64.9 
  Metro Statuse 
      
< 0.001***
 
Non-metro 1432 30.7
 
3228 69.3 
   Metro 7904 34.0  15319 66.0   
a = cmh chi square test of general association 
    b = cmh chi square test of location shift using table scores 
   c =  cmh chi square test of location shift using modified ridit scores 
  d = Fisher's exact chi square test  
      e = Pearson's chi square test of association 
     BCS = breast-conserving surgery 
      * p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 3 
Associations with Guideline-Concordant Care among Elderly Women with Stages I, II, and III Breast 
Cancer  
SEER-Medicare, 2004-2009 
  
Concordant vs. Discordant 
All  AOR 95% CI Sig. 
     Year of Diagnosis 
   
 
2004 1.00 ― 
 
 
2005 0.93 [0.82,1.05] 
 
 
2006 0.95 [0.84,1.07] 
 
 
2007 1.01 [0.90,1.14] 
 
 
2008 1.09 [0.98,1.21] 
 
 
2009 1.07 [0.97,1.20] 
 Age & Health 
Age at Diagnosis 
   
 
66-69 1.00 ― 
 
 
70-74 0.71 [0.65,0.77] *** 
 
75-79 0.44 [0.40,0.48] *** 
 
> 80 0.19 [0.17,0.21] *** 
Comorbidity Score 
   
 
0 1.00 ― 
 
 
1 0.91 [0.84,0.97] ** 
 
> 2 0.71 [0.65,0.78] *** 
PCP Visits 
   
 
Low 1.00 ― 
 
 
High 1.04 [0.97,1.11] 
 Clinical Prognostic Factors 
Stage at Diagnosis 
   
 
I 1.00 ― 
 
 
II 0.46 [0.40,0.54] *** 
 
III 0.93 [0.75,1.16] 
 Tumor Size  
   
 
< 1 cm 1.00 ― 
 
 
< 2 cm 0.05 [0.04,0.05] *** 
 
2 - 5 cm 0.13 [0.11,0.15] *** 
 
> 5 cm 0.06 [0.05,0.07] *** 
Lymph Nodes 
   
 
Positive 1.00 ― 
 
 
Negative 0.49 [0.44,0.56] *** 
ER Status 
   
 
Positive 1.00 ― 
 
 
Negative 1.89 [1.69,2.11] *** 
 
Borderline/Unknown 0.04 [0.02,0.07] *** 
* p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 3 
Associations with Guideline-Concordant Care among Elderly Women with Stages I, II, and III Breast 
Cancer  
SEER-Medicare, 2004-2009 
  
Concordant vs. Discordant 
All  AOR 95% CI Sig. 
PR Status 
   
 
Positive 1.00 ― 
 
 
Negative 1.20 [1.10,1.32] *** 
 
Borderline/Unknown 0.32 [0.22,0.47] *** 
Tumor Grade 
   
 
Well Differentiated 1.00 ― 
 
 
Moderately Differentiated 1.15 [1.06,1.25] *** 
 
Poorly Differentiated 1.63 [1.48,1.80] *** 
 
Undifferentiated/Unknown 1.02 [0.87,1.19] 
 Oncology Care Resources 
Mammography Screening Centers 
  
 
Low 1.00 ― 
 
 
High 0.99 [0.90,1.09] 
 Oncology Treatment Centers 
   
 
Low 1.00 ― 
 
 
High 1.01 [0.91,1.12] 
 Type of Surgeon Seen 
   
 
General Only  1.00 ― 
 
 
Oncology Only 1.47 [1.26,1.72] *** 
 
Both 1.84 [1.67,2.03] *** 
Socio-Demographic Characteristics 
Race 
    
 
White 1.00 ― 
 
 
Other 0.81 [0.73,0.89] *** 
Education 
   
 
< 15% college degree 1.00 ― 
 
 
> 15%  college degree 1.09 [1.00,1.18] * 
Annual Income 
   
 
< $35,000 1.00 ― 
 
 
> $35,000 1.07 [0.97,1.20] 
 Metro Status 
   
 
Non-metro 1.00 ― 
  Metro 1.00 [0.90,1.10]   
* p < 0.05; ** p < 0.01; *** p < 0.001 
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Table 4 
Associations with Tests & Treatment among Elderly Women with Stages I, II, and III Breast Cancer  
SEER-Medicare, 2004-2009 
  
Age > 70 vs. Age 66-69 years 
All  AOR 95% CI Sig. 
Guideline-Concordant Care 
   
 
Yes 0.51 [0.48,0.54] *** 
 
No 1.00 ― 
 ER Status Tested 
   
 
Yes 0.80 [0.70,0.92] ** 
 
No  1.00 ― 
 PR Status Tested 
   
 
Yes 0.78 [0.68,0.89] *** 
 
No 1.00 ― 
 Lymph Nodes Tested 
   
 
Yes 0.91 [0.82,1.01] 
 
 
No  1.00 ― 
 Had any Surgery 
   
 
Yes 2.51 [1.76,3.58] *** 
 
No 1.00 ― 
 Had BCS 
   
 
Yes 0.76 [0.71,0.81] *** 
 
No 1.00 ― 
 Had Mastectomy 
   
 
Yes 1.31 [1.23,1.39] *** 
 
No 1.00 ― 
 Had Radiation  
   
 
Yes 0.63 [0.60,0.67] *** 
 
No 1.00 ― 
 Had Chemotherapy 
   
 
Yes 0.30 [0.28,0.32] *** 
 
No 1.00 ― 
 Time to Chemotherapy 
   
 
Appropriate 0.78 [0.68,0.89] *** 
 
Not Appropriate 1.00 ― 
  No Chemotherapy 2.71 [2.38,3.09] *** 
BCS = breast-conserving surgery       
* p < 0.05; ** p < 0.01; *** p < 0.001 
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Appendix 1. Claims Codes Used for Identifying Types of Treatment 
 
Type of Treatment ICD-9 Diagnostic ICD-9 Procedure HCPCS/CPT Revenue Center 
Lymph Node Surgery  40.3, 40.41-40.42, 40.50-
40.54, 40.59, 85.43, 
85.48 
38500, 38510, 38520, 
38525, 38530, 39542, 
38720, 38740, 38745, 
38792, 78195, 78800-
78801 
 
Lumpectomy  85.20-85.29 19120, 19125-19126, 
19160, 19162, 19301-
19302 
 
Mastectomy  85.33-85.36, 85.40-85.48 19140, 19180, 19182, 
19300, 19303-19307, 
19200, 19220, 19240, 
19260, 19271-19272 
 
Radiation Therapy V58.0, V66.1, V67.1 92.20-92.39  77261-77799, G0256, 
G0261, G0173-G0174, 
G0243, G0251, G0338-
G03340 
0330, 0333 
Chemotherapy V58.1, V66.2, V67.2,  99.25, 99.28 96400-96599, C8953-
C8955, G0355-G0363, 
G902-G9032, J0640, 
J8510, J8520-J8521, 
J8530-J8999, J9000-
J9999, Q0083-Q0085, 
S9329-S9331,  
0331, 0332, 0335 
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Appendix 1. Guideline-Concordant Treatment Options by Tumor Size and Lymph Node 
Status 
 
Stage Treatment Option A Treatment Option B 
Stage I: 
       T < 1 cm, N- 
 BCS                    •    ERST & PRST 
 RT                 
 LNT  
 Mastectomy 
  LNT 
  ERST & PRST 
Stage I: 
       1 cm < T < 2 cm, N- 
 BCS                    •     CT 
 RT                      •     CT < 120days          
 LNT                    •     ERST & PRST  
 Mastectomy         •     CT < 120days    
 LNT                     •     ERST & PRST 
 CT 
Stage IIA: 
       0 cm < T < 2 cm, N+ 
 BCS                    •     CT 
 RT                      •     CT < 120days          
 LNT                    •     ERST & PRST 
 Mastectomy         •     CT < 120days    
 LNT                     •     ERST & PRST 
 CT 
Stage IIA: 
       2 cm < T < 5 cm, N- 
 BCS                    •     CT 
 RT                      •     CT < 120days          
 LNT                    •     ERST & PRST 
 Mastectomy         •     CT < 120days    
 LNT                     •     ERST & PRST 
 CT 
Stage IIB: 
       2 cm < T < 5 cm, N+ 
 BCS                    •     CT 
 RT                      •     CT < 120days          
 LNT                    •     ERST 
 Mastectomy         •     CT < 120days    
 LNT                     •     ERST & PRST 
 CT 
Stage IIB: 
       T > 5 cm, N- 
 Mastectomy        •     CT < 120days    
 LNT                    •     ERST & PRST 
 CT 
 
Stage IIIA: 
       0 cm < T < 5 cm, N+ 
 BCS                    •     CT 
 RT                      •     CT < 120days          
 LNT                    •     ERST 
 Mastectomy         •     CT < 120days    
 LNT                     •     ERST & PRST 
 CT 
Stage IIIA: 
       T > 5 cm, N+ 
 Mastectomy        •     CT < 120days    
 LNT                    •     ERST & PRST 
 CT 
 
Stage IIIB & IIIC  Mastectomy        •     CT < 120days    
 LNT                    •     ERST & PRST 
 CT 
 
T = tumor size; N = nodal status; BCS = breast-conserving surgery; RT = radiation therapy; LNT = lymph node 
testing; ERST = estrogen receptor status testing; PRST = progesterone receptor status testing; CT = chemotherapy;  
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Abstract 
Objectives: Overall breast cancer survival has improvement dramatically over the past 20 years 
and survival rates are relatively high, especially when detected at an early stage. Still, several 
factors remain formidable influences on breast cancer survival. This study examined factors 
associated with overall 5-year breast cancer survival among three different large groups of 
elderly US women with non-metastatic invasive breast cancer.  
Methods: The linked SEER-Medicare data set was used to identify 1) a broadly inclusive group 
of women age > 66 years diagnosed with stage I, II, and II breast cancer in 2003 to 2009 (N = 
53,830), 2) women age > 66 years diagnosed with early-stage invasive breast cancer in 2003 to 
2009 (N = 45,981) by initial loco-regional treatment patterns (breast-conserving surgery (BCS) 
plus radiation therapy (RT), mastectomy or BCS without RT), and 3) women age > 66 years with 
pathologically staged I, II, and III breast cancer in 2004 to 2009 (N = 27,883) by individual tests 
and treatments receipt of guideline-concordant care (GCC), among fee-for-service beneficiaries 
continuously enrolled in Part A and B services. Five-year survival rates, adjusted hazard ratios, 
and Kaplan Meier survival curves were computed for each sample according to study covariates.  
Results: Among elderly women in cohort 1, the average time till death was 1,247.2 days (SD = + 
722.3) with an 82% 5-year survival rate. Groups with the highest 5-year survival rates were age 
66-69 years (91%) (P < 0.001), with a comorbidity score = 0 (86%) (P < 0.001), and diagnosed 
at stage I (88%) (P < 0.001). Groups with the greatest mortality risk within 5 years of diagnosis 
were those age > 80 years (AHR, 4.01; 95% CI, 3.74, 4.29), with a comorbidity score > 2 (AHR, 
2.17; 95% CI, 2.06, 2.28), and diagnosed at stage III (AHR, 3.95; 95% CI, 3.74, 4.18). In cohort 
2, the average time till death was 1,410.6 days (SD = + 696.9) with 86% 5-year survival rate. 
Groups with highest 5-year survival rates were those who were age 66-69 years (94%) (P < 
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0.001), with a comorbidity score = 0 (90%) (P < 0.001), diagnosed at stage I (90%) (P < 0.001), 
treated by both an oncology surgeon (87%) (P < 0.001) or both an oncology and general surgeon 
(88%) (P < 0.001), and received BCS plus RT (92%) (P < 0.001). Groups of women with the 
greatest mortality risk within 5 years of diagnosis were those age > 80 years (AHR, 3.76; 95% 
CI, 3.45, 4.10), a comorbidity score > 2 (AHR, 2.39; 95% CI, 2.25, 2.55), and had BCS without 
RT (AHR, 1.94; 95% CI, 1.82, 2.06). In cohort 3 the average time till death was 1,246.7 days 
(SD = + 600.8) with a 88% 5-year survival rate. Groups with the highest 5-year survival rates 
were those age 66-69 years (94%) (P < 0.001), with a comorbidity score = 0 (91%) (P < 0.001), 
a low frequency of primary care visits (90%) (P < 0.001), diagnosed at stage I (93%) (P < 
0.001), lymph node negative (91%) (P < 0.001), ER positive (89%) (P < 0.001), PR positive 
(90%) (P < 0.001), treated by an oncology surgeon (90%) (P < 0.001) or both an oncology and 
general surgeon (88%) (P < 0.001), received GCC (93%) (P < 0.001), and had RT (91%) (P < 
0.001). Groups of women with the greatest risk within 5 years of diagnosis were those age > 80 
years (AHR, 2.85; 95% CI, 2.54, 3.20), a comorbidity score > 2 (AHR, 2.09; 95% CI, 1.92, 
2.27), diagnosed at stage III (AHR, 1.81; 95% CI, 1.48, 2.21), received GCC (AHR, 1.18; 95% 
CI, 1.04, 1.35), and did not have RT (AHR, 1.53; 95% CI, 1.39, 1.68).  
Conclusions: Across all three study samples, age, health, stage at diagnosis, and type of 
treatment, were strong and consistent factors associated with overall 5-year breast cancer 
survival. Undertreatment among elderly women with breast cancer was associated with a greater 
risk of death within 5 years of diagnosis, particularly for women who did not receive RT 
following BCS for early-stage breast cancer or receive GCC for all invasive non-metastatic. In 
order to increase survival, older women with breast cancer should receive aggressive treatment in 
accordance with recommended guidelines as long as they are healthy enough to do so.  
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Modifiable factors such as stage at diagnosis should continue to be targeted by encouraging 
persistent mammography screening among elderly women. Reducing comorbidity burden among 
US women would be an effective means for improving overall breast cancer survival among all 
groups of women, and especially among older women whose vitality and functional status is 
already at risk for decline.     
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Introduction  
 While breast cancer is the most frequently diagnosed type of cancer among women in the 
United States (US), it also has among the highest survival rates, relative to other types of cancer.  
Relative to women who have never been diagnosed with breast cancer, breast cancer survivors 
have 89% 5-year and 83% 10-year survival rates. 1,2 Moreover, earlier stage diagnosis is 
associated with greater survival, such that women diagnosed at Stage I, II, and III have 100%, 
93%, and 72% 5-year survival rates, respectively. 3 Decreasing mortality and increasing survival 
rates throughout the years are attributed to improvements in understanding of the disease and its 
treatment, alongside earlier detection due to increased routine breast cancer screening. 4 Yet, 
despite these advancements, several factors still affect survival outcomes. These factors 
encompass clinical characteristics of the cancer, receiving the standard of oncology care, such 
that treatment is in concordance with evidence based recommended treatment guidelines without 
the omission of necessary tests and treatments, otherwise referred to as guideline-concordant 
care (GCC), age, health, access to specialty care, and socio-demographic characteristics. Clinical 
characteristics associated with greater survival are earlier stage at diagnosis, smaller tumor size, 
less or no lymph node invasion, well differentiated tumor grade, and estrogen and progesterone 
positive tumors. 3,5-7 Receiving GCC is associated with greater breast cancer survival, while 
guideline-discordant care (GDC), particularly the omission of recommended treatments and 
testing, is associated with poorer survival. 8-11 The most commonly omitted treatments are 
radiation therapy (RT) following breast-conserving surgery (BCS) or mastectomy when 
indicated, chemotherapy, adjuvant hormone therapy, and lymph node sampling. The appropriate 
course of treatment for each women is determined by tumor size, lymph node invasion, and 
hormone receptor status. When diagnosed at an early-stage, women often have an option for the 
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type of local treatment received. Women with tumors < 5 cm have the option of mastectomy or 
BCS followed by RT. Multiple randomized clinical studies have shown BCS followed by RT to 
be as equally effective as mastectomy for long-term survival of invasive early-stage breast 
cancer.12-15 Since the National Institutes of Health's (NIH) 1991 endorsement of BCS plus RT as 
an appropriate alternative to mastectomy for treatment of invasive early-stage breast cancer, 
mastectomy rates have decreased while rates of BCS plus RT have steadily increased.16  In fact, 
BCS, with or without RT, has become the preferred choice of primary surgical treatment among 
women with early-stage breast cancer, with ~ 60% or more receiving BCS. 17-19 Yet, in recent 
years, rates of mastectomy have started to slowly increase.18-20 Associations with receipt of 
mastectomy when BCS is an option, include a desire to avoid radiation therapy due to side 
effects, fear of recurrence, larger tumor size, positive lymph nodes, tumors with negative 
hormone receptors, moderately or poorly differentiated tumors, lower income, being insured by 
Medicaid or uninsured, residing in a rural location, increased travel distance for RT, the 
increased cost of BCS plus RT, compared to mastectomy, and surgeon characteristics that 
include being male, not trained in the U.S., and less recent training.18,19,21-25  
 Regardless of stage or treatment options, there are several factors that are indirectly 
associated with survival via their association with receipt of GCC. Age and comorbidity are two 
related and strongly associated predictors of GCC. While increasing age has its own associated 
frailty, it is also associated with increasing comorbidity, that together, may make some 
treatments with adverse and toxic effects intolerable for some women, to the point that the harms 
of such treatments outweigh the benefits. 26-31 In fact, clinical evidence-based treatment 
guidelines put forth by the National Comprehensive Cancer Network (NCCN) do not make 
recommendations for or against chemotherapy in women age > 70 years, but suggest 
113 
 
chemotherapy be given on a case-by-case basis, depending on the patient's health.32 Additionally, 
guidelines specify that RT following BCS may be omitted among women meeting the following 
requirements: age > 70 years, tumors < 2 cm, node negative, estrogen-receptor positive, and 
receiving adjuvant hormone therapy.33 This change to recommended treatment guidelines that 
had previously recommended RT following BCS for all age groups, was made after the 2004 
publication of the Cancer and Leukemia Group B (CALGB) C9343 trial study results 
demonstrated similar 5-year survival between women with these clinical characteristics who 
received BCS plus RT or BCS alone. However, since this change in treatment recommendations, 
evidence suggests that a greater number of elderly women do not receive RT or chemotherapy, 
than those that meet exemption requirements from RT or who are in too poor of health to 
undergo chemotherapy. 34-36 Women's receipt of GCC is often affected by their access to 
oncology services due to their location of residence and socio-demographic characteristics. 
Women residing in rural vs. urban areas, in areas with a lower density of oncology service 
providers, and that have greater distances to travel for care are more likely to not receive 
adjuvant treatments such as RT and chemotherapy, or delay the initiation of treatment. 26,36-38 
Women who are of black or non-white Hispanic race, lower income, lower education, publically 
insured or uninsured are less likely to receive GCC. 27,39,40 Race is also directly associated with 
survival outcomes. Black women have markedly worse survival outcomes, as compared to white 
women, such that 5-year survival for white and black women is 90% and 79%, respectively. 
1,41,42 In addition to vulnerable socio-demographic factors that decrease the likelihood of 
receiving GCC, black women diagnosed with breast cancer are more to have tumors with less 
favorable characteristics and aggressive cancers. 43,44   
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Statement of the Problem 
 While one can see from this review of the literature that numerous studies on breast 
cancer survival have been conducted throughout the years, the data sources, subsets of  
populations, stage at diagnosis, year of diagnosis, treatment patterns, and covariates, have also 
been numerous and of wide ranging. In contrast, this study seeks to provide a comprehensive 
understanding of overall breast cancer survival by examining all of the previously discussed 
factors associated with survival using large, nationally representative data set with recent 
survival data. Moreover, this study will focus on the survival of elderly women with breast 
cancer, who are uniquely vulnerable to worse survival outcomes due to increasing age and 
comorbidity.  
 Keeping these thoughts in mind, this study aims to examine overall 5-year survival and 
age, health, clinical prognostic factors, access to oncology care resources, socio-demographic 
characteristics, and treatment patterns among three different cohorts of elderly women with 
breast cancer sampled from the SEER-Medicare linked dataset. Survival analysis of the first 
cohort, a broadly inclusive group of women with stage I, II, and III breast cancer, will examine 
how age, health, clinical prognostic factors, and socio-demographic characteristics are associated 
with overall 5-year survival and provide a baseline understanding of survival as a cohort and by 
stage. The second cohort analyses will examine survival among women with early-stage (stage I 
and II) breast cancer according to the factors listed in cohort 1, and by type of loco-regional 
treatment (BCS plus RT, mastectomy, and BCS without RT). Building upon the first two 
analysis, the third cohort analysis will additionally determine how receipt of individual tests, 
treatments, and GCC vs. GDC are differentially associated with overall 5-year survival among 
elderly women with pathologically staged I, II, and III breast cancer.   
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Methods 
Data & Study Design 
 This retrospective cohort study was conducted using the linked SEER-Medicare dataset. 
The SEER-Medicare database was created in a collaborative effort by the National Cancer 
Institute (NCI) and Centers for Medicare and Medicaid Services (CMS) to combine clinical 
information gathered by the Surveillance Epidemiology and End Results cancer registry program 
with Medicare insurance claims. The SEER program collects basic socio-demographic, clinical, 
and vital status information on incident cancer cases from multiple reporting sources. This 
information is found the Patient Entitlement and Diagnosis Summary File (PEDSF). SEER data 
used for this study consisted of 17 population-based registries, representing 26% of the U.S. 
population. An algorithm based on name, Social Security number, sex, and date of birth 
successfully matched 94% SEER cases to their Medicare claims beginning from the time of 
eligibility till death.45 This study used Medicare claims providing information regarding 
beneficiary enrollment (Denominator File), hospital inpatient claims (MedPAR file), hospital 
outpatient claim (Outpatient file), physician office visits (NCH file), and durable medical 
equipment (DME file).46  Additionally, county and state of diagnosis were used to identify the 
area-level density of mammography screening and oncology centers from the U.S. Department 
of Health and Human Resource's 2009 Area Resource File (ARF).47    
Study Populations 
Cohort 1: All Women with Stage I, II, & III Breast Cancer 
 This study sample consisted of American Joint Commission on Cancer (AJCC) clinically 
and/or pathologically staged I, II, and III incident cases of breast cancer recorded in SEER 
during years 2003 to 2009, among female age-eligible Medicare beneficiaries who were 
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continuously enrolled in Medicare Part A and B fee-for-service programs 1 year before and after 
diagnosis, and were therefore age > 66 years at the time of diagnosis. Women were excluded if 
they were enrolled in a managed care program at any time during year before to the year after 
diagnosis, diagnosed at the time of death or upon autopsy, had end-stage renal disease, did not 
have primary surgical treatment, or surgeon specialty was missing. The final sample size was n = 
53,830 elderly women.  
Cohort 2: Local Treatment among Women with Stage I & II Breast Cancer  
 This study sample consisted of American Joint Commission on Cancer (AJCC) clinically 
and/or pathologically staged I and II incident cases of breast cancer recorded in SEER during 
years 2003 to 2009, among female age-eligible Medicare beneficiaries who were continuously 
enrolled in Medicare Part A and B fee-for-service programs 1 year before and after diagnosis, 
and were therefore age > 66 years at the time of diagnosis. Women were excluded if they were 
enrolled in a managed care program at any time during year before to the year after diagnosis, 
diagnosed at the time of death or upon autopsy, had end-stage renal disease, did not have primary 
surgical treatment, or surgeon specialty was missing. The final sample size was n = 45,981 
elderly women.  
Cohort 3: Guideline-Concordant Care among Women with Stage I, II, & III Breast Cancer 
 This study sample consisted of American Joint Commission on Cancer (AJCC) 
pathologically staged I, II, and III incident cases of breast cancer recorded in SEER during years 
2004 to 2009, among female age-eligible Medicare beneficiaries who were continuously enrolled 
in Medicare Part A and B fee-for-service programs 1 year before and after diagnosis, and were 
therefore age > 66 years at the time of diagnosis. Women were excluded if they were enrolled in 
a managed care program at any time during year before to the year after diagnosis, diagnosed at 
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the time of death or upon autopsy, died within the first year of diagnosis, had end-stage renal 
disease, did not have primary surgical treatment, or surgeon specialty was missing. The final 
sample size was n = 27,883 elderly women.  
Measures 
Dependent Variable 
 Overall survival is measured by examining all-cause mortality (breast cancer specific and 
all other causes of death). Survival outcomes measured were average time-to-death in days and 
5-year survival as calculated by subtracting the date of diagnosis from the Medicare date of death 
(DOD) or end of follow-up. Medicare DOD is captured from CMS's Master Enrollment (EDB) 
and MedPAR data files. The EDB obtains information regarding DOD from the Social Security 
Administration (SSA). The DOD is flagged as a "valid" date if it has been validated by a death 
certificate. If the DOD has not been validated then the DOD is set the last day of the month in 
which the beneficiary died. MedPAR records the DOD for those who died in a hospital. SEER 
registries also collect information regarding DOD from state death certificates and other sources. 
SEER and Medicare DOD information are in 99.5% level of agreement with one another.  
Observations were censored for women who were alive as of February 29, 2012.  
Independent Variables 
 Specific to cohort 2, initial loco-regional treatment received for early-stage breast cancer 
(BCS plus RT, mastectomy, or BCS only) was identified using surgical and radiation claims 
where the claim date was no later than 366 days from the date of diagnosis. Surgery claims were 
identified using the Medicare Provider and Analysis Review (MEDPAR), Physician/Supplier 
(NCH), and Outpatient files using International Classification of Diseases, 9th Revision (ICD-9) 
procedure codes, Healthcare Common Procedure Coding System (HCPCS), and Current 
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Procedural Terminology (CPT) to identify BCS (i.e. lumpectomy, partial mastectomy, segmental 
mastectomy) and mastectomy. When multiple claims for lumpectomy were present, or when a 
claim for lumpectomy was followed by a claim for mastectomy, only the first surgical claim was 
used, to identify initial choice for primary surgical treatment. Receipt of RT was identified from 
MEDPAR, NCH, Outpatient, and DME files using ICD-9 diagnosis codes, ICD-9 procedure 
codes, and HCPCS/CPT codes. Only the first claim was used to identify the initiation of RT. 
 Specific to cohort 3, GCC vs. guideline-discordant care (GDC) was determined by 
comparing the correct course of care according to tumor size and nodal status of each women as 
per NCCN evidence-based clinical practice guidelines, to the actual care received (Table 1). Care 
was also determined to be guideline-concordant if chemotherapy was initiated within 120 days of 
diagnosis, when chemotherapy was indicated, as per ASCO/NCCN quality measures, and if 
lymph node invasion, and hormone receptor statuses were tested. Although ASCO/NCCN 
quality measures indicate RT should be initiated within 1 year of diagnosis, this was not 
considered in the determination of GCC, as all claims used for this study were made within 1 
year after diagnosis. For this study purpose, being of age > 70 years was not considered a 
determining factor for GCC vs. GDC when RT or chemotherapy was indicated, in order to 
determine the extent that younger and older women receive differential care.  
 Within cohort 3, receipt of individual treatments and tests were also examined and 
included lymph node testing (yes or no), ER status testing (yes or no), PR status testing (yes or 
no), had any primary surgery (BCS or mastectomy) (yes or no), had BCS (yes or no), had 
mastectomy (yes or no), had RT (yes or no), had chemotherapy (yes or no), and chemotherapy 
was initiated within 120 day of diagnosis (yes, no, or not applicable).  Hormone receptor status 
testing was assessed using the status given by the ER status and PR status variable in the Patient 
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Entitlement and Diagnosis Summary File (PEDSF) file. If the status was listed as "positive", 
"negative", or "borderline", then the receptor status was determined to have been tested. If the 
status was listed as "unknown", then it was considered as not having been tested. Lymph node 
testing was defined by the claims codes for axillary lymph node dissection (ALND) or sentinel 
lymph node (SNB) biopsy. Surgical, RT, and chemotherapy treatments were determined using 
ICD-9 diagnostic and procedure, HCPCS/CPT codes found in the MEDPAR, Outpatient, and 
NCH data files. All claims codes are shown in Appendix 1. 
 Others measures examined in relation to survival were year of diagnosis, age at diagnosis 
(66-69, 70-74, 75-79, > 80), health, clinical prognostic factors, oncology care resources, and 
socio-demographic characteristics. Age was also dichotomized (66-69 or > 70) to estimate the 
probability of receipt of individual tests and treatments between younger and older elderly 
women in the third cohort. Health was measured examining patient comorbidity and frequency 
of primary care provider (PCP) visits. Patient comorbidity was calculated by applying an 
algorithm to Medicare claims that identifies a comorbid condition as the presence of at least one 
in-patient or two out-patient claims using ICD-9 diagnoses codes for each co-morbid condition. 
Overall comorbidity was then classified using the Klabunde adaption of the Charlson 
comorbidity index score (0, 1, > 2).48,49 An index of PCP visit intensity was identified by 
counting of number of unique PCP claim dates the year before diagnosis in the NCH file. PCP 
visits were categorized by lower and upper 50th percent median cutoff (low, high). Clinical 
prognostic factors examined were stage diagnosis (I, II, III) using the AJCC Stage Group 6th 
edition. Women in the cohort 3, were limited to those who were pathologically staged. Other 
clinical measures included tumor size (< 1cm, < 2 cm, 2 - 5 cm, > 5 cm), lymph node status 
(positive or negative), estrogen-receptor (ER) status, progesterone-receptor (PR) status (positive, 
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negative, borderline/unknown) and tumor grade (well differentiated, moderately differentiated, 
poorly differentiated, undifferentiated/unknown). Access to oncology care resources was 
examined using the density of area-level mammography screening and oncology treatment 
centers, and surgeon specialty. The density of area-level mammography screening centers and 
oncology treatment centers, relative to each women, was measured using data from the ARF and 
categorized lower and upper 50th percent median cutoff (low, high). Surgeon specialty was 
assessed using provider specialty claims codes 02, 49 (general) and 83, 90, 91, 98 (oncology) 
from the NCH file to determine the type of surgeon seen (general only, oncology only, both). 
Socio-demographic characteristics examined were race (white or other), education (measured by 
the 2000 Census tract survey of percent of persons age > 25 with at least 4 years college 
education) (< 15%, > 15%), annual income (measured by the 2000 Census tract survey of 
median income by census) (< $35,000, > $35,000), and metro status (non-metro, metro).  
Analysis 
 Descriptive analysis was performed for all study variables. Mantel-Haenszel chi-square 
tests of location shift using modified ridit scores or table scores and Mantel-Haenszel chi-square 
tests of general association (depending on whether the independent measure was dichotomous, 
nominal, or ordinal) were used to test for significant group differences between independent 
measures and women who were dead or alive 5 years after diagnosis, with significance set at P < 
.05. Cox proportional hazards regression models were used to estimate the hazard, or risk, of 
death at any time within 5 years of diagnosis, adjusting for independent variables. Parameter 
estimates calculated in the regression models are presented as adjusted hazard ratios (AHR) with 
their corresponding 95% confidence intervals (CI). The probability of death from time of 
diagnosis till end of follow-up was also estimated via survival functions for each study cohort 
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and stratified by stage at diagnosis, type of loco-regional treatment, and receipt of GCC using the 
Kaplan Meier method. All analysis were conducted using SAS version 9.4 software (SAS 
Institute Inc., Cary, NC). 
Results 
Cohort 1: All Women with Stage I, II, & III Breast Cancer 
Cohort Characteristics 
 Among elderly women diagnosed with stage I, II, and III breast cancer in 2003 to 2009, 
the average time-to-death was 1,247.2 (SD = + 722.3) days. The majority were > 80 years old 
(30.0%), had a comorbidity score = 0 (56.3%), had a low frequency of PCP visits (54.6%), 
diagnosed at stage I (56.0%), had ER positive (77.7%) and PR positive (64.8%) tumors, 
moderately differentiated tumor grades (42.7%), lived in areas with a low density of 
mammography screening centers (51.6%) and oncology treatment centers (56.0%), were treated 
by both a general and oncology surgeon (75.7%), white (88.6%), lived in metro areas (83.4%), 
areas where 15% or more of the population was college educated (69.9%) or where the average 
annual income was greater than $35,000 (75.7%).    
Group Differences in 5-Year Survival 
 All group comparisons (shown in Table 3) were significant at the P < 0.001 level. The 
average time-to-death between women who were alive and dead 5 years after diagnosis was 
2,327.2 days (SD = + 357.6) vs. 938.9 days (SD = + 454.1) (P < 0.001).  
Age & Health 
 As age at diagnosis increased, 5-year survival rates decreased, with 91.3% of women 
diagnosed at 66-69 years vs. 66.5% of women diagnosed at age > 80 years still living. Five-year 
survival rates decreased with increasing comorbidity, such that 86.2% of women with a 
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comorbidity score = 0 vs. 69.6% of women with a comorbidity score > 2 were still alive 5 years 
after diagnosis. Women with a lower frequency of PCP visits (84.5%) had higher 5-year survival 
rates than women with a higher frequency of visits (78.1%). 
Clinical Prognostic Factors  
 Women diagnosed at stage I (88.3%) had higher 5-year survival rates than those 
diagnosed at stage II (77.4%) and III (58.1%). Women whose tumors were ER and PR positive 
(84.1% & 84.9%) had higher 5-year survival rates, than those that were ER and PR negative 
(72.0% & 75.8%). Women with well differentiated tumors also had higher 5-year survival rates 
(88.1%), than those who were moderately (83.8%), poorly (73.3%) differentiated, or 
undifferentiated/unknown (75.9%). 
Oncology Care Resources 
 Women who resided in areas with higher densities of mammography screening centers 
(82.1%) and oncology treatment centers (82.4%) had slightly higher 5-year survival rates, than 
those living in lower density areas (81.0% & 80.9%, respectively). Higher 5-year survival rates 
were observed among women treated by and oncology surgeon (82.4%) or both a general and 
oncology surgeon (83.6%), as compared to women treated by a general surgeon only (73.5%). 
Socio-Demographic Characteristics 
 In regards to race, 81.8% of white women vs. 79.4% of women of other race were still 
alive 5 years after diagnosis. Women residing in areas where the population was > 15% college 
educated (82.8%) and had average income > $35,000 (82.9%) had higher 5-year survival rates 
than those living in areas where < 15% was college educated (78.6%) and the average income 
was < $35,000 (77.2%). Similarly, women residing in metro areas (82.0%) had higher survival 
rates, than those living in non-metro areas (79.6%).  
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Risk of Death within 5 Years of Diagnosis 
Age & Health 
 Adjusted hazard ratios estimating the risk of death 5 years after diagnosis according to 
study covariates are presented in Table 4. The risk of death at any time within 5 years of 
diagnosis increased substantially as age at diagnosis increased, with women diagnosed at 70-74 
years, 75-79 years, and > 80 years being 24% (AHR, 1.24; 95% CI, 1.15, 1.35), 86% (AHR, 
1.86; 95% CI, 1.73, 2.01), and over 400% (AHR, 4.01; 95% CI, 3.74, 4.29) more likely to die 
than women diagnosed at age 66-69 years. Compared to women with a comorbidity score = 0, 
those with a score = 1 or score > 2 were 1.44 (95% CI, 1.37, 1.51) and 2.17 (95% CI, 2.06, 2.28) 
times more likely to die within 5 years of diagnosis. Similarly, women with a high frequency of 
PCP visits were 1.14 times more likely to die (95% CI, 1.10, 1.19), than women with a low 
frequency of visits, adjusting for all other variables.  
Clinical Prognostic Factors 
 Later stage at diagnosis was strongly associated with 5-year survival, such that women 
diagnosed at stage II and stage III had an 82% (AOR, 1.82; 95% CI, 1.74, 1.91) and 395% 
(AOR, 3.95; 95% CI, 3.74, 4.18) greater risk of death at any time within 5 years of diagnosis, 
compared to women diagnosed at stage I. Women with tumors that were ER and PR negative 
were 1.36 (95%CI, 1.27, 1.45) and 1.19 (95% CI, 1.12, 1.26) times more likely to die within 5 
years of diagnosis, than women with ER and PR positive tumors. Compared to women with well 
differentiated tumors, those with moderately, poorly, and undifferentiated/unknown tumors were 
1.14 (95% CI, 1.07, 1.21), 1.54 (95% CI, 1.44, 1.65), and 1.38 (95% CI, 1.27, 1.50) times more 
likely to die within 5 years of diagnosis. 
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Oncology Care Resources 
 Compared to women treated by a general surgeon, those who were treated by an 
oncology surgeon or both an oncology and general surgeon had a 22% (AOR, 0.78; 95%, 0.72, 
0.86) and 32% (AOR, 0.68; 95%, 0.65, 0.71) decreased risk of death within 5 years of diagnosis, 
adjusting for all other independent variables.  
Socio-Demographic Characteristics 
 Women residing in areas where > 15% of the population was college educated were 0.92 
times less likely (95% CI, 0.88, 0.99) to die within 5 years of diagnosis, than women living in 
less college educated areas. Similarly, women residing in areas with an average income > 
$35,000 were also less likely to die within 5 years of diagnosis. 
Kaplan Meier Estimates 
 Five-year overall survival rates for all women in cohort 1and stratified by stage at 
diagnosis are shown in Figures 1 and 2, with the number at risk for death given in 366 day 
intervals. Figure 2 shows that women with earlier stage at diagnosis have significantly greater 
probability of overall 5-year survival at all time points, than those with later stage at diagnosis (P 
< 0.001).  
Cohort 2: Local Treatment among Women with Stage I & II Breast Cancer 
Cohort Characteristics 
 The average time to death was 1,410.6 days (SD = + 696.9) among women diagnosed 
with early-stage breast cancer in 2003 to 2009. The majority of elderly women were age > 80 
years at diagnosis (28.7%), had a comorbidity score = 0 (56.7%), and a low frequency of PCP 
visits (54.0%). About 63% of women were diagnosed at stage I, most had ER (79.1%) and PR 
(66.3%) positive tumors, and moderately differentiated (43.6%) tumors. A little over half of 
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women lived in areas with a low density of mammography screening centers (51.7%), and low 
density of oncology treatment centers (56.0%). The majority of women were treated by both a 
general and oncology surgeon (75.6%). In regards to socio-demographics, most women were 
white (89.4%), lived in metro areas (83.3%), areas where the population was > 15% college 
educated (70.5%), and had an annual income > $35,000 (76.4%). More than half of the women 
received BCS plus RT (54.5%) as their initial loco-regional treatment, while 23.4% had 
mastectomy and 22.1% had lumpectomy without RT.  
Group Differences in 5-Year Survival 
 All group comparisons between women who were alive or dead 5 years after diagnosis 
were significant at the P < 0.001, except race (P = 0.092). Women still living 5 years after 
diagnosis had a significantly greater time-to-death (M = 2,338.7 days, SD = + 361.6), than those 
who died (M = 1055.1 days, SD = + 406.5) (P < 0.001). 
Age & Health 
 Survival rates decreased with increasing age. About 94% of women age 66-69 years vs. 
73.3% of women age > 80 years were still living 5 years after diagnosis. Those with a 
comorbidity score = 0 had higher 5-year survival rates (89.9%), than women with a score = 1 
(79.8%) and score > 2 (75.2%). Compared to women with a high frequency of PCP visits 
(82.8%), women with a low frequency of PCP visits had higher 5-year survival rates (88.6%). 
Clinical Prognostic Factors 
 Elderly women diagnosed at stage I had an 89.5% 5-year survival rate, whereas women 
diagnosed at stage II had a 79.9% 5-year survival rate. Similar differences were observed 
between positive and negative tumor receptors. Those with ER and PR positive tumors had 
87.6% and 88.1% 5-year survival rates, in contrast to 79.1% and 81.9% survival rates among 
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those with ER and PR negative tumors. Women with well-differentiated tumor grades had the 
highest 5-year survival rates (89.9%), compared to women with moderately (86.9%), poorly 
(80.2%), and undifferentiated/unknown tumor grades (85.0%). 
Oncology Care Resources 
 Women residing in areas with a high density of mammography screening centers and 
oncology treatment centers had slightly higher 5-year survival rates (86.5% & 86.7%), than those 
residing in lower density areas (85.4% & 85.4%, respectively). Whereas women who were 
treated by an oncology surgeon (87.3%) or both an oncology and general surgeon had higher 5-
year survival rates (87.8%), than those treated by a general surgeon (78.0%). 
Socio-Demographic Characteristics 
 Women who resided in metro vs. non-metro areas (86.3% vs. 84.3%), areas where > 15% 
of the population was college educated vs. < 15% college educated (87.0% vs. 83.5%) or annual 
income > $35,000 vs. < $35,000 (87.0% vs. 82.6%) had higher 5-year survival rates.  
Treatment 
 Women who were received BCS plus RT as their initial loco-regional treatment had 
higher 5-year survival rates at almost 92%, compared to women who were treated with 
mastectomy (79.3%) or BCS only (78.2%).  
Risk of Death within 5 Years of Diagnosis 
Age & Health 
 Women who age 70-74, 75-79, and > 80 years had a 21% (AHR, 1.21; 95% CI 1.10, 
1.34), 90% (AHR, 1.90; 95% CI, 1.73, 2.09), and 376% (AHR, 3.76; 95% CI, 3.45, 4.10) 
increased risk of death within 5 years of diagnosis, adjusting for all other independent variables, 
than women age 66-69 years at diagnosis. Compared to women with a comorbidity score = 0, 
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those with a score = 1 or score > 2 were 1.49 (95% CI, 1.41, 1.58) and 2.39 (95% CI, 2.25, 2.55) 
times more likely to die within 5 years of diagnosis. 
Clinical Prognostic Factors 
 Women diagnosed at stage II had a 65% increased risk of death within 5 years of 
diagnosis (AHR, 1.66; 95% CI, 1.57, 1.74), compared to women diagnosed at stage I. Women 
with ER and PR negative tumors were 33% (AHR, 1.33; 95% CI, 1.23, 1.45) and 17% (AHR, 
1.17; 95% CI, 1.09, 1.26) more likely to die within 5 years of diagnosis. Having poorly 
differentiated tumors increased the hazard of death by 49% (AHR, 1.49; 95% CI, 1.38, 1.61), 
while having moderately tumors increased the hazard of death by 15% (AHR, 1.15; 95% CI, 
1.08, 1.24), compared well differentiated tumors. 
Oncology Care Resources 
 Women treated by an oncology surgeon or both an oncology and general surgeon had a 
lower risk of death within 5 years of diagnosis, (AHR, 0.81, 95% CI, 0.72, 0.91) and (AHR, 
0.72; 95% CI, 0.68, 0.76), than women treated by a general surgeon only. 
Socio-Demographic Characteristics 
 Those who resided in areas where > 15% of the population was college educated were 
0.91 times less likely (95% CI, 0.86, 0.97) to die within 5 years of diagnosis, than those residing 
in areas where < 15% of the population is college educated.  
Treatment 
 Compared to women received BCS plus RT as their initial loco-regional treatment for 
early-stage breast cancer, those who had BCS without RT had a 94% (AOR, 1.94; 95% CI, 1.82, 
2.06) and 81% (AOR, 1.81; 95% CI, 1.70, 1.93) increased risk of death within 5 years of 
diagnosis.  
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Kaplan Meier Estimates 
 Overall 5-year survival curves for all women with early-stage breast cancer and 
according to type of treatment received are shown in Figures 3 & 4 with the number at risk in 
366 day intervals. Women who received BCS plus RT had significantly lower probability of 
death at all time points within 5 years of diagnosis, than those who had mastectomy or BCS only.  
Cohort 3: Guideline-Concordant Care among Women with Stage I, II, & III Breast Cancer 
Cohort Characteristics 
 Among women diagnosed with pathologically staged I, II, and III breast cancer in 2004 
to 2009, the average time to death was 1,246.1 days (SD = + 600.8). The majority of women 
were diagnosed at age 70-74 years (27.1%), had a comorbidity score = 0 (55.7%), and had a low 
frequency of PCP visits (55.1%). More than half of the women were diagnosed at stage I 
(56.4%), while about a third were diagnosed at stage II (34.1%), and the rest at stage III (9.5%). 
Most women had ER and PR positive tumors (80.0% & 67.3%) moderately differentiated tumors 
(44.1%), tumors < 2 cm (38.4%), and were lymph node negative (73.1%). The majority of 
women lived in areas with a low density of mammography screening (56.2%) and a high density 
of oncology treatment centers (55.0%). About 80% were treated by both an oncology and general 
surgeon. Most, women were white (88.2%), lived in metro areas (83.3%), areas where > 15% of 
the population was college educated (69.5%), and had an annual income > $35,000 (75.6%).  
Treatment 
 Less than 34% of elderly women with stage I, II, and III breast cancer received GCC. The 
vast majority of women had the ER (95.0%) and PR (94.8%) status of their tumors tested and 
lymph nodes tested (92.1%). Almost all women had some form of primary surgical treatment 
(99.5%), while 74.8% had BCS and 41.7% had mastectomy. Type of surgery adding up to 
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greater than 100%, reflects women who had both BCS and mastectomy. About 61% of women 
had RT, while only a quarter (25.1%) had chemotherapy. Breaking it down further, 20.8% of the 
total sample had timely chemotherapy, while 4.3% didn't have timely chemotherapy.  
Group Differences in 5-Year Survival 
 Most group differences between women who alive or dead 5 years after diagnosis were 
significant at the P < 0.001 level, with the exception of density of oncology treatment centers (P 
= 0.002), had any surgery (P = 0.172), and had chemotherapy (P = 0.036). Time-to-death was 
significantly greater among women who were still living 5 years after diagnosis (M = 2,192.3 
days, SD = + 261.0), than those who were not (M = 1016.8 days, SD = + 402.4) (P < 0.001).  
Age & Health 
 Five-year survival rates decreased with increasing age at diagnosis, such that 93.6% of 
women age 66-69 years were alive within 5 years of diagnosis, whereas 76.7% of women age > 
80 years were still living. Women with a comorbidity score = 0, had higher 5-year survival rates 
were higher (90.8%), than those with a comorbidity score = 1 (86.2%), or score > 2 (78.9%). 
Women with a lower frequency of PCP visits also had higher 5-year survival rates (89.6%), than 
women with a higher frequency of visits (84.9%).  
Clinical Prognostic Factors 
 Five-year survival rates decreased with increasing stage at diagnosis. Women diagnosed 
at stage I had a survival rate of 92.6%, where as those diagnosed at stage II and III had survival 
rates of 84.5% and 67.7%, respectively. Similarly, 5-year survival rates decreased with 
increasing tumor size, such that women with tumors < 1 cm had a 94.1% survival rate, while 
those with tumors > 5 cm had a 5-year survival rate of 68.1%. Women with ER and PR positive 
tumors had higher 5-year survival rates (89.2% & 89.7%), than those with ER and PR negative 
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tumors (79.4% & 82.7%). Those with well differentiated tumors had the highest survival rates 
(92.4%), while those with poorly differentiated tumors had the lowest (80.6%). Elderly women 
who were lymph node negative had a 5-year survival rate of 90.8%, compared to 78.6% among 
women who were lymph node positive. 
Oncology Care Resources 
 Greater 5-year survival rates were observed among women residing in areas with a higher 
density of mammography screening centers (88.5%) and oncology treatment centers (88.1%) vs. 
low density areas (86.7% & 86.8%, respectively). Women receiving treatment from an oncology 
surgeon had the highest 5-year survival rates (89.7%), followed by those treated by both 
oncology and general surgeons (88.2%), and then those treated by a general surgeon only 
(82.7%). 
Socio-Demographic Characteristics 
 Higher survival rates were observed among white women vs. women of other race 
(87.9% vs. 84.8%), women residing in metro areas vs. non-metro areas (87.9% vs. 85.3%), in 
areas where > 15% of the population was college education vs. < 15% (88.6% vs. 84.9%), and 
areas with an annual income > $35,000 vs. < $35,000 (88.6% vs. 84.3%). 
Treatment 
  Among women who received GCC, 5-year survival rates were 92.8%, while they were 
84.9% among women who received GDC. Women who had their ER & PR status tested (87.7% 
& 87.7%), than those who did not (83.9% & 84.0%). Likewise, women who had their lymph 
nodes tested had higher 5-year survival rates (88.1%), than women who did not have them tested 
(80.5%). Five-year survival rates were higher among those who had BCS (90.3%), compared to 
those who did not have BCS (79.3%), while survival rates were higher among those who did not 
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have mastectomy (92.0%), compared to those who had mastectomy (81.2%). Individuals who 
had RT had higher 5-year survival rates (91.1%), than those who did not have RT (81.8%). 
Women who had timely chemotherapy had higher 5-year survival rates (87.5%), than women 
who did not have chemotherapy in the recommended time period (83.4%).  
Risk of Death within 5 Years of Diagnosis 
Age & Health 
 Compared to women diagnosed at age 66-69 years, those diagnosed at age 70-74, age 75-
79, and age > 80 years were 1.17 (95% CI, 1.04, 1.33), 1.73 (95% CI, 1.54, 1.95), and 2.85 (95% 
CI, 2.54, 3.20) times more likely to die within 5 years of diagnosis. In contrast to women with a 
comorbidity score = 0, those with a comorbidity score = 1 or score > 2, had an increased risk of 
death within 5 years of diagnosis by 38% (AHR, 1.38; 95% CI, 1.27, 1.50) and 209% (AHR, 
2.09; 95% CI, 1.92, 2.27). Those with a high frequency of PCP visits had an 18% increased 
hazard of death (AHR, 1.18; 95% CI, 1.10, 1.26), compared to women with a low frequency of 
visits. 
Clinical Prognostic Factors 
 Compared to women diagnosed at stage I, those diagnosed at stage III had an 81% (AHR, 
1.81; 95% CI, 1.48, 2.21) increased hazard for death within 5-years of diagnosis. The hazard of 
death increased with increasing tumor size, with women with tumors > 5 cm having the greatest 
risk (AHR, 2.30; 95% CI, 1.89, 2.80), compared to women with tumors < 1 cm. Women with ER 
& PR negative tumors were 1.48 (95% CI, 1.32, 1.65) and 1.13 (95% CI, 1.03, 1.25) times more 
likely to die within 5 years of diagnosis, than women with ER & PR positive tumors. Those with 
poorly differentiated tumor grades were 1.49 (95% CI, 1.33, 1.67) times more likely to die within 
5 years of diagnosis, compared to women with well differentiated tumors. Being lymph node 
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negative decreased to hazard for death within 5 years of diagnosis by 32% (AHR, 0.68; 95% CI, 
0.61, 0.76), compared to being lymph node positive. 
Oncology Care Resources 
 Women who were treated by an oncology surgeon or both an oncology and general 
surgeon had 26% (AHR, 0.74; 95% CI, 0.62, 0.87) and 22% (AHR, 0.78; 95% CI, 0.71, 0.85) 
decreased risk of death, compared to those treated by a general surgeon only. 
Kaplan Meier Estimates 
 Figures 5 & 6 show 5-year survival rates for all women with pathologically staged I, II, 
and III breast cancer and by receipt of GCC, with the number remaining at risk in 366 day 
intervals. Women who received GCC had a lower probability of death within 5-years of 
diagnosis at all time points, than women who received GDC (P < 0.001).  
Discussion 
 Breast cancer mortality has decreased by 34% from 1990 to 2010 among all populations 
of women. 3 Simultaneously, long-term overall survival has increased to 89% for 5-year survival 
among all women diagnosed with breast cancer, and as high as 100% for women diagnosed at 
stage I and 99% for women diagnosed with localized breast cancer (lymph node negative/non-
metastasized). 2,3 Despite these promising statistics, multiple factors remain associated with 
differential survival outcomes among elderly with breast cancer. This study began by examining 
overall 5-year survival among a broadly inclusive cohort of elderly women with stage I, II, and 
III breast cancer and how the risk of death is associated with age, health, clinical prognostic 
factors, oncology care resources, and socio-demographic characteristics. A strong association for 
increased risk of death within 5 years of diagnosis was observed with increasing age, 
comorbidity, and stage at diagnosis. The next survival analysis addressed the controversy with 
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differential type of loco-regional treatment among elderly women with early-stage breast cancer 
and demonstrated that women who have BCS without RT or mastectomy have a substantially 
increased risk of death within 5 years of diagnosis, compared to women who have BCS plus RT. 
Study findings from the first cohort analysis were also confirmed. Examination of the link 
between treatment patterns and survival was extended in the third cohort analysis to determine 
the association between receipt of individual tests and treatments and receipt of GCC, among 
women with pathologically staged I, II, and III breast cancer. This analysis observed that women 
who did not have RT, chemotherapy, or GCC were at increased risk of death, in addition to the 
associations observed by the first two analysis. Overall 5-year survival rates observed among 
cohorts ranged from 82% - 88%. A more in-depth discussion of these findings follows.  
Age & Health 
 Across all three study cohorts, age, comorbidity, and frequency of PCP visits were of the 
strongest and most consistent predictors of overall breast cancer survival. In all analyses the 
hazard of 5-year mortality increased substantially with increasing age. Compared to women age 
66-69 years at diagnosis, those who were a 70-74 had a 17% to 24% increased hazard of death, 
while those who were age > 80 years had a 3 to 4 fold increased hazard of death. With increasing 
age, comes increased comorbidity. Some degree of comorbidity was observed in up to 44% of 
women. Compared to women no comorbidity, a comorbidity score = 1 had a 38% to 49% 
increased risk of death while women with comorbidity score > 2 had as much as 239% increased 
risk of death. The increased hazard of death associated with comorbidity was most likely 
reflected in the increased hazard of death associated with a high frequency of PCP visits. Age 
and comorbidity are intrinsic risk factors for mortality, regardless of a history of breast cancer. 
However, the mortality risk associated with age and comorbidity alone may be amplified given a 
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history of breast cancer. Moreover, increasing age and comorbidity are associated with receipt of 
less aggressive treatment that may also increase the risk of mortality. Patnaik and colleagues 
(2011) observed similar increased 5-year mortality hazard ratios associated with age and 
comorbidity among elderly women with breast cancer. 50 Schonberg et al. (2010) also found that 
age and comorbidity increased the risk breast cancer specific and other-cause mortality, though 
the effect was less pronounced for breast cancer-specific mortality. 51 
 Clinical Prognostic Factors 
 Not surprisingly, one of the strongest predictors of overall 5-year survival across all three 
study samples was stage at diagnosis. Five-year survival rates ranged from 88% to 93% for 
women diagnosed with stage I breast cancer, in contrast to 58% to 68% for those diagnosed with 
stage III breast cancer. What is more, the hazard of death as much as 4 times higher among 
women diagnosed at stage III, compared to those diagnosed at stage I. Breast cancer prognosis is 
very good at earlier stages when the cancer remains localized to the breast tissue and has not 
spread to the lymphatic system or metastasized to the rest of the bodily organs. In fact, 
Schonberg and colleagues (2011) found that when elderly women are diagnosed at stage 0 or 
stage I, they are no more likely to die within 10 years of diagnosis than elderly without a history 
of breast cancer. 52 In similar fashion, other clinical cancer characteristics directly associated 
with stage at diagnosis, such as tumor size and lymph node status were associated with overall 
survival. Increasing tumor size was negatively associated with survival, such that women with 
tumors 2-5 cm and > 5 cm had roughly a two-fold risk of death within 5-years of diagnosis. For 
women whose cancer had spread into the lymph nodes, the hazard of death increased more than 
30%, compared to those who were lymph node negative. A study by Colzani and colleagues 
(2011) reported a two-fold increase for hazard of death within 5 years of diagnosis among 
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women with 1-3 positive lymph nodes, and almost four-fold increase for those with > 4 positive 
lymph nodes. 53 Aside from chemo prevention or prophylactic use of hormone therapy among 
women at increased risk for breast cancer, the next best approach to maximizing survival is early 
detection by means of routine mammography screening. Unfortunately, the well-documented 
decline in routine mammography screening among elderly women decreases the likelihood for 
early detection. 54,55 Despite the positive association between age and increased risk, guidelines 
for mammography screening make no recommendation for routine screening among women age 
> 75 years. 56 Although routine mammography screening among elderly women is associated 
with earlier stage at diagnosis and better survival, the debate regarding continued screening 
among women age > 75 years persists. 57 The debate revolves around lack of clinical trial based 
evidence for continued screening among older women, life-expectancy, competing health 
demands, and harms of false-positive and over diagnosis. 58  
 However, some clinical prognostic factors are unaffected by stage at diagnosis. Factors 
with a biological basis, such as tumor grade and hormone receptor status, are also associated 
with survival outcomes. Women whose tumors are well-differentiated and are ER/PR positive 
have greater survival, than women with poorly differentiated and ER/PR negative. 53,50 Only 
about a quarter of women in each cohort had well-differentiated tumors. Poorly differentiated 
tumors increased the hazard of 5-year mortality by about 50%. Over 3/4 of elderly had ER 
positive tumors, while 65% to 67% had PR positive tumors. Negative ER tumors increased the 
hazard of 5-year mortality by 33% to 48%, while negative PR tumors only increased the hazard 
by 13% to 19% among elderly women. Breast cancers that are ER and PR negative are often 
times more aggressive and fast growing cancers. Since they do not respond to adjuvant hormone 
therapy, they tend to be more challenging to treat.  
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Oncology Care Resources 
 Although the risk of death within 5 years of diagnosis was not different based on density 
of area-level mammography screening and oncology treatment centers, surgeon specialty was 
associated with risk of death. Women who were treated by an oncology surgeon had a 19% - 
26% decreased risk of 5-year mortality, than women treated by a general surgeon. While women 
treated by both an oncology and general surgeon had a 22% - 32% decreased risk of mortality. 
Being treated by both specialties might be associated with a lower mortality risk because division 
of care may be an indication of high patient volume, a factor associated with increased GCC.59 
Also, having an oncologist participate in the woman's cancer treatment may ensure coordination 
of guideline recommended care.  
Socio-Demographic Characteristics 
 Women who resided in areas with greater education and income were at somewhat of a 
decreased risk of death within 5 years of diagnosis, compared to women residing less educated or 
lower income areas. Specialty health care services are generally more common to in areas with 
greater education and income. Also, individuals with greater education and income may be more 
knowledgeable about breast cancer, be more confident navigating the health care system, and 
have a greater propensity to seek health care services. 60-62 In contrast with previous studies, an 
association with black race and poorer survival was not observed in this study. This difference in 
findings may be due to the way race was categorized by this study (white vs. non-white). 
Additionally, some of the poorer survival historically observed among women of black race, may 
have already been adjusted for with other socio-demographic characteristics and access to 
oncology care.  
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Treatment Patterns 
 The course of breast cancer treatment is most often determined by cancer characteristics 
and guided by evidence-based clinical treatment guidelines. In some instances, the course of 
treatment may be modified in consideration of patient preferences or health status. Women with 
early-stage breast cancer usually have a choice of primary treatment. Breast-conserving surgery 
followed by RT is equally as effective for long-term survival as mastectomy for women with 
tumors < 5 cm. 12-15 For many women, BCS plus RT is the preferred choice of treatment because 
of breast preservation. In spite of that, adjuvant treatments such as RT and chemotherapy often 
have adverse short and long-term side effects that may be intolerable for older women 
considered to be frail or in poor health, and may be perceived as an unnecessary burden for those 
with a short life expectancy. 28-31 In 2004, the NCCN modified guidelines for RT after BCS 
applicable to a select group of women age > 70, following results of the CALGB C9343 trial that 
found overall survival to be equal between women age > 70 years with early-stage ER positive 
breast cancer receiving BCS and tamoxifen vs. BCS plus RT and tamoxifen. 32,33,63 Additionally, 
NCCN treatment guidelines make no recommendation for or against chemotherapy in women 
age > 70 years, when otherwise indicated, but suggest the decision be made on a case-by-case 
basis considering patient health. However, concern has been raised whether the omission of RT 
for early-stage ER positive breast cancers when tamoxifen is taken, is actually as effective for 
overall survival, since there is a small increase in locoregional recurrence among women who 
omitted RT. Moreover, retrospective studies have shown that a large proportion of elderly 
women do not receive RT or chemotherapy, raising the question whether more elderly are 
omitted from these treatments than should be, and consequently jeopardizing survival.     
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 Among the sample of elderly women with early-stage breast cancer in this study, 55% 
had BCS plus RT, 23% had mastectomy, and 22% had BCS without RT. Notably, elderly 
women who were treated with BCS without RT were at almost twice the risk of 5-year mortality, 
compared to women who were treated with BCS plus RT. Those who were had mastectomy were 
also 1.80 times more likely to die within 5 years of diagnosis, compared to women treated with 
BCS plus RT. Findings from the analysis of elderly women with pathologically staged I thru III 
breast cancer, also indicate a 53% increased hazard for 5-year mortality among women who did 
not receive RT, a 16% increased mortality risk for women who did not have chemotherapy, and a 
22% increased risk of death for who did not receive chemotherapy within a timely manner. 
Furthermore, women who did not receive GCC had about a 20% increased risk of death within 5 
years of diagnosis, compared to women who received GCC. The observed increased risk of 
breast cancer specific and overall mortality among women receiving BCS without vs. BCS plus 
RT, is corroborated by multiple published studies. 51,64,65 Yood and colleagues (2008) observed 
that elderly women treated with BCS without vs. BCS plus RT were 1.86 times the risk of 10-
year overall mortality, a finding strikingly similar to this study. 65 Additional findings regarding 
the receipt of RT, chemotherapy, and GCC may be partially explained by the propensity to use 
less aggressive or lengthy treatments among elderly women or women who are already in poor 
health or have a short life expectancy. 51,66  
Limitations & Strengths  
 Several limitations should be kept in mind when interpreting the results of this study. 
First of all, this study assessed overall survival and not breast-cancer specific survival. While 
many of the factors examined in this study have been directly and indirectly associated with 
breast cancer specific mortality, the results of this study should not be generalized to breast 
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cancer specific mortality, but overall mortality, which includes both breast cancer specific 
mortality and all other causes of death. Another limitation is that this study did not look at the 
association between more race/ethnicity classifications. Survival disparities among black women 
have been well-document, but was not captured by this study. Additionally, when examining the 
association between GCC, receipt of individual treatments, and survival, this study did not make 
allowances for women age > 70 years to be omitted from treatment, but rather included older 
women in the definition of GCC to make comparisons in receipt of aggressive treatment between 
younger and older women. Completion of adjuvant therapies was not assessed, only the initiation 
of therapy. Also, tumor receptor status was used as a proxy measure of for tumor receptor testing 
and does not provide any information regarding the initiation of adjuvant hormone therapy when 
indicated. Additionally, several of socio-demographic characteristics examined were aggregate 
census level measures, rather than individual level measures. Finally, the SEER individuals 
within the SEER database have been found to be of higher income, and higher concentrations of 
racial and ethnic minorities, as compared to the U.S. population.67  
 Despite these limitations, this study holds several strengths that impart credibility to its 
findings. First and foremost, this study provides a comprehensive description of how numerous 
factors are associated with overall survival, beginning by examining the relationship between 
age, health, clinical prognostic factors, oncology care resources, and socio-demographic 
characteristics and survival among a large inclusive cohort of women with stage I, II, and III 
breast cancer. Additional analysis examined the associations between various aspects of 
treatment and survival among more specific cohorts of elderly women with breast cancer. 
Moreover, this study examined survival outcomes using a large cohorts spanning 8 years of 
relatively recent data. Algorithms were used to identify receipt of GCC based on the 
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recommended course of treatment according to cancer characteristics put forth by the NCCN and 
ACSO. Despite containing slightly greater proportions of affluent and minority individuals, 
SEER is widely accepted as representative of the U.S. population, making these results 
generalizable to the greater population of elderly women with invasive early-stage breast cancer 
insured by Medicare.     
Significance & Conclusions 
 In conclusion, despite the twenty-plus year improvement in breast cancer survival and 
relatively high survival rates, several factors remain formidable influences on survival. While 
certain factors with direct effects on survival, such as stage at diagnosis, are modifiable via 
earlier detection, others are non-modifiable. Non-modifiable factors, such as age at diagnosis, 
cannot be changed, and may require novel approaches to improving breast cancer survival in 
relation to increasing age. This is particularly challenging given the tendency for elderly women 
to be undertreated, a finding in of itself associated with an increased risk of death. However, a 
factor that is strongly associated with both survival and age, and may be a promising area to 
target increased survival among all populations, but especially the elderly, is comorbidity. 
Multiple chronic disease and its burden of illness is a growing epidemic in the US and 
throughout developing countries, due to increasing obesity rates and lifestyle. The effects of 
obesity, lifestyle behaviors, and associated chronic disease are far-reaching. While it would not 
eliminate all incidence and mortality from breast cancer, decreasing the prevalence of chronic 
disease, by decreasing obesity and improving lifestyle behaviors, would have a meaningful and 
positive impact on the incidence and survival from breast cancer.      
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Table 1 
Characteristics of Elderly Women with Invasive Non-Metastatic Breast Cancer 
  
All Stage I, II, III Stage I, II/Local Treatment Stage I, II, III/GCC 
    SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009 
  
N 
 
% 
 
N   %   N   %   
All  53,830  100.0  45,981   100.0   27,883   100.0   
Time to Death (Days) 
            
 
Mean(SD)  1247.2 (722.3)
 
1410.6 (696.9) 
 
1246.7 (600.8) 
 Alive 5 Years After Diagnosis 
           
 
Yes 43899 
 
81.6
 
39520 
 
86.0 
 
24398 
 
87.5 
 
 
No 9931 
 
18.5 
 
6461 
 
14.1 
 
3485 
 
12.5 
 Year of Diagnosis 
            
 
2003 7477
 
13.9
 
6667 
 
14.5 
 
― 
 
― 
 
 
2004 7728 
 
14.4 
 
6527 
 
14.2 
 
3885 
 
13.9 
 
 
2005 7669 
 
14.3 
 
6418 
 
14.0 
 
3726 
 
13.4 
 
 
2006 7665 
 
14.2 
 
6494 
 
14.1 
 
3873 
 
13.9 
 
 
2007 7696 
 
14.3 
 
6564 
 
14.3 
 
4025 
 
14.4 
 
 
2008 7739 
 
14.4 
 
6629 
 
14.4 
 
6151 
 
22.1 
 
 
2009 7856 
 
14.6 
 
6682 
 
14.5 
 
6223 
 
22.3 
 Age & Health 
Age at Diagnosis 
            
 
66-69 11965
 
22.2
 
10331 
 
22.5 
 
6694 
 
24.0 
 
 
70-74 13413 
 
24.9 
 
11741 
 
25.5 
 
7551 
 
27.1 
 
 
75-79 12322 
 
22.9 
 
10731 
 
23.3 
 
6704 
 
24.0 
 
 
> 80 16130 
 
30.0 
 
13178 
 
28.7 
 
6934 
 
24.9 
 Comorbidity Score 
            
 
0 30287
 
56.3
 
26061 
 
56.7 
 
15520
 
55.7
 
 
1 14483 
 
26.9 
 
12439 
 
27.1 
 
7559 
 
27.1 
 
 
> 2 9060 
 
16.8 
 
7481 
 
16.3 
 
4804 
 
17.2 
 PCP Visits 
            
 
Low 29367
 
54.6
 
24834 
 
54.0 
 
15354
 
55.1
 
 
High 24463 
 
45.4 
 
21147 
 
46.0 
 
12529 
 
44.9 
 Clinical Prognostic Factors 
Stage at Diagnosis 
            
 
I 30153
 
56.0
 
28931 
 
62.9 
 
15731
 
56.4
 
 
II 18196 
 
33.8 
 
17050 
 
37.1 
 
9514 
 
34.1 
 
 
III 5481 
 
10.2 
 
― 
 
― 
 
2638 
 
9.5 
 ER Status 
            
 
Positive 41840
 
77.7
 
36364 
 
79.1 
 
22298
 
80.0
 
 
Negative 7904 
 
14.7 
 
6301 
 
13.7 
 
4136 
 
14.8 
 
 
Borderline/Unknown 4086 
 
7.6 
 
3316 
 
7.2 
 
1449 
 
5.2 
 PR Status 
            
 
Positive 34894
 
64.8
 
30504 
 
66.3 
 
18762
 
67.3
 
 
Negative 14377 
 
26.7 
 
11766 
 
25.6 
 
7463 
 
26.8 
 
 
Borderline/Unknown 4559 
 
8.5 
 
3711 
 
8.1 
 
1658 
 
6.0 
 Tumor Grade 
            
 
Well Differentiated 13093
 
24.3
 
12118 
 
26.4 
 
6741
 
24.2
 
 
Moderately Differentiated 22957 
 
42.7 
 
20046 
 
43.6 
 
12287 
 
44.1 
 
 
Poorly Differentiated 13856 
 
25.7 
 
10831 
 
23.6 
 
7302 
 
26.2 
 
 
Undifferentiated/Unknown 3924 
 
7.3 
 
2986 
 
6.5 
 
1553 
 
5.6 
 BCS = breast-conserving surgery 
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Table 1 
Characteristics of Elderly Women with Invasive Non-Metastatic Breast Cancer 
  
All Stage I, II, III Stage I, II/Local Treatment Stage I, II, III/GCC 
    SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009 
  
N 
 
% 
 
N   %   N   %   
All  53,830  100.0  45,981   100.0   27,883   100.0   
             
             Tumor Size  
            
 
< 1 cm ― 
 
― 
 
― 
 
― 
 
8201 
 
29.4 
 
 
< 2 cm ― 
 
― 
 
― 
 
― 
 
10701 
 
38.4 
 
 
2 - 5 cm ― 
 
― 
 
― 
 
― 
 
7834 
 
28.1 
 
 
> 5 cm ― 
 
― 
 
― 
 
― 
 
1147 
 
4.1 
 Lymph Nodes 
            
 
Positive ― 
 
― 
 
― 
 
― 
 
7505 
 
26.9 
 
 
Negative ― 
 
― 
 
― 
 
― 
 
20378 
 
73.1 
 Oncology Care Resources 
Mammography Screening Centers 
         
 
Low 27783 
 
51.6 
 
23789 
 
51.7 
 
15665
 
56.2
 
 
High 26047 
 
48.4 
 
22192 
 
48.3 
 
12218 
 
43.8 
 Oncology Treatment Centers 
           
 
Low 30146 
 
56.0
 
25761 
 
56.0 
 
12541
 
45.0
 
 
High 23684 
 
44.0 
 
20220 
 
44.0 
 
15342 
 
55.0 
 Type of Surgeon Seen 
            
 
General Only  9613 
 
18.2 
 
8555 
 
18.6 
 
4045 
 
14.5 
 
 
Oncology Only 3235 
 
6.1 
 
2644 
 
5.8 
 
1638 
 
5.9 
 
 
Both 40001 
 
75.7 
 
34782 
 
75.6 
 
22200 
 
79.6 
 Socio-Demographic Characteristics 
Race 
            
 
White 47698
 
88.6
 
41090 
 
89.4 
 
24594
 
88.2
 
 
Other 6132 
 
11.4 
 
4891 
 
10.6 
 
3289 
 
11.8 
 Education 
            
 
< 15% college degree 16232
 
30.2
 
13557 
 
29.5 
 
8493
 
30.5
 
 
> 15%  college degree 37598 
 
69.9 
 
32424 
 
70.5 
 
19390 
 
69.5 
 Annual Income 
            
 
< $35,000 13057
 
24.3
 
10853 
 
23.6 
 
6806
 
24.4
 
 
> $35,000 40773 
 
75.7 
 
35128 
 
76.4 
 
21077 
 
75.6 
 Metro Status 
            
 
Non-metro 8965
 
16.7
 
7686 
 
16.7 
 
4660
 
16.7
 
 
Metro 44865 
 
83.4 
 
38295 
 
83.3 
 
23223 
 
83.3 
 Tests & Treatments 
Loco-Regional Treatment 
           
 
BCS+Radiation ― 
 
― 
 
25067 
 
54.5 
 
― 
 
― 
 
 
Mastectomy ― 
 
― 
 
10768 
 
23.4 
 
― 
 
― 
 
 
BCS Only ― 
 
― 
 
10146 
 
22.1 
 
― 
 
― 
 Guideline-Concordant Care 
           
 
Yes ― 
 
― 
 
― 
 
― 
 
9336 
 
33.5 
 
 
No ― 
 
― 
 
― 
 
― 
 
18547 
 
66.5 
 ER Status Tested 
            
 
Yes ― 
 
― 
 
― 
 
― 
 
26482 
 
95.0 
 
 
No  ― 
 
― 
 
― 
 
― 
 
1401 
 
5.02 
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Table 1 
Characteristics of Elderly Women with Invasive Non-Metastatic Breast Cancer 
  
All Stage I, II, III Stage I, II/Local Treatment Stage I, II, III/GCC 
    SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009 
  
N 
 
% 
 
N   %   N   %   
All  53,830  100.0  45,981   100.0   27,883   100.0   
PR Status Tested 
            
 
Yes ―
 
―
 
―
 
―
 
26435
 
94.8
 
 
No ― 
 
― 
 
― 
 
― 
 
1448 
 
5.19 
 BCS = Breast-Conserving Surgery 
            Lymph Nodes Tested 
            
 
Yes ― 
 
― 
 
― 
 
― 
 
25685 
 
92.1 
 
 
No  ― 
 
― 
 
― 
 
― 
 
2198 
 
7.9 
 Had any Surgery 
            
 
Yes ― 
 
― 
 
― 
 
― 
 
27754 
 
99.5 
 
 
No ― 
 
― 
 
― 
 
― 
 
129 
 
0.5 
 Had BCS 
            
 
Yes ― 
 
― 
 
― 
 
― 
 
20865 
 
74.8 
 
 
No ― 
 
― 
 
― 
 
― 
 
7018 
 
25.2 
 Had Mastectomy 
            
 
Yes ― 
 
― 
 
― 
 
― 
 
11636 
 
41.7 
 
 
No ― 
 
― 
 
― 
 
― 
 
16247 
 
58.3 
 Had Radiation  
            
 
Yes ― 
 
― 
 
― 
 
― 
 
17023 
 
61.1 
 
 
No ― 
 
― 
 
― 
 
― 
 
10860 
 
39.0 
 Had Chemotherapy 
            
 
Yes ― 
 
― 
 
― 
 
― 
 
6992 
 
25.1 
 
 
No ― 
 
― 
 
― 
 
― 
 
20891 
 
74.9 
 Time to Chemotherapy 
            
 
Appropriate ― 
 
― 
 
― 
 
― 
 
5796 
 
20.8 
 
 
Not Appropriate ― 
 
― 
 
― 
 
― 
 
1196 
 
4.3 
  No Chemotherapy ―  ―  ―  ―  20891  74.9  
BCS = breast-conserving surgery 
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Table 2  
Comparison of Characteristics Between Elderly Women Alive and Dead 5 Years After Invasive Non-Metastatic Breast Cancer Diagnosis 
  
All Stage I, II, III Stage I, II/Local Treatment Stage I, II, III/GCC 
  
SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009 
    Alive Dead     Alive Dead     Alive Dead     
  
N % N % p-value N % N % p-value N % N % p-value 
All 43899 81.6 9931 18.5     39520 86.0 6461 14.1     24398 87.5 3485 12.5     
Time to Deatha 
  
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
Mean(SD)    2327.2 (357.6) 938.9 (454.1) 
 
2338.7 (361.6) 1055.1 (406.5) 
 
2192.3 (261.0) 1016.8 (402.4) 
 Year of Diagnosisc 
  
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
2003 5737 76.7 1740 23.3 
  
5378 80.7 1289 19.3 
  
― ― ― ― 
  
 
2004 5986 77.5 1742 22.5 
  
5358 82.1 1169 17.9 
  
3188 82.1 697 17.9 
  
 
2005 6016 78.5 1653 21.6 
  
5344 83.3 1074 16.7 
  
3096 83.1 630 16.9 
  
 
2006 6044 78.9 1621 21.2 
  
5467 84.2 1027 15.8 
  
3230 83.4 643 16.6 
  
 
2007 6297 81.8 1399 18.2 
  
5674 86.4 890 13.6 
  
3417 84.9 608 15.1 
  
 
2008 6691 86.5 1048 13.5 
  
5981 90.2 648 9.8 
  
5591 90.9 560 9.1 
  
 
2009 7128 90.7 728 9.3 
  
6318 94.6 364 5.5 
  
5876 94.4 347 5.6 
  Age & Health 
Age at Diagnosisd 
  
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
66-69 10921 91.3 1044 8.7 
  
9690 93.8 641 6.2 
  
6264 93.6 430 6.4 
  
 
70-74 11954 89.1 1459 10.9 
  
10808 92.1 933 8.0 
  
6956 92.1 595 7.9 
  
 
75-79 10299 83.6 2023 16.4 
  
9358 87.2 1373 12.8 
  
5858 87.4 846 12.6 
  
 
> 80 10725 66.5 5405 33.5 
  
9664 73.3 3514 26.7 
  
5320 76.7 1614 23.3 
  Comorbidity Scored 
  
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
0 26091 86.2 4196 13.9 
  
23428 89.9 2633 10.1 
  
14090 90.8 1430 9.2 
  
 
1 11507 79.5 2976 20.6 
  
10463 84.1 1976 15.9 
  
6517 86.2 1042 13.8 
  
 
> 2 6301 69.6 2759 30.5 
  
5629 75.2 1852 24.8 
  
3791 78.9 1013 21.1 
  PCP Visitse 
   
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
Low 24804 84.5 4563 15.5 
  
22008 88.6 2826 11.4 
  
13762 89.6 1592 10.4 
  
 
High 19095 78.1 5368 21.9 
  
17512 82.8 3635 17.2 
  
10636 84.9 1893 15.1 
  a = t-test of mean differences 
b = cmh chi square test of general association 
c = cmh chi square test of location shift using table scores 
d =  cmh chi square test of location shift using modified ridit scores 
e = Pearson's chi square test of association 
* p < 0.05; ** p < 0.01; *** p < 0.001 
BCS = Breast-Conserving Surgery 
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Table 2  
Comparison of Characteristics Between Elderly Women Alive and Dead 5 Years After Invasive Non-Metastatic Breast Cancer Diagnosis 
  
All Stage I, II, III Stage I, II/Local Treatment Stage I, II, III/GCC 
  
SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009 
    Alive Dead     Alive Dead     Alive Dead     
  
N % N % p-value N % N % p-value N % N % p-value 
All 43899 81.6 9931 18.5     39520 86.0 6461 14.1     24398 87.5 3485 12.5     
Clinical Prognostic Factors 
Stage at Diagnosisd 
  
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
I 26632 88.3 3521 11.7 
  
25897 89.5 3034 10.5 
  
14573 92.6 1158 7.4 
  
 
II 14085 77.4 4111 22.6 
  
13623 79.9 3427 20.1 
  
8038 84.5 1476 15.5 
  
 
III 3182 58.1 2299 41.9 
  
― ― ― ― 
  
1787 67.7 851 32.3 
  ER Statusb 
   
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
Positive 35197 84.1 6643 15.9 
  
31842 87.6 4522 12.4 
  
19897 89.2 2401 10.8 
  
 
Negative 5687 72.0 2217 28.1 
  
4982 79.1 1319 20.9 
  
3282 79.4 854 20.7 
  
 
Borderline/Unknown 3015 73.8 1071 26.2 
  
2696 81.3 620 18.7 
  
1219 84.1 230 15.9 
  PR Statusb 
   
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
Positive 29617 84.9 5277 15.1 
  
26860 88.1 3644 12.0 
  
16823 89.7 1939 10.3 
  
 
Negative 10894 75.8 3483 24.2 
  
9633 81.9 2133 18.1 
  
6174 82.7 1289 17.3 
  
 
Borderline/Unknown 3388 74.3 1171 25.7 
  
3027 81.6 684 18.4 
  
1401 84.5 257 15.5 
  Tumor Gradeb 
  
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
Well Differentiated 11537 88.1 1556 11.9 
  
10891 89.9 1227 10.1 
  
6228 92.4 513 7.6 
  
 
Moderately Differentiated 19231 83.8 3726 16.2 
  
17409 86.9 2637 13.2 
  
10945 89.1 1342 10.9 
  
 
Poorly Differentiated 10152 73.3 3704 26.7 
  
8681 80.2 2150 19.9 
  
5882 80.6 1420 19.5 
  
 
Undifferentiated/Unknown 2979 75.9 945 24.1 
  
2539 85.0 447 15.0 
  
1343 86.5 210 13.5 
  Tumor Sized  
               
< 0.001*** 
 
 
< 1 cm ― ― ― ― 
  
― ― ― ― 
  
7720 94.1 481 5.9 
  
 
< 2 cm ― ― ― ― 
  
― ― ― ― 
  
9610 89.8 1091 10.2 
  
 
2 - 5 cm ― ― ― ― 
  
― ― ― ― 
  
6287 80.3 1547 5.6 
  
 
> 5 cm ― ― ― ― 
  
― ― ― ― 
  
781 68.1 366 31.9 
  a = t-test of mean differences 
              b = cmh chi square test of general association 
              c = cmh chi square test of location shift using table scores 
             d =  cmh chi square test of location shift using modified ridit scores 
            e = Pearson's chi square test of association 
              * p < 0.05; ** p < 0.01; *** p < 
0.001 
                 BCS = Breast-Conserving Surgery 
                 
152 
 
Table 2  
Comparison of Characteristics Between Elderly Women Alive and Dead 5 Years After Invasive Non-Metastatic Breast Cancer Diagnosis 
  
All Stage I, II, III Stage I, II/Local Treatment Stage I, II, III/GCC 
  
SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009 
    Alive Dead     Alive Dead     Alive Dead     
  
N % N % p-value N % N % p-value N % N % p-value 
All 43899 81.6 9931 18.5     39520 86.0 6461 14.1     24398 87.5 3485 12.5     
Lymph Nodese 
               
< 0.001*** 
 
 
Positive ― ― ― ― 
  
― ― ― ― 
  
5897 78.6 1877 9.2 
  
 
Negative ― ― ― ― 
  
― ― ― ― 
  
18501 90.8 1608 21.4 
  Oncology Care Resources 
Mammography Screening Centerse 
 
0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
Low 22514 81.0 5269 19.0 
  
20317 85.4 3472 14.6 
  
13588 86.7 2077 13.3 
  
 
High 21385 82.1 4662 17.9 
  
19203 86.5 2989 13.5 
  
10810 88.5 1408 11.5 
  Oncology Treatment Centerse < 0.001*** 
    
< 0.001*** 
     
0.002** 
 
 
Low 24394 80.9 5752 19.1 
  
21995 85.4 3766 14.6 
  
10890 86.8 1651 13.2 
  
 
High 19505 82.4 4179 17.6 
  
17525 86.7 2695 13.3 
  
13508 88.1 1834 12.0 
  Type of Surgeon Seenb 
 
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
General Only  7062 73.5 2551 26.5 
  
6675 78.0 1880 22.0 
  
3344 82.7 701 17.3 
  
 
Oncology Only 2664 82.4 571 17.7 
  
2307 87.3 337 12.8 
  
1469 89.7 169 10.3 
  
 
Both 33444 83.6 6557 16.4 
  
30538 87.8 4244 12.2 
  
19585 88.2 2615 11.8 
  Socio-Demographic Characteristics 
Racee 
   
< 0.001*** 
     
0.092 
    
< 0.001*** 
 
 
White 39028 81.8 8670 18.2 
  
35355 86.0 5735 14.0 
  
21609 87.9 2985 12.1 
  
 
Other 4871 79.4 1261 20.6 
  
4165 85.2 726 14.8 
  
2789 84.8 500 15.2 
  Educatione 
   
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
< 15% college degree 12752 78.6 3480 21.4 
  
11315 83.5 2242 16.5 
  
7211 84.9 1282 15.1 
  
 
> 15%  college degree 31147 82.8 6451 17.2 
  
28205 87.0 4219 13.0 
  
17187 88.6 2203 11.4 
  Annual Incomee 
  
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
< $35,000 10085 77.2 2972 22.8 
  
8962 82.6 1891 17.4 
  
5734 84.3 1072 15.8 
  
 
> $35,000 33814 82.9 6959 17.1 
  
30558 87.0 4570 13.01 
  
18664 88.6 2413 11.5 
  a = t-test of mean differences 
               b = cmh chi square test of general association 
             c = cmh chi square test of location shift using table scores 
           d =  cmh chi square test of location shift using modified ridit scores 
           e = Pearson's chi square test of association 
            * p < 0.05; ** p < 0.01; *** p < 0.001 
             BCS = Breast-Conserving Surgery 
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Table 2  
Comparison of Characteristics Between Elderly Women Alive and Dead 5 Years After Invasive Non-Metastatic Breast Cancer Diagnosis 
  
All Stage I, II, III Stage I, II/Local Treatment Stage I, II, III/GCC 
  
SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009 
    Alive Dead     Alive Dead     Alive Dead     
  
N % N % p-value N % N % p-value N % N % p-value 
All 43899 81.6 9931 18.5     39520 86.0 6461 14.1     24398 87.5 3485 12.5     
Metro Statuse 
   
< 0.001*** 
    
< 0.001*** 
    
< 0.001*** 
 
 
Non-metro 7134 79.6 1831 20.4 
  
6477 84.3 1209 15.7 
  
3975 85.3 685 14.7 
  
 
Metro 36765 82.0 8100 18.1 
  
33043 86.3 5252 13.7 
  
20423 87.9 2800 12.1 
  Tests & Treatments 
Loco-Regional Treatmentb 
       
< 0.001*** 
       
 
BCS+Radiation ― ― ― ― 
  
23043 91.9 2024 8.1 
  
― ― ― ― 
  
 
Mastectomy ― ― ― ― 
  
8541 79.3 2227 20.7 
  
― ― ― ― 
  
 
BCS Only ― ― ― ― 
  
7936 78.2 2210 21.8 
  
― ― ― ― 
  Guideline-Concordant Caree 
             
< 0.001*** 
 
 
Yes ― ― ― ― 
  
― ― ― ― 
  
8659 92.8 677 7.3 
  
 
No ― ― ― ― 
  
― ― ― ― 
  
15739 84.9 2808 15.1 
  ER Status Testede 
              
< 0.001*** 
 
 
Yes ― ― ― ― 
  
― ― ― ― 
  
23222 87.7 3260 12.3 
  
 
No  ― ― ― ― 
  
― ― ― ― 
  
1176 83.9 225 16.1 
  PR Status Testede 
              
< 0.001*** 
 
 
Yes ― ― ― ― 
  
― ― ― ― 
  
23182 87.7 3253 12.3 
  
 
No  ― ― ― ― 
  
― ― ― ― 
  
1216 84.0 232 16.0 
  Lymph Nodes Testede 
             
< 0.001*** 
 
 
Yes ― ― ― ― 
  
― ― ― ― 
  
22629 88.1 3056 11.9 
  
 
No  ― ― ― ― 
  
― ― ― ― 
  
1769 80.5 429 19.5 
  Had any Surgerye 
               
0.172 
 
 
Yes ― ― ― ― 
  
― ― ― ― 
  
24280 87.5 3474 12.5 
  
 
No ― ― ― ― 
  
― ― ― ― 
  
118 91.5 11 8.5 
  a = t-test of mean differences 
                 b = cmh chi square test of general association 
             c = cmh chi square test of location shift using table scores 
            d =  cmh chi square test of location shift using modified ridit scores 
            e = Pearson's chi square test of association 
            * p < 0.05; ** p < 0.01; *** p < 0.001 
               BCS = Breast-Conserving Surgery 
                 
                  
154 
 
Table 2  
Comparison of Characteristics Between Elderly Women Alive and Dead 5 Years After Invasive Non-Metastatic Breast Cancer Diagnosis 
  
All Stage I, II, III Stage I, II/Local Treatment Stage I, II, III/GCC 
  
SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009 
    Alive Dead     Alive Dead     Alive Dead     
  
N % N % p-value N % N % p-value N % N % p-value 
All 43899 81.6 9931 18.5     39520 86.0 6461 14.1     24398 87.5 3485 12.5     
Had BCSe 
               
< 0.001*** 
 
 
Yes ― ― ― ― 
  
― ― ― ― 
  
18830 90.3 2035 9.8 
  
 
No ― ― ― ― 
  
― ― ― ― 
  
5568 79.3 1450 20.7 
  Had Mastectomye 
              
< 0.001*** 
 
 
Yes ― ― ― ― 
  
― ― ― ― 
  
9446 81.2 2190 18.8 
  
 
No ― ― ― ― 
  
― ― ― ― 
  
14952 92.0 1295 8.0 
  Had Radiatione  
              
< 0.001*** 
 
 
Yes ― ― ― ― 
  
― ― ― ― 
  
15514 91.1 1509 8.9 
  
 
No ― ― ― ― 
  
― ― ― ― 
  
8884 81.8 1976 18.2 
  Had Chemotherapye 
               
0.036* 
 
 
Yes ― ― ― ― 
  
― ― ― ― 
  
6068 86.8 924 13.2 
  
 
No ― ― ― ― 
  
― ― ― ― 
  
18330 87.7 2561 12.3 
  Time to Chemotherapyb 
             
< 0.001*** 
 
 
Appropriate ― ― ― ― 
  
― ― ― ― 
  
5070 87.5 726 12.5 
  
 
Not Appropriate ― ― ― ― 
  
― ― ― ― 
  
998 83.4 198 16.6 
   No Chemotherapy ― ― ― ―     ― ― ― ―     18330 87.7 2561 12.3    
a = t-test of mean differences 
               b = cmh chi square test of general association 
             c = cmh chi square test of location shift using table scores 
            d =  cmh chi square test of location shift using modified ridit scores 
          e = Pearson's chi square test of association 
              * p < 0.05; ** p < 0.01; *** p < 0.001 
               BCS = Breast-Conserving Surgery 
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Table 3 
Hazard of Death 5 Years After Diagnosis of Invasive Non-Metastatic Breast Cancer in Elderly Women 
  
All Stage I, II, II Stage I, II/Local Treatment Stage I, II, III/GCC 
    SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009 
  
Dead vs. Alive   Dead vs. Alive   Dead vs. Alive   
All AOR 95% CI Sig.   AOR 95% CI Sig.   AOR 95% CI Sig.   
Year of Diagnosis 
            
 
2003 1.00 ― 
  
1.00 ― 
  
― ― ― 
 
 
2004 0.94 [0.88,1.01] 
  
0.95 [0.88,1.03] 
  
1.00 ― 
  
 
2005 0.88 [0.82,0.94] *** 
 
0.88 [0.81,0.95] ** 
 
0.90 [0.81,1.01] 
  
 
2006 0.87 [0.81,0.93] *** 
 
0.82 [0.75,0.89] *** 
 
0.92 [0.83,1.03] 
  
 
2007 0.81 [0.75,0.87] *** 
 
0.77 [0.71,0.84] *** 
 
0.92 [0.83,1.03] 
  
 
2008 0.80 [0.74,0.86] *** 
 
0.78 [0.71,0.86] *** 
 
0.87 [0.77,0.98] * 
 
 
2009 0.77 [0.71,0.85] *** 
 
0.69 [0.62,0.78] *** 
 
0.82 [0.71,0.95] ** 
 Age & Health 
Age at Diagnosis 
            
 
66-69 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
70-74 1.24 [1.15,1.35] *** 
 
1.21 [1.10,1.34] *** 
 
1.17 [1.04,1.33] * 
 
 
75-79 1.86 [1.73,2.01] *** 
 
1.90 [1.73,2.09] *** 
 
1.73 [1.54,1.95] *** 
 
 
> 80 4.01 [3.74,4.29] *** 
 
3.76 [3.45,4.10] *** 
 
2.85 [2.54,3.20] *** 
 Comorbidity Score 
            
 
0 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
1 1.44 [1.37,1.51] *** 
 
1.49 [1.41,1.58] *** 
 
1.38 [1.27,1.50] *** 
 
 
> 2 2.17 [2.06,2.28] *** 
 
2.39 [2.25,2.55] *** 
 
2.09 [1.92,2.27] *** 
 PCP Visits 
            
 
Low 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
High 1.14 [1.10,1.19] *** 
 
1.15 [1.09,1.21] *** 
 
1.18 [1.10,1.26] *** 
 Clinical Prognostic Factors 
Stage at Diagnosis 
            
 
I 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
II 1.82 [1.74,1.91] *** 
 
1.66 [1.57,1.74] *** 
 
1.00 [0.86,1.16] 
  
 
III 3.95 [3.74,4.18] *** 
 
― ― ― 
 
1.81 [1.48,2.21] *** 
 ER Status 
            
 
Positive 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
Negative 1.36 [1.27,1.45] *** 
 
1.33 [1.23,1.45] *** 
 
1.48 [1.32,1.65] *** 
 
 
Borderline/Unknown 1.22 [1.02,1.45] * 
 
1.08 [0.87,1.35] 
  
0.72 [0.30,1.74] 
  PR Status 
            
 
Positive 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
Negative 1.19 [1.12,1.26] *** 
 
1.17 [1.09,1.26] *** 
 
1.13 [1.03,1.25] * 
 
 
Borderline/Unknown 1.09 [0.91,1.29] 
  
1.04 [0.84,1.29] 
  
0.88 [0.59,1.31] 
  Tumor Grade 
            
 
Well Differentiated 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
Moderately Differentiated 1.14 [1.07,1.21] *** 
 
1.15 [1.08,1.24] *** 
 
1.11 [1.00,1.23] 
  
 
Poorly Differentiated 1.54 [1.44,1.65] *** 
 
1.49 [1.38,1.61] *** 
 
1.49 [1.33,1.67] *** 
 
 
Undifferentiated/Unknown 1.38 [1.27,1.50] *** 
 
1.09 [0.98,1.22] 
  
1.15 [0.98,1.36] 
  * p < 0.05; ** p < 0.01; *** p < 0.001 
          BCS = Breast-Conserving Surgery 
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Table 3 
Hazard of Death 5 Years After Diagnosis of Invasive Non-Metastatic Breast Cancer in Elderly Women 
  
All Stage I, II, II Stage I, II/Local Treatment Stage I, II, III/GCC 
    SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009 
  
Dead vs. Alive   Dead vs. Alive   Dead vs. Alive   
All AOR 95% CI Sig.   AOR 95% CI Sig.   AOR 95% CI Sig.   
Tumor Size 
            
 
< 1 cm ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
< 2 cm ― ― ― 
 
― ― ― 
 
1.36 [1.20,1.54] *** 
 
 
2 - 5 cm ― ― ― 
 
― ― ― 
 
1.90 [1.62,2.23] *** 
 
 
> 5 cm ― ― ― 
 
― ― ― 
 
2.30 [1.89,2.80] *** 
 Lymph Nodes 
            
 
Positive ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
Negative ― ― ― 
 
― ― ― 
 
0.68 [0.61,0.76] *** 
 Oncology Care Resources 
Mammography Screening Centers 
          
 
Low 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
High 1.04 [0.95,1.13] 
  
1.03 [0.93,1.15] 
  
1.05 [0.93,1.17] 
  Oncology Treatment Centers 
          
 
Low 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
High 0.96 [0.88,1.04] 
  
0.93 [0.84,1.04] 
  
1.00 [0.89,1.12] 
  Type of Surgeon Seen 
           
 
General Only  1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
Oncology Only 0.78 [0.72,0.86] *** 
 
0.81 [0.72,0.91] *** 
 
0.74 [0.62,0.87] *** 
 
 
Both 0.68 [0.65,0.71] *** 
 
0.72 [0.68,0.76] *** 
 
0.78 [0.71,0.85] *** 
 Socio-Demographic Characteristics 
Race 
            
 
White 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
Other 1.00 [0.93,1.06] 
  
0.92 [0.85,1.00] 
  
0.99 [0.89,1.10] 
  Education 
            
 
< 15% college degree 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
> 15%  college degree 0.92 [0.88,0.97] ** 
 
0.91 [0.86,0.97] ** 
 
0.92 [0.85,1.00] 
  Annual Income 
            
 
< $35,000 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  
 
> $35,000 0.94 [0.89,1.00] * 
 
0.94 [0.88,1.01] 
  
1.03 [0.93,1.13] 
  Metro Status 
            
 
Non-metro 1.03 [0.96,1.09] 
  
0.99 [0.91,1.07] 
  
1.12 [1.00,1.25] * 
 
 
Metro 1.00 ― 
  
1.00 ― 
  
1.00 ― 
  Treatment 
Loco-Regional Treatment 
           
 
BCS+Radiation ― ― ― 
 
1.00 ― 
  
― ― ― 
 
 
Mastectomy ― ― ― 
 
1.81 [1.70,1.93] *** 
 
― ― ― 
 
 
BCS Only ― ― ― 
 
1.94 [1.82,2.06] *** 
 
― ― ― 
 Guideline-Concordant Care 
           
 
Yes ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
No ― ― ― 
 
― ― ― 
 
1.18 [1.04,1.35] * 
 Lymph Nodes Tested 
            
 
Yes ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
No  ― ― ― 
 
― ― ― 
 
1.09 [0.98,1.21] 
  * p < 0.05; ** p < 0.01; *** p < 0.001 
          BCS = Breast-Conserving Surgery 
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Table 3 
Hazard of Death 5 Years After Diagnosis of Invasive Non-Metastatic Breast Cancer in Elderly Women 
  
All Stage I, II, II Stage I, II/Local Treatment Stage I, II, III/GCC 
    SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009 
  
Dead vs. Alive   Dead vs. Alive   Dead vs. Alive   
All AOR 95% CI Sig.   AOR 95% CI Sig.   AOR 95% CI Sig.   
ER Status Testede 
            
 
Yes ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
No  ― ― ― 
 
― ― ― 
 
1.29 [0.43,3.87] 
  PR Status Testede 
            
 
Yes ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
No  ― ― ― 
 
― ― ― 
 
1.34 [0.62,2.87] 
  Had any Surgery 
            
 
Yes ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
No ― ― ― 
 
― ― ― 
 
0.73 [0.40,1.34] 
  Had BCS 
            
 
Yes ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
No ― ― ― 
 
― ― ― 
 
1.20 [1.10,1.32] *** 
 Had Mastectomy 
            
 
Yes ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
No ― ― ― 
 
― ― ― 
 
1.10 [0.99,1.23] 
  Had Radiation 
            
 
Yes ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
No ― ― ― 
 
― ― ― 
 
1.53 [1.39,1.68] *** 
 Had Chemotherapy 
            
 
Yes ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
No ― ― ― 
 
― ― ― 
 
1.16 [1.03,1.32] * 
 Time to Chemotherapy 
           
 
Appropriate ― ― ― 
 
― ― ― 
 
1.00 ― 
  
 
Not Appropriate ― ― ― 
 
― ― ― 
 
1.22 [1.02,1.46] * 
  No Chemotherapy ― ― ―   ― ― ―   ― ―    
* p < 0.05; ** p < 0.01; *** p < 0.001 
          BCS = Breast-Conserving Surgery 
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Appendix 1. Claims Codes Used for Identifying Types of Treatment 
 
Type of Treatment ICD-9 Diagnostic ICD-9 Procedure HCPCS/CPT Revenue Center 
Lymph Node Surgery  40.3, 40.41-40.42, 40.50-
40.54, 40.59, 85.43, 
85.48 
38500, 38510, 38520, 
38525, 38530, 39542, 
38720, 38740, 38745, 
38792, 78195, 78800-
78801 
 
Lumpectomy  85.20-85.29 19120, 19125-19126, 
19160, 19162, 19301-
19302 
 
Mastectomy  85.33-85.36, 85.40-85.48 19140, 19180, 19182, 
19300, 19303-19307, 
19200, 19220, 19240, 
19260, 19271-19272 
 
Radiation Therapy V58.0, V66.1, V67.1 92.20-92.39  77261-77799, G0256, 
G0261, G0173-G0174, 
G0243, G0251, G0338-
G03340 
0330, 0333 
Chemotherapy V58.1, V66.2, V67.2,  99.25, 99.28 96400-96599, C8953-
C8955, G0355-G0363, 
G902-G9032, J0640, 
J8510, J8520-J8521, 
J8530-J8999, J9000-
J9999, Q0083-Q0085, 
S9329-S9331,  
0331, 0332, 0335 
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Appendix 1. Guideline-Concordant Treatment Options by Tumor Size and Lymph Node 
Status 
 
Stage Treatment Option A Treatment Option B 
Stage I: 
       T < 1 cm, N- 
 BCS                    •    ERST & PRST 
 RT                 
 LNT  
 Mastectomy 
  LNT 
  ERST & PRST 
Stage I: 
       1 cm < T < 2 cm, N- 
 BCS                    •     CT 
 RT                      •     CT < 120days          
 LNT                    •     ERST & PRST  
 Mastectomy         •     CT < 120days    
 LNT                     •     ERST & PRST 
 CT 
Stage IIA: 
       0 cm < T < 2 cm, N+ 
 BCS                    •     CT 
 RT                      •     CT < 120days          
 LNT                    •     ERST & PRST 
 Mastectomy         •     CT < 120days    
 LNT                     •     ERST & PRST 
 CT 
Stage IIA: 
       2 cm < T < 5 cm, N- 
 BCS                    •     CT 
 RT                      •     CT < 120days          
 LNT                    •     ERST & PRST 
 Mastectomy         •     CT < 120days    
 LNT                     •     ERST & PRST 
 CT 
Stage IIB: 
       2 cm < T < 5 cm, N+ 
 BCS                    •     CT 
 RT                      •     CT < 120days          
 LNT                    •     ERST 
 Mastectomy         •     CT < 120days    
 LNT                     •     ERST & PRST 
 CT 
Stage IIB: 
       T > 5 cm, N- 
 Mastectomy        •     CT < 120days    
 LNT                    •     ERST & PRST 
 CT 
 
Stage IIIA: 
       0 cm < T < 5 cm, N+ 
 BCS                    •     CT 
 RT                      •     CT < 120days          
 LNT                    •     ERST 
 Mastectomy         •     CT < 120days    
 LNT                     •     ERST & PRST 
 CT 
Stage IIIA: 
       T > 5 cm, N+ 
 Mastectomy        •     CT < 120days    
 LNT                    •     ERST & PRST 
 CT 
 
Stage IIIB & IIIC  Mastectomy        •     CT < 120days    
 LNT                    •     ERST & PRST 
 CT 
 
T = tumor size; N = nodal status; BCS = breast-conserving surgery; RT = radiation therapy; LNT = lymph node 
testing; ERST = estrogen receptor status testing; PRST = progesterone receptor status testing; CT = chemotherapy;  
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Figure 1. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive Non-
Metastatic Breast Cancer, SEER-Medicare 2003-2009 
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Figure 2. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive Non-
Metastatic Breast Cancer By Stage, SEER-Medicare 2003-2009 
 
 
 
Log-Rank P < 0.0001 
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Figure 3. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive Early-
Stage Breast Cancer, SEER-Medicare 2003-2009 
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Figure 4. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive Early-
Stage Breast Cancer By Local Treatment, SEER-Medicare 2003-2009 
 
Log-Rank P < 0.0001 
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Figure 5. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive Non-
Metastatic Breast Cancer, SEER-Medicare 2004-2009 
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Figure 3. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive Non-
Metastatic Breast Cancer By Guideline-Concordant Care, SEER-Medicare 2004-2009 
 
 
Guideline-Concordant Care    ————       Guideline-Discordant Care     
Log-Rank P < 0.0001 
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CHAPTER 5 
Study Review  
Epidemiology  
 Breast cancer is the second most commonly diagnosed type of cancer in the United States 
(US) and the first among women.1 It is estimated that in 2014, 232,670 incident diagnoses and 
40,000 deaths will be attributed to breast cancer. The average age at diagnosis is 61 years. About 
21% of breast cancer cases occur in women age < 50 years, 22% among women age 50 – 59 
years, and 57% among women age > 60 years. 2 While breast cancer is the most frequently 
diagnosed type of cancer among women in the US, it also has among the highest survival rates, 
relative to other types of cancer. Relative to women who have never been diagnosed with breast 
cancer, breast cancer survivors have 89% 5-year and 83% 10-year survival rates. 3,4 Moreover, 
earlier stage diagnosis is associated with greater survival, such that women diagnosed at Stage I, 
II, and III have 100%, 93%, and 72% 5-year survival rates, respectively. 1 Decreasing mortality 
and increasing survival rates throughout the years are attributed to improvements in 
understanding of the disease and its treatment, alongside earlier detection due to increased 
routine breast cancer screening. 5  
Disparities in Treatment & Survival 
 Yet, despite these advancements, disparities in treatment patterns and survival outcomes 
persist. The most common disparities in treatment are the omission of recommended treatments 
and services or receiving non-preferential treatments. The most commonly omitted treatments 
are radiation therapy following breast-conserving surgery or mastectomy when indicated, 
chemotherapy, adjuvant hormone therapy, and lymph node sampling. While the course of breast 
cancer treatment is determined for each women by her tumor size, lymph node invasion, and 
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hormone receptor status, women diagnosed at an early-stage often times have the option for 
breast-conserving surgery (i.e. lumpectomy) plus radiation therapy or mastectomy. Breast-
conserving surgery plus radiation therapy has been found to be an equally effective treatment as 
mastectomy for long-term survival of invasive early-stage breast cancer and is usually the 
preferred treatment choice due to breast preservation and functional performance. 6-10  
While about 60% or more women have BCS, one in four women who have BCS will undergo 
additional surgery, and about one in ten will eventually undergo mastectomy after treatment 
failure with BCS. 11-15 Whether it is the initial choice of surgery or not, epidemiological studies 
have reported an increase in the use of mastectomy in recent years. 12,13,16 Women who elect for 
mastectomy when BCS plus RT is an option tend to be younger, have a desire to avoid RT, fear 
recurrence, are diagnosed with later stage and more aggressive cancers, have cancers with 
clinical characteristics associated with poorer survival, are of lower income, insured by Medicaid 
or uninsured, reside in rural locations, have increased travel distances for RT, have a surgeon that 
is male surgeon, not trained in the U.S., and less recent training. 12,13, 16-21 
 In actuality, treatment disparities span across the entire course of breast cancer care, and 
lead to disparities in survival. Numerous factors have been associated with treatment and 
survival disparities, but several are particularly common among elderly women. Age and 
comorbidity are two inter-related factors that are strongly associated with treatment and survival 
outcomes. Due to an intolerance to toxic effects of radiation therapy and chemotherapy observed 
among some populations of older women, the National Comprehensive Cancer Network 
(NCCN) do not make recommendations for or against chemotherapy  in women age > 70 years, 
but suggest chemotherapy be given on a case-by-case basis, depending on the patient's health.22 
Additionally, guidelines specify that radiation therapy following BCS may be omitted among 
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women meeting the following requirements: age > 70 years, tumors < 2 cm, node negative, 
estrogen-receptor positive, and receiving adjuvant hormone therapy.23 Despite these 
recommendations, the decision to omit adjuvant therapies due to old age remains a topic of 
debate. What is more, study findings of treatment patterns among elderly women with breast 
cancer suggest that more women are not receiving radiation therapy and or chemotherapy than 
those who meet exemption criteria or may be too poor of health to undergo treatment. 24-29 In 
turn, multiple studies have demonstrated poorer survival among elderly women who do not 
receive RT following BCS or chemotherapy when indicated. 30-36   
 Additional factors associated with treatment and survival outcomes are socio-
demographic characteristics, access to specialty oncology services, and clinical prognostic 
characteristics. Vulnerable socio-demographic characteristics such as being of non-white race, 
publicly insured or uninsured, being or residing in areas of low income, low education, residing 
in rural locations, and having greater driving distances to treatment centers are associated with 
breast cancer treatment disparities.37-42 Race is also directly associated with survival outcomes. 
Black women have markedly worse survival outcomes, as compared to white women, such that 
5-year survival for white and black women is 90% and 79%, respectively. 3,43,44 Clinical 
characteristics associated with greater survival are earlier stage at diagnosis, smaller tumor size, 
less or no lymph node invasion, well differentiated tumor grade, and estrogen and progesterone 
positive tumors. 1,45-47  
Statement of the Problem 
 To address gaps in the literature and build upon existing knowledge this series of studies 
focused upon the treatment patterns and survival of elderly women with breast cancer, a 
population with the highest incidence of the disease, but for whom many are undertreated due to 
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age and declining health. Specifically, these studies sought to determine how age, health, clinical 
prognostic factors, oncology care resources, and socio-demographic characteristics are 
associated with these outcomes. The first study investigated the initial type of loco-regional 
treatment received for early-stage breast cancer. Most studies reporting on treatment patterns for 
early-stage breast cancer present rates that reflects the end result of multiple surgeries, such that 
a woman who first had BCS with or without RT, but eventually had a mastectomy, was classified 
as having a mastectomy and not BCS. This study captured, the initial treatment, with the 
intention of describing treatment preference and recommendation patterns among elderly women 
with early-stage breast cancer, as many women with this diagnosis have a choice of treatment. 
The second study sought to determine to what degree women with stage I, II, and III breast 
cancer receive GCC according to NCCN and ASCO treatment guidelines, by comprehensively 
comparing clinical characteristics and the care received by each women, including individual 
diagnostic tests and treatment, using a large, nationally representative dataset. In contrast, 
previous studies that have examined GCC in piecemeal fashion by studied narrowly defined 
groups of women, focusing on loco-regional or adjuvant therapies, or using smaller and older 
dataset. The third study will examine overall 5-year survival among the two previously described 
study populations and how each of those study outcomes (initial loco-regional treatment and 
receipt of individual tests, treatments, and GCC) and independent variables are associated with 
survival. Additionally, overall 5-year survival will be examined among a third, more broadly 
inclusive sample of women with stage I, II, III breast cancer, to gain a baseline understanding of 
overall survival of elderly women with invasive non-metastatic breast cancer. 
 In view of these findings, the goal of this dissertation was to 1) examine initial loco-
regional treatment patterns among elderly women with stage I and II breast cancer, 2) receipt of 
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individual tests, treatments, and guideline-concordant care among elderly women with 
pathologically stage I, II, and III breast cancer, and 3) overall 5-year survival among a broadly 
inclusive group of elderly women with stage I, II, and III breast cancer and among the first two 
study samples using the linked SEER-Medicare dataset.  
Summary of Findings 
 The first study sample consisted of 45,981elderly women diagnosed with stage I and II 
breast cancer in 2003 thru 2009. Of these women, about 55% received breast-conserving surgery 
plus radiation therapy as their primary treatment, while 23% were treated with mastectomy and 
22% had breast-conserving surgery only. About 63% were diagnosed at stage I, 23%, 26%, 23%, 
and 29% were diagnosed at age 66-69, 70-74, 75-59, and > 80 years, and 57% had a comorbidity 
score of zero. Receipt of mastectomy or breast-conserving surgery only, compared to breast-
conserving surgery plus radiation therapy, shared many of the same predictors with associations 
in the same direction. Compared to women who received breast-conserving surgery plus 
radiation therapy, those who were diagnosed at older age vs. age 66-69 years, had greater 
comorbidity vs. no comorbidity, diagnosed at stage II vs. stage I, of non-white race vs. white, 
lived in non-metro areas vs. metro, lived in areas of lower income vs. higher, lived in areas of 
lower education vs. higher, were treated by a general surgeon only vs. oncology or both 
specialties, and were more likely to receive mastectomy or breast-conserving surgery only. The 
second study sample was comprised of 27,883 women diagnosed with pathologically staged I, II, 
and III breast cancer in 2004 thru 2009. Among this sample, fewer than 34% of elderly women 
received guideline-concordant care as per NCCN and ASCO treatment guidelines. About 56% of 
women were diagnosed at stage I, 34% at stage II, and 10% at stage III. Age at diagnosis was 
fairly evenly distributed, ranging from 24% - 27% for each age group and 56% had a 
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comorbidity score of zero. Ninety-five percent of women had their tumor estrogen-receptor, 
progesterone-receptor status, and 92% had their lymph nodes tested, but only 61% had radiation 
therapy and 25% had chemotherapy. About 75% of women had breast-conserving surgery and 
42% of women initially or eventually had a mastectomy. Perhaps not coincidently, most of the 
same predictors of treatment for early-stage breast cancer that were not breast-conserving 
surgery plus radiation therapy, were also similarly associated with receipt of guideline-
concordant care among women with stage I, II, and III breast cancer. Older age, greater 
comorbidity, later stage at diagnosis, non-white race, residing in lower income areas, residing in 
lower education areas, and being treated by a general surgeon only were associated with a 
decreased likelihood of receiving guideline-concordant care. In fact, women age > 70 years old, 
were less than half as likely to receive guideline-concordant care, than women age 66-69 years at 
diagnosis. Women 70 years of age and older were 24%, 37%, and 70% less likely to receive 
breast-conserving surgery, radiation therapy, or chemotherapy, respectively. The third study 
examined overall 5-year survival among the previously two described study samples and a 
broader sample (N = 53,830) of women diagnosed in 2003 thru 2009 with stage I, II, and III 
breast cancer. Across the three samples, 5-year survival rates ranged from 82% to 88%, rates that 
are similar to those previously reported 89% 5-year survival rate for all women diagnosed with 
breast cancer in the US. Women who were diagnosed at age 66-69 years, stage I, had a 
comorbidity score = 0, had positive estrogen and progesterone tumor receptors, and well 
differentiated tumors had the highest overall 5-year survival rates. Again, many of the same 
factors that were associated with less than optimal treatment in the first two studies, were 
associated with poorer survival.  The risk of death within 5 years of diagnosis increased with 
each age category, such that women age > 80 years at diagnosis, were 2.8 to 4 times more likely 
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to die. Similarly, women with a comorbidity score > 2 were more than twice as likely to die 
within 5 years of diagnosis. Additionally, the hazard of death within 5 years of diagnosis also 
increased with increasing stage at diagnosis, increasing tumor size, decreasing tumor grade, 
positive lymph node status, and negative estrogen or progesterone receptors statuses. The hazard 
of death was also increased for those who were treated by a general surgeon, mastectomy, breast-
conserving surgery only, did not have radiation therapy or chemotherapy, and did not have GCC.  
Discussion & Conclusions 
 Several common themes can be drawn from these study findings. First of all, many of the 
same reasons for health disparities that are prevalent among all women with breast cancer, or 
even the population at large, can also be observed among elderly women with breast cancer, who 
should in theory have uniform health insurance coverage. Whether it relates to receipt of 
preferential or guideline-concordant care, women who are characterized by vulnerable socio-
demographic characteristics, such as non-white race, low income, low education, residing in 
rural areas, or areas with fewer oncology screening and treatment centers are more likely to 
experience health disparities in treatment. Elderly women with early-stage breast cancer of these 
characteristics more likely to be treated with breast-conserving surgery without radiation therapy 
or mastectomy when the option of breast-conserving surgery plus radiation therapy was an 
available option. What is more, vulnerable demographics of elderly women with all stages of 
invasive non-metastatic breast cancer were less likely to receive guideline-concordant care. 
Consequently, and perhaps for additional reasons, poorer overall 5-year survival rates were also 
observed among these same at risk populations. Taken together, these findings suggests that 
some women are better equipped to access care, regardless of the oncology service centers in 
their area. One cannot be certain why disparities persist among a population of women in the 
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presence of equivalent health care coverage. Then again, women of white race, higher education, 
higher income, residing in metro areas or closer to oncology services may have more trust in 
health care providers, may be more comfortable navigating the health care system, may be more 
knowledgeable about breast cancer risk, treatment options, and prognosis, and may generally be 
more empowered to pursue and overcome treatment obstacles. These attributes that may lend 
themselves to increased mammography screening, thus earlier stage at diagnosis, and more 
aggressive and informed health care seeking behaviors. However, it is worth noting that 
vulnerable socio-demographic characteristics have additional consequences for overall breast 
cancer survival. Race, particularly black race, has been linked to poorer breast cancer survival 
due to aggressive types of breast cancer that are more frequently diagnosed among this group of 
women for biological reasons. Aside from biology, women who have lived a lifetime with 
limited access to health care or with riskier environmental and behavioral exposures may have 
poorer health and resiliency in old age that result in an increased risk of breast cancer mortality.  
 Another common theme that can be discerned from these study findings, is that elderly 
women experience unique breast cancer disparities because of their age. This finding is 
somewhat alarming because this is the demographic for which incidence of breast cancer is the 
greatest, but on the other hand, the under treatment and poor survival experienced by elderly 
women is somewhat intuitive given the health and functional declines associated with increasing 
age. The reason these findings can be both alarming and intuitive is because it is to be expected 
for women who are in too poor of health or functional status to be omitted from taxing 
treatments such as radiation therapy or chemotherapy, especially when their life-expectancy is 
relatively short. In fact, this is why treatment guidelines make such allowances or advise 
discretion in the use of such treatments for women older than 70 years of age. However, with 
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that said, when only 34% of women over the age of 65 years receive guideline-concordant care 
or a little over half are treated with breast-conserving surgery plus radiation therapy, but almost a 
quarter receive breast-conserving surgery without radiation therapy, it seems probable that a 
greater number of women are not receiving the standard of care than there are of those who are 
actually in too poor of health to endure it. This seems to be a likely conclusion when one 
observes that more than two-thirds of the women with no comorbidity did not receive guideline-
concordant care. It is not clear why some women would not receive recommended treatments 
when they are healthy enough to do so. Possible reasons for under treatment may be that older 
women are more likely to refuse extensive treatments than younger women, it is too burdensome 
to arrange travel for repeated treatments, their families or caregivers do not believe it is in their 
best interest to undergo some treatments, or their oncologist may believe the benefits of such 
treatments do not outweigh their associated harms. Regardless of the reason for under treatment, 
the survival of women who could have benefited from aggressive treatment will be 
compromised. In addition to patterns of under treatment, the increasing obesity epidemic in the 
US and its associated chronic comorbid conditions further compromise the overall survival of 
elderly women with breast cancer.  
Future Research & Direction 
 Even though breast cancer treatment and survival have improved markedly over the past 
twenty-some years and increased mammography screening has increased rates of early stage 
diagnosis, disparities in treatment and survival still exist, with unique disparities affecting the 
population with the highest incidence of breast cancer. While there is no logical reason for stage 
at diagnosis disparities to exist in the age of routine screening among a group of women with 
little out-of-pocket costs for the service, and yet they do exist and have negative impact on 
survival. Whether a later stage at diagnosis is attributed to declines in screening that are 
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commonly observed among elderly women or for other reasons, health care providers and public 
awareness campaigns should emphasize mammography screening persistence among elderly 
women. Current screening guidelines put forth by the United States Preventive Services Task 
Force do not make recommendations for or against mammography screening after the age of 75 
years. However, this should not be taken as an excuse to discontinue screening among older 
women. Similarly, treatment guidelines make exceptions for the omission of radiation therapy 
and chemotherapy among women older than 70 years, but it appears that more women than those 
who would meet this exemption do not receive these and other treatments when they would 
otherwise be indicated. Retrospective and secondary-database studies cannot definitively 
determine why these disparities exist. Prospective studies that can capture physician and patient 
perspective, in additional to clinical measures, are necessary to better understand the nature of 
this disparity in order to address it. Patient education and navigation programs available at the 
time of diagnosis could be helpful to further address treatment disparities among various 
vulnerable socio-demographic populations. These programs have shown to be beneficial for 
patients who are less knowledgeable about the disease and its treatment options, as well as, 
continuity of care and treatment completion. Beyond patient age and access to care, the other 
major factor associated with breast cancer disparities among the elderly is high rates of 
comorbidity. Yet, this pervasive problem that effects much of the US population may be harder 
to address. While the elderly may experience a wide range of health problems, many can be 
linked to obesity and unhealthy lifestyles. This health crisis has been the focus of many 
researchers, health care providers, government agencies, and other special interest groups. 
Although it is common knowledge that the way to preventing this problem is by being physically 
active and eating healthy foods, a mechanism for increasing these behaviors has yet to be 
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identified. There will be no quick or easy solution to this problem, but efforts should continue to 
raise awareness and motive change to improve health, longevity, and resiliency for the 
population as a whole, and for elderly women with breast cancer.  
 Aside from the issues addressed by the current study, future studies of breast cancer 
outcomes among elderly women could investigate whether the improvement in targeted and low-
dose radiation therapies increase radiation therapy rates among elderly women, the uptake of 
sentinel lymph node biopsy vs. axillary lymph node dissection across different populations of 
women, factors associated with repeated lumpectomy and treatment failure resulting in 
mastectomy, and factors associated with being treated by a general surgeon vs. an oncology 
surgeon. 
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